var title_f15_10_15520="Causes of cardiomyopathy I";
var content_f15_10_15520=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=CARD%2F78298%7ECARD%2F52168&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=3\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=CARD%2F78298%7ECARD%2F52168&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=3\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Etiologic classification of cardiomyopathy-I",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\" class=\"container\">",
"     <tbody>",
"      <tr>",
"       <td class=\"container\">",
"        <table cellspacing=\"0\">",
"         <tbody>",
"          <tr>",
"           <td class=\"subtitle1_single\">",
"            Infectious",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"subtitle2_single\">",
"            Bacterial",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            Diptheria*",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            Tuberculosis*",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            Typhoid fever*",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            Rheumatic fever*",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            Scarlet fever*",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            Meningococcal*",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            Pneumococcal",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            Gonococcal",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            Brucellosis",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            Tetanus",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            Meliodosis",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            Tularemia",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            Pertussis",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"subtitle2_single\">",
"            Spirochetal",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            Syphilis",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            Leptospirosis*",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            Lyme disease*",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"subtitle2_single\">",
"            Rickettsial",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            Typhus",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            Rocky mountain spotted fever*",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            Q fever",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"subtitle2_single\">",
"            Viral",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            Parvovirus B19*",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            Human herpesvirus 6*",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            Poliomyelitis*",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            Influenza*",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            Mumps*",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            Rubella*",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            Rubeola*",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            Variola*",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            Varicella*",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            Epstein-Barr*",
"           </td>",
"          </tr>",
"         </tbody>",
"        </table>",
"       </td>",
"       <td class=\"container\">",
"        <table cellspacing=\"0\">",
"         <tbody>",
"          <tr>",
"           <td class=\"subtitle2_single\">",
"            Viral (cont'd)",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            Coxsackievirus*",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            Echovirus*",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            Cytomegalovirus*",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            Hepatitis*",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            Rabies*",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            Mycoplasma*",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            Psittacosis*",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            Herpes",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            Encephalitis",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            Arboviruses*",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"subtitle2_single\">",
"            Mycotic",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            Actinomycosis",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            Blastomycosis",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            Moniliasis",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            Aspergiliosis",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            Histoplasmosis*",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            Coccidiomycosis",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            Cryptococcosis*",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            Candidiasis",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"subtitle2_single\">",
"            Protozoal",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            South American",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            trypanosomiasis*",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            African trypanosomiasis*",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            Toxoplasmosis*",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            Malaria",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            Amebiasis",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            Leishmaniasis",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            Balantidiasis",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            Sarcosporidiosis",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"subtitle2_single\">",
"            Helminthic",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            Trichiniasis*",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            Echinococcosis",
"           </td>",
"          </tr>",
"         </tbody>",
"        </table>",
"       </td>",
"       <td class=\"container\">",
"        <table cellspacing=\"0\">",
"         <tbody>",
"          <tr>",
"           <td class=\"subtitle2_single\">",
"            Helminthic (cont'd)",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            Schistosomiasis*",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            Ascariasis",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            Heterophydiasis",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            Filariasis",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            Paragonimiasis",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            Strongyloidiasis",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            Cysticercosis",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            Visceral larva migrans",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"subtitle1_single\">",
"            Toxins and drugs",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Adriamycin*",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Amphetamine*",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Antimony",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Arsenic*",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Carbon monoxide",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Carbon tetrachloride",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Catecholamines*",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Cobalt*",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Cocaine*",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Cyclophosphamide",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Emetine",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Ethyl alcohol*",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Lithium",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Lead",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Methysergide",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Phenothiazine drugs",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Phosphorus*",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Tricyclic antidepressants",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Zidovudine*",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Radiation*&bull;",
"           </td>",
"          </tr>",
"         </tbody>",
"        </table>",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     * Conditions that may manifest clinically as dilated cardiomyopathy.",
"     <br>",
"      <span class=\"bullet\">",
"       &bull;",
"      </span>",
"      Conditions that may manifest clinically as restrictive cardiomyopathy.",
"     </br>",
"    </div>",
"    <div class=\"reference\">",
"     Adapted with permission from: Abelmann, WH. Introduction to Atlas of Heart Diseases, Vol. II: Cardiomyopathies, Myocarditis and Pericardial disease, Abelmann, WH (Ed), Current Medicine, Philadelphia, 1995, p. 1.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Etiologic classification of cardiomyopathy-II",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\" class=\"container\">",
"     <tbody>",
"      <tr>",
"       <td class=\"container\">",
"        <table cellspacing=\"0\">",
"         <tbody>",
"          <tr>",
"           <td class=\"subtitle1_single\">",
"            Genetic",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Genetic hypertrophic cardiomyopathy*&bull;",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Genetic dilated cardiomyopathy&Delta;",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"subtitle1_single\">",
"            Metabolic",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"subtitle2_single\">",
"            Endocrine",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            Acromegaly*&bull;&Delta;",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            Thyrotoxicosis&Delta;",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            Hypothyroidism*&bull;&Delta;",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            Pheochromocytoma*&bull;&Delta;",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            Diabetes melllitus",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"subtitle2_single\">",
"            Familial storage diseases",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            Glycogen storage diseases*&Delta;",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            Refsum disease",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            Niemann-Pick disease",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            Hand-Schuller-Christian disease",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            Fabry's disease*&Delta;",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            Gangliosiderosis",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            Gaucher's disease&bull;&Delta;",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            Sandhoff's disease&Delta;",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            Mucopolysaccharidosis&Delta;",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            Hunter's syndrome",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            Hurler's syndrome",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"subtitle2_single\">",
"            Nutritional",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            Beriberi&Delta;",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            Kwashiokor&Delta;",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            Pellagra",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            Selenium deficiency",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            (Keshan's disease)&Delta;",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"subtitle2_single\">",
"            Other",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            Hypokalemia&Delta;",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            Carnitine deficiency&Delta;",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            Uremia&Delta;",
"           </td>",
"          </tr>",
"         </tbody>",
"        </table>",
"       </td>",
"       <td class=\"container\">",
"        <table cellspacing=\"0\">",
"         <tbody>",
"          <tr>",
"           <td class=\"subtitle1_single\">",
"            Hematologic/oncologic",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"subtitle2_single\">",
"            Hematologic disorders",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            Leukemia&Delta;",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            Myeloma",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            Sickle cell anemia&Delta;",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            Anemia&Delta;",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            Henoch-Schonlein purpura&Delta;",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"subtitle2_single\">",
"            Neoplastic diseases",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            Primary neoplasms&bull;",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            Metastatic neoplasms&bull;",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"subtitle1_single\">",
"            Deposits",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Hemochromatosis&bull;&Delta;",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Oxalosis",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Ochronosis",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Amyloid disease&bull;",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"subtitle1_single\">",
"            Heredofamilial neurologic and neuromuscular diseases",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Progressive muscular dystrophy (Duchenne)&Delta;",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Limb-girdle muscular dystrophy (Erb)&Delta;",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Fascioscapulohumeral dystrophy (Landouzy-Dejerine)",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Humeroperoneal ataxia",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Friedreich's ataxia*",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Myotonia atrophica (Steinert)&Delta;",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Myasthenia gravis",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Chronic progressive external opthmoplegia (Kearns-Savre)",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Familial centronuclear myopathy",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Juvenile progressive spinal muscular atrophy (Kugelberg-Welander)",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Neurofibromatosis*",
"           </td>",
"          </tr>",
"         </tbody>",
"        </table>",
"       </td>",
"       <td class=\"container\">",
"        <table cellspacing=\"0\">",
"         <tbody>",
"          <tr>",
"           <td class=\"subtitle1_single\">",
"            Endomyocardial diseases",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Endomyocardial fibrosis&bull;&Delta;",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Hypereosiinophilic heart disease",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            (Loffler's)&bull;",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Endocardial fibroelastosis&bull;&Delta;",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"subtitle1_single\">",
"            Inflammatory",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"subtitle2_single\">",
"            Connective tissue diseases",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            Rheumatoid heart disease&Delta;",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            Ankylosing spondylitis",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            Systemic lupus erythematosus&Delta;",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            Scleroderma&bull;&Delta;",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            Dermatomyositis&Delta;",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            Periarteritis nodosa",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"subtitle2_single\">",
"            Granulomatous",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            Sarcoid&Delta;",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            Wegener's granulomatosis&Delta;",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            Granulomatous myocarditis&Delta;",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"subtitle2_single\">",
"            Other inflammation",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            Giant cell myocarditis&Delta;",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            Hypersensitivity myocarditis&Delta;",
"           </td>",
"          </tr>",
"         </tbody>",
"        </table>",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     * Conditions that may manifest clinically as hypertrophic cardiomyopathy. (These designations are neither obligatory nor exclusive.)",
"     <br>",
"      <span class=\"bullet\">",
"       &bull;",
"      </span>",
"      Conditions that may manifest clinically as restrictive cardiomyopathy.",
"      <br>",
"       &Delta; Conditions that may manifest clinically as dilated cardiomyopathy.",
"      </br>",
"     </br>",
"    </div>",
"    <div class=\"reference\">",
"     Adapted with permission from: Abelmann WH. Introduction to Atlas of Heart Diseases, Vol. II: Cardiomyopathies, Myocarditis and Pericardial disease, Abelmann, WH (Ed), Current Medicine, Philadelphia, 1995, p.1.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f15_10_15520=[""].join("\n");
var outline_f15_10_15520=null;
var title_f15_10_15521="Kelley clamps";
var content_f15_10_15521=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=OBGYN%2F64793&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=OBGYN%2F64793&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Kelley clamps",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 432px; height: 325px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Application of (A) straight Kelly clamp and (B) curved Kelly clamp.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f15_10_15521=[""].join("\n");
var outline_f15_10_15521=null;
var title_f15_10_15522="Indigo carmine: Drug information";
var content_f15_10_15522=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Indigo carmine: Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"ex_sect_xr thclist drugH1Div drugBrandNames\" id=\"F13806078\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      Diagnostic Agent, Kidney Function",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block doa drugH1Div\" id=\"F7306227\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adult",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Localizing ureteral orifices:",
"     </b>",
"     I.M., I.V. (preferred): Usually 5 mL; doses &lt;5 mL preferred in underweight adults to avoid skin discoloration",
"    </p>",
"   </div>",
"   <div class=\"block dop drugH1Div\" id=\"F7306226\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Pediatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Localizing ureteral orifices:",
"     </b>",
"     I.M., I.V. (preferred): Infants and Children: Doses &lt;5 mL preferred to avoid skin discoloration (usual adult dose: 5 mL)",
"    </p>",
"   </div>",
"   <div class=\"block dor drugH1Div\" id=\"F15897837\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Renal Impairment",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No dosage adjustment provided in manufacturer&rsquo;s labeling.",
"    </p>",
"   </div>",
"   <div class=\"block doh drugH1Div\" id=\"F15897838\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Hepatic Impairment",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No dosage adjustment provided in manufacturer&rsquo;s labeling.",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F243434\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Injection, solution: 8 mg/mL (5 mL)",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F7306228\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Administer intravenously (preferred) or intramuscularly. Prior to administration, inspect solution for precipitation and discoloration.",
"    </p>",
"   </div>",
"   <div class=\"block scp drugH1Div\" id=\"F7306222\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Compatibility",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Do not dilute or mix with other solutions.",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F243435\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Localizing ureteral orifices during cystoscopy and ureteral catheterization",
"    </p>",
"   </div>",
"   <div class=\"block ars drugH1Div\" id=\"F7306215\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions Significant",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Frequency not defined: Cardiovascular: Bradycardia, hypertension",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Postmarketing and/or case reports: AV block (second degree), bronchospasm,  hypotension (severe), idiosyncratic reaction, urticaria",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F243438\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Known hypersensitivity to indigotindisulfonate sodium",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F243425\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings/Precautions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      <i>",
"       Concerns related to adverse effects:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Hypersensitivity reactions: Idiosyncratic drug reactions may occur rarely.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Pressor effects: Mild pressor effect may occur during use.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      <i>",
"       Other warnings/precautions:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Administration: Solution must not be diluted or administered with other solutions prior to injection due to risk for precipitation.",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F243431\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     C (",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F7306211\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Reproduction studies have not been conducted. Use during pregnancy only if clearly needed.",
"    </p>",
"   </div>",
"   <div class=\"block lac drugH1Div\" id=\"F7306213\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Lactation",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Excretion in breast milk unknown/use caution",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F243437\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics/Kinetics",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Half-life elimination: I.V. injection: 4-5 minutes; I.M. injection: Delayed (compared to I.V. administration)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Excretion: Urine (usually appears within 10 minutes following I.V. administration; retains blue color)",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      Hobai IA, &ldquo;Atrioventricular Block Induced by Indigo Carmine,&rdquo;",
"      <i>",
"       Can J Anaesth",
"      </i>",
"      , 2008, 55(10):717-8.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?15/10/15522/abstract-text/18835972/pubmed\" id=\"18835972\" target=\"_blank\">",
"        18835972",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Naitoh J and Fox BM, &ldquo;Severe Hypotension, Bronchospasm, and Urticaria from Intravenous Indigo Carmine,&rdquo;",
"      <i>",
"       Urology",
"      </i>",
"      , 1994, 44(2):271-2.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?15/10/15522/abstract-text/8048206/pubmed\" id=\"8048206\" target=\"_blank\">",
"        8048206",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Nguyen AC, Kost E, and Framstad M, &ldquo;Indigo Carmine-Induced Severe Hypotension,&rdquo;",
"      <i>",
"       Anesth Analg",
"      </i>",
"      , 1998, 87(5):1194-5.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?15/10/15522/abstract-text/9806707/pubmed\" id=\"9806707\" target=\"_blank\">",
"        9806707",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 9088 Version 30.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0604-118.195.65.243-2BB6473422-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f15_10_15522=[""].join("\n");
var outline_f15_10_15522=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13806078\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F7306227\">",
"      Dosing: Adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F7306226\">",
"      Dosing: Pediatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F15897837\">",
"      Dosing: Renal Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F15897838\">",
"      Dosing: Hepatic Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F243434\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F7306228\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F7306222\">",
"      Compatibility",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F243435\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F7306215\">",
"      Adverse Reactions Significant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F243438\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F243425\">",
"      Warnings/Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F243431\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F7306211\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F7306213\">",
"      Lactation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F243437\">",
"      Pharmacodynamics/Kinetics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/9088\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/9088|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f15_10_15523="Linear morphea";
var content_f15_10_15523=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=DERM%2F51218%7EDERM%2F60348&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=DERM%2F51218%7EDERM%2F60348&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Linear morphea",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 432px; height: 324px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    A shiny, sclerotic, hyperpigmented plaque is present in a linear distribution on the arm.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: www.visualdx.com. Copyright Logical Images, Inc.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Linear morphea",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 76px; height: 504px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Sclerotic, hyperpigmented, linear plaques are present on the arm.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f15_10_15523=[""].join("\n");
var outline_f15_10_15523=null;
var title_f15_10_15524="TTE 4Ch IAS";
var content_f15_10_15524=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic2\" style=\"width: 1040px;\">",
"  <div class=\"videoplayer\" h264=\"./images/CARD/65962/intsepat_conv.mp4?title=TTE+4Ch+IAS\" style=\"width:320px;height:256px\">",
"  </div>",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Interatrial septal aneurysm",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 260px; height: 438px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    The four chamber view from a 2-D echocardiogram shows a large aneurysm of the interatrial septum and an enlarged left atrium.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Thomas Binder, MD. University of Vienna.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f15_10_15524=[""].join("\n");
var outline_f15_10_15524=null;
var title_f15_10_15525="Travelers' diarrhea and cholera vaccine: Drug information";
var content_f15_10_15525=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Travelers' diarrhea and cholera vaccine: Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?1/33/1556?source=see_link\">",
"    see \"Travelers' diarrhea and cholera vaccine: Patient drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F3274459\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Dukoral&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ex_sect_xr thclist drugH1Div drugBrandNames\" id=\"F3275023\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      Vaccine",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block doa drugH1Div\" id=\"F6131824\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adult",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Cholera:",
"     </b>",
"     Oral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <i>",
"      Primary immunization:",
"     </i>",
"     2 doses given at intervals of &ge;1 week and completed at least 1 week prior to trip to endemic/epidemic areas; restart treatment if interval between doses &gt;6 weeks",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <i>",
"      Booster:",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     2-5 years",
"     <b>",
"      since last dose",
"     </b>",
"     : 1 booster dose",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     &gt;5 years",
"     <b>",
"      since last dose",
"     </b>",
"     : Repeat primary immunization schedule",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      ETEC:",
"     </b>",
"     Oral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <i>",
"      Primary immunization:",
"     </i>",
"     2 doses given at intervals of &ge;1 week and completed at least 1 week prior to trip to endemic/epidemic areas; restart treatment if interval between doses &gt;6 weeks",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <i>",
"      Booster:",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     3 months to 5 years",
"     <b>",
"      since last dose",
"     </b>",
"     : 1 booster dose",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     &gt;5 years",
"     <b>",
"      since last dose",
"     </b>",
"     : Repeat primary immunization schedule",
"    </p>",
"   </div>",
"   <div class=\"block dop drugH1Div\" id=\"F6131823\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Pediatric",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Cholera:",
"     </b>",
"     Oral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <i>",
"      Primary immunization:",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Children 2-6 years: 3 doses given at intervals of &ge;1 week and completed at least 1 week prior to trip to endemic/epidemic areas; restart treatment if interval between doses &gt;6 weeks",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Children &gt;6 years: Refer to adult dosing.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <i>",
"      Booster:",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Children 2-6 years:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">",
"     6 months to 5 years",
"     <b>",
"      since last dose",
"     </b>",
"     : 1 booster dose",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">",
"     &gt;5 years",
"     <b>",
"      since last dose",
"     </b>",
"     : Repeat primary immunization schedule",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Children &gt;6 years: Refer to adult dosing.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      ETEC:",
"     </b>",
"     Oral: Children &ge;2 years: Refer to adult dosing.",
"    </p>",
"   </div>",
"   <div class=\"block doe drugH1Div\" id=\"F3275045\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Geriatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Refer to adult dosing.",
"    </p>",
"   </div>",
"   <div class=\"block foccan drugH1Div\" id=\"F5951005\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: Canada",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Suspension [vial]:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Dukoral&reg;: 2.5 x 10",
"     <sup>",
"      10",
"     </sup>",
"     of each of the following",
"     <i>",
"      Vibrio cholerae",
"     </i>",
"     O1 strains: Inaba classic (heat inactivated), Inaba El Tor (formalin inactivated), Ogawa classic (heat inactivated), Ogawa classic (formalin inactivated), and 1 mg recombinant cholera toxin B subunit (rCTB) (3 mL) [may contain trace amounts of formaldehyde; packaged with sachet containing 5.6 g sodium hydrogen carbonate (contains saccharin, raspberry flavor)]",
"    </p>",
"   </div>",
"   <div class=\"block prod-avail drugH1Div\" id=\"F11234362\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Product Availability",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Not available in U.S.",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F3275046\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     <b>",
"      For oral use only; do not administer I.M., I.V., or SubQ.",
"     </b>",
"     Oral administration of other medications, vaccines, and consumption of food or drink should be avoided 1 hour before and 1 hour following vaccine administration.",
"    </p>",
"    <p style=\"text-indent:0em;margin-left:0em;margin-top:2em;text-align:justify;\">",
"     <b>",
"      Administration with other vaccines",
"     </b>",
"     (manufacturer recommendations):",
"     <i>",
"      Typhoid vaccine, oral:",
"     </i>",
"     Separate by at least 8 hours",
"    </p>",
"    <p style=\"text-indent:0em;margin-left:0em;margin-top:2em;text-align:justify;\">",
"     Acetaminophen may be used when needed to provide comfort; however, routine prophylactic administration of acetaminophen to prevent fever due to vaccine use is not recommended. There is evidence of a decreased immune response to some vaccines associated with acetaminophen administration; the clinical significance of this reduction in immune response has not been established.",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F3274761\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Protection against travelers&rsquo; diarrhea and/or cholera in adults and children &ge;2 years of age who will be visiting areas where there is a risk of contracting travelers&rsquo; diarrhea caused by enterotoxigenic",
"     <i>",
"      E. coli",
"     </i>",
"     (ETEC) or cholera caused by",
"     <i>",
"      V. cholerae",
"     </i>",
"     O1 (classical and El Tor biotypes; Inaba and Ogawa serotypes)",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     <b>",
"      Note:",
"     </b>",
"     The Centers for Disease Control and Prevention (CDC)",
"     <i>",
"      Health Information for International Travel",
"     </i>",
"     (&ldquo;The Yellow Book&rdquo;) categorizes the following areas of risk (CDC, 2012):",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;\">",
"     - Low-risk countries include the United States, Canada, Australia, New Zealand, Japan, and countries in Northern and Western Europe.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;\">",
"     -	Intermediate-risk countries include those in Eastern Europe, South Africa, and some of the Caribbean islands.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;\">",
"     - High-risk areas include most of Asia, the Middle East, Africa, Mexico, and Central and South America.",
"    </p>",
"   </div>",
"   <div class=\"block ars drugH1Div\" id=\"F3275033\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions Significant",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     All serious adverse reactions related to the administration of the product should be reported to local provincial/territorial health agencies or to the Vaccine Safety Section at Public Health Agency of Canada (1-866-844-0018) and to the Senior Product Safety Officer, Pharmacovigilance Department, Aventis Pasteur Limited, 1755 Steeles Avenue West, Toronto, ON, M2R 3T4, Canada. 1-888-621-1146 (phone) or 416-667-2435 (fax).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;text-align:justify;\">",
"     &lt;1% (Limited to important or life-threatening): Abdominal cramps/discomfort/pain, angioedema, appetite decreased, chills, cough, dehydration, diaphoresis, diarrhea, dizziness, drowsiness, dyspepsia, dyspnea, fainting, fatigue, fever, flatulence, flu-like syndrome, gastroenteritis, headache, hypertension, insomnia, joint pain, lymphadenitis, malaise, nausea, pain, paresthesia, pruritus, rash, rhinitis, shivering, sore throat, sputum increased, taste disturbance, urticaria, vomiting, weakness",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F3275028\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Hypersensitivity to any component of the formulation or packaging; acute illness (excluding minor illnesses such as a mild upper respiratory tract infection)",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F3275029\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings/Precautions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concerns related to adverse effects:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hypersensitivity reactions: Immediate treatment (including epinephrine 1:1000) for anaphylactoid and/or hypersensitivity reactions should be available during vaccine administration.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Disease-related concerns:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Cholera infection: Vaccine has not been shown to protect against cholera caused by",
"     <i>",
"      V. cholerae",
"     </i>",
"     serogroup O139 or other species of",
"     <i>",
"      Vibrio",
"     </i>",
"     .",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; HIV: Vaccine may be administered to patients with HIV infection. No specific studies have been conducted in this patient population; however, a field study exhibited 84% immunity in a population with ~25% HIV prevalence.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concurrent drug therapy issues:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     &bull; Concurrent drug therapy: Avoid oral administration of other medications (including oral vaccines) for 1 hour before and 1 hour after vaccine administration.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     &bull; Vaccines: In order to maximize vaccination rates, the Canadian Immunization Guide recommends simultaneous administration of all age-appropriate vaccines (live or inactivated) for which a person is eligible at a single clinic visit, unless contraindications exist.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Special populations:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Altered immunocompetence: Use with caution in severely immunocompromised patients (eg, patients receiving chemo/radiation therapy or other immunosuppressive therapy [including high-dose corticosteroids]); may have a reduced response to vaccination.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Dosage form specific issues:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Formaldehyde: Some dosage forms may contain trace amounts of formaldehyde.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Other warnings/precautions:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Appropriate use: Cholera vaccination: The World Health Organization (WHO) recommends vaccination, in conjunction with other preventative and control strategies (eg, provision of safe water and sanitation efforts), in endemic areas (eg, south and southeast Asia and Africa) and in areas at risk for outbreaks. Vaccination should be targeted at high-risk populations (eg, children) when resources are limited. Reactive vaccination may be considered to control the spread of current outbreaks. In addition, the WHO recommends vaccination for travelers who are at an increased risk for the disease (eg, emergency relief and health workers in refugee situations) (WHO, 2010). The Public Health Agency of Canada currently includes cholera vaccination on its list of recommended vaccines for Canadian travelers. Currently, the U.S Center for Disease Control (CDC) does not recommend oral cholera vaccination for most U.S. travelers due to the low risk of cholera to travelers and the brief and incomplete immunity the vaccines confer (CDC, 2009).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Effective immunity: Vaccination may not result in effective immunity in all patients. Response depends upon multiple factors (eg, type of vaccine, age of patient) and may be improved by administering the vaccine at the recommended dose, route, and interval. Vaccines may not be effective if administered during periods of altered immune competence (CDC, 2011).",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F13300162\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     None known.",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F3275037\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Belimumab: May diminish the therapeutic effect of Vaccines (Inactivated).",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Fingolimod: May diminish the therapeutic effect of Vaccines (Inactivated).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Immunosuppressants: May diminish the therapeutic effect of Vaccines (Inactivated).",
"     <b>",
"      Exceptions:",
"     </b>",
"     Cytarabine (Liposomal).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block foi drugH1Div\" id=\"F3275038\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Ethanol/Nutrition/Herb Interactions",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Food: May affect efficacy of vaccine. Avoid food 1 hour before and 1 hour following vaccine administration.",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F3275024\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Safety and efficacy in pregnant women have not been established; the vaccine is not recommended for use during pregnancy.  However, since the vaccine is given orally in an inactivated form, acts locally in the gut, and does not replicate, it may not (in theory) cause a risk to the fetus. Use should only be considered if the potential benefit to the mother outweighs the potential risk to the fetus.",
"    </p>",
"   </div>",
"   <div class=\"block brc drugH1Div\" id=\"F3275027\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Breast-Feeding Considerations",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     The manufacturer states that the vaccine may be given to lactating women.",
"    </p>",
"   </div>",
"   <div class=\"block dic drugH1Div\" id=\"F3276395\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dietary Considerations",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Food may affect efficacy of vaccine; avoid 1 hour before and 1 hour following vaccine administration.",
"    </p>",
"   </div>",
"   <div class=\"list fbnlist drugH1Div drugBrandNames\" id=\"F4301379\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     International Brand Names",
"    </span>",
"    <ul>",
"     <li>",
"      Dukoral&reg; (CA)",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F10204253\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Contains killed",
"     <i>",
"      V. cholerae",
"     </i>",
"     O1 bacteria and recombinant cholera toxin B subunit (CTB); the toxin of enterotoxigenic",
"     <i>",
"      E. coli",
"     </i>",
"     (ETEC) is structurally, functionally, and immunologically similar to CTB and is neutralized by antibodies against CTB.  Vaccine administration induces immunity and an IgA antitoxic and antibacterial response locally within the gastrointestinal tract; immunity is specific to",
"     <i>",
"      V. cholerae",
"     </i>",
"     O1 (classical and El Tor biotypes; Inaba and Ogawa serotypes) and ETEC.",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F3275042\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics/Kinetics",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Onset of action: ETEC diarrhea and cholera immunity: ~1 week after primary immunization",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Duration: ETEC immunity: 3 months after primary immunization; Cholera immunity: Children 2-6 years of age: 6 months after primary immunization; Children &ge;6 years and Adults: 2 years after primary immunization",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      &ldquo;Canadian Immunization Guide, Seventh Edition, 2006,&rdquo; Ottawa, ONT: Minister of Public Works and Government Services Canada, Public Health Agency of Canada, National Advisory Committee on Immunization, 2006. Available at file://www.phac-aspc.gc.ca/publicat/cig-gci/index.html",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Centers for Disease Control and Prevention (CDC), &ldquo;CDC Health Information for International Travel 2012,&rdquo; Atlanta: U.S. Department of Health and Human Services, Public Health Service, 2012. Available at",
"      <a href=\"file://wwwnc.cdc.gov/travel/yellowbook/2012/chapter-3-infectious-diseases-related-to-travel/cholera.htm\" target=\"_blank\">",
"       file://wwwnc.cdc.gov/travel/yellowbook/2012/chapter-3-infectious-diseases-related-to-travel/cholera.htm",
"      </a>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Centers for Disease Control and Prevention (CDC), &ldquo;Recommendations of the Advisory Committee on Immunization Practices (ACIP): General Recommendations on Immunization,&rdquo;",
"      <i>",
"       MMWR Recomm Rep",
"      </i>",
"      , 2011, 60(2):1-64.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?15/10/15525/abstract-text/21293327/pubmed\" id=\"21293327\" target=\"_blank\">",
"        21293327",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Prymula R, Siegrist CA, Chlibek R, et al, &ldquo;Effect of Prophylactic Paracetamol Administration at Time of Vaccination on Febrile Reactions and Antibody Responses in Children: Two Open-Label, Randomised Controlled Trials,&rdquo;",
"      <i>",
"       Lancet",
"      </i>",
"      , 2009, 374(9698):1339-50.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?15/10/15525/abstract-text/19837254/pubmed\" id=\"19837254\" target=\"_blank\">",
"        19837254",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Steering Committee on Quality Improvement and Management, Subcommittee on Febrile Seizures American Academy of Pediatrics, &ldquo;Febrile seizures: Clinical Practice Guideline for the Long-Term Management of the Child With Simple Febrile Seizures,&rdquo;",
"      <i>",
"       Pediatrics",
"      </i>",
"      , 2008,  121(6):1281-6.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?15/10/15525/abstract-text/18519501/pubmed\" id=\"18519501\" target=\"_blank\">",
"        18519501",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      World Health Organization, &ldquo;Cholera Vaccines: WHO Position Paper,&rdquo;",
"      <i>",
"       Wkly Epidemiol Rec",
"      </i>",
"      , 2010, 85(13):117-28.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?15/10/15525/abstract-text/20349546/pubmed\" id=\"20349546\" target=\"_blank\">",
"        20349546",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      World Health Organization, &ldquo;International Health and Travel,&rdquo; Geneva, Switzerland, 2011. Available at file://www.who.int/ith/chapters/en/index.html",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 9489 Version 30.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1004-115.25.216.6-8C22B84DCE-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f15_10_15525=[""].join("\n");
var outline_f15_10_15525=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F3274459\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F3275023\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F6131824\">",
"      Dosing: Adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F6131823\">",
"      Dosing: Pediatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F3275045\">",
"      Dosing: Geriatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5951005\">",
"      Dosage Forms: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F11234362\">",
"      Product Availability",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F3275046\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F3274761\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F3275033\">",
"      Adverse Reactions Significant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F3275028\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F3275029\">",
"      Warnings/Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13300162\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F3275037\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F3275038\">",
"      Ethanol/Nutrition/Herb Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F3275024\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F3275027\">",
"      Breast-Feeding Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F3276395\">",
"      Dietary Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F4301379\">",
"      International Brand Names",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10204253\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F3275042\">",
"      Pharmacodynamics/Kinetics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/9489\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/9489|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?1/33/1556?source=related_link\">",
"      Travelers' diarrhea and cholera vaccine: Patient drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f15_10_15526="Fibrosing mediastinitis";
var content_f15_10_15526=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Fibrosing mediastinitis",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?15/10/15526/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?15/10/15526/contributors\">",
"     Steven E Weinberger, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?15/10/15526/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?15/10/15526/contributors\">",
"     Kevin R Flaherty, MD, MS",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?15/10/15526/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?15/10/15526/contributors\">",
"     Geraldine Finlay, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?15/10/15526/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Nov 2, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Fibrosing mediastinitis, also known as sclerosing mediastinitis or mediastinal fibrosis, is a disorder characterized by an excessive fibrotic reaction in the mediastinum. It can result in compromise of airways, great vessels, and other mediastinal structures, with morbidity directly related to the location and extent of fibrosis. Fibrosing mediastinitis is usually a sequel of histoplasmosis [",
"    <a class=\"abstract\" href=\"UTD.htm?15/10/15526/abstract/1,2\">",
"     1,2",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The etiology, natural history, clinical presentation, diagnosis, treatment, and outcome of fibrosing mediastinitis are reviewed here. The presentation and treatment of pulmonary histoplasmosis are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?41/24/42376?source=see_link\">",
"     \"Pathogenesis and clinical features of pulmonary histoplasmosis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?21/23/21881?source=see_link\">",
"     \"Diagnosis and treatment of pulmonary histoplasmosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     ETIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Fibrosing mediastinitis usually results from an excessive host response to a prior infection that involved the mediastinal lymph nodes.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H141984\">",
"    <span class=\"h2\">",
"     Histoplasmosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;The vast majority of cases of fibrosing mediastinitis are thought to be sequelae of infection with Histoplasma capsulatum, a dimorphic fungus that is found commonly in the southeastern, mid-Atlantic, and central United States. Infection with H. capsulatum is subclinical in the vast majority of patients. It begins as an asymptomatic pulmonary infection and disseminates to the mediastinal lymph nodes and other reticuloendothelial organs before specific cell-mediated immunity develops and contains the fungus. Depending upon the inoculum and the extent of host response, the involved mediastinal lymph nodes can enlarge and coalesce into an inflamed caseous mass referred to as a mediastinal granuloma, or can lead to a sclerosing process called fibrosing mediastinitis:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Mediastinal granuloma &ndash; Mediastinal granuloma is more common (comprises 5 to 10 percent of mediastinal masses in most surgical series [",
"      <a class=\"abstract\" href=\"UTD.htm?15/10/15526/abstract/3\">",
"       3",
"      </a>",
"      ]) and more benign than fibrosing mediastinitis. It usually presents as a mediastinal mass that is discovered either incidentally or because it compresses compliant mediastinal structures such as the superior vena cava (SVC) or esophagus. The mediastinal granuloma consists of encapsulated caseous lymph nodes that are easily removed surgically.",
"     </li>",
"     <li>",
"      Fibrosing mediastinitis &ndash; The events that lead to the development and perpetuation of fibrosing mediastinitis are incompletely understood. It is believed that fibrosing mediastinitis results from the leakage of fungal antigens from lymph nodes into the mediastinal space, leading to a hypersensitivity reaction followed by an exuberant fibrotic response [",
"      <a class=\"abstract\" href=\"UTD.htm?15/10/15526/abstract/1\">",
"       1",
"      </a>",
"      ]. Fibroblasts adjacent to evolving granulomata are stimulated and proliferate, leading to fibrosis, entrapment, and invasion of adjacent normal structures. The resulting tissue pathology consists of caseous central foci surrounded by mature, concentrically deposited acellular collagen [",
"      <a class=\"abstract\" href=\"UTD.htm?15/10/15526/abstract/1\">",
"       1",
"      </a>",
"      ]. Fibrosing mediastinitis is not believed to reflect extranodal infection because the organism cannot typically be cultured from biopsy specimens [",
"      <a class=\"abstract\" href=\"UTD.htm?15/10/15526/abstract/1,3\">",
"       1,3",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?21/23/21881?source=see_link\">",
"       \"Diagnosis and treatment of pulmonary histoplasmosis\"",
"      </a>",
"      .)",
"      <br/>",
"      <br/>",
"      It is unknown why only a minority of patients infected with H. capsulatum develop fibrosing mediastinitis. However, genetic influences on the immune response may play a role. This was suggested by a case-control study that included 19 consecutive patients with fibrosing mediastinitis and 21,086 cadaveric kidney donors serving as controls [",
"      <a class=\"abstract\" href=\"UTD.htm?15/10/15526/abstract/4\">",
"       4",
"      </a>",
"      ]. The study found that the relative risk of fibrosing mediastinitis was 3.3 among persons with the HLA-A2 antigen. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?23/38/24167?source=see_link\">",
"       \"Human leukocyte antigens (HLA): A roadmap\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Some investigators contend that mediastinal granuloma and fibrosing mediastinitis are separate disease processes, with fibrosing mediastinitis occurring idiosyncratically in people predisposed to excessive fibrogenesis in response to antigenic stimuli [",
"    <a class=\"abstract\" href=\"UTD.htm?15/10/15526/abstract/1\">",
"     1",
"    </a>",
"    ]. Others believe that fibrosing mediastinitis is due to the rupture of mediastinal granulomas into the mediastinal space, leading to a fibrotic host response. In support of the latter hypothesis, one series of 31 patients with mediastinal granuloma found that 11 patients (35 percent) developed fibrosing mediastinitis over a two year period [",
"    <a class=\"abstract\" href=\"UTD.htm?15/10/15526/abstract/5\">",
"     5",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Other precipitants",
"    </span>",
"    &nbsp;&mdash;&nbsp;Tuberculosis is often included as a potential precipitant of fibrosing mediastinitis, but it rarely stimulates an invasive fibrotic reaction similar to that seen following histoplasmosis. However, mediastinal granulomas due to tuberculosis are well described [",
"    <a class=\"abstract\" href=\"UTD.htm?15/10/15526/abstract/3,6\">",
"     3,6",
"    </a>",
"    ]. Case reports have also described the development of fibrosing mediastinitis secondary to mediastinal radiation [",
"    <a class=\"abstract\" href=\"UTD.htm?15/10/15526/abstract/7\">",
"     7",
"    </a>",
"    ] or infection with Aspergillus [",
"    <a class=\"abstract\" href=\"UTD.htm?15/10/15526/abstract/8-10\">",
"     8-10",
"    </a>",
"    ], Wuchereria bancrofti [",
"    <a class=\"abstract\" href=\"UTD.htm?15/10/15526/abstract/11\">",
"     11",
"    </a>",
"    ], or Blastomyces [",
"    <a class=\"abstract\" href=\"UTD.htm?15/10/15526/abstract/12\">",
"     12",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    An idiopathic form of fibrosing mediastinitis has also been described [",
"    <a class=\"abstract\" href=\"UTD.htm?15/10/15526/abstract/13,14\">",
"     13,14",
"    </a>",
"    ]. Unlike patients with fibrosing mediastinitis believed to be due to histoplasmosis, patients with the idiopathic form lack calcification on imaging studies. The idiopathic form of fibrosing mediastinitis may be autoimmune and can in some cases be associated with fibrosing processes in other sites, such as retroperitoneal fibrosis, orbital pseudotumor, and Riedel's (fibrous) thyroiditis [",
"    <a class=\"abstract\" href=\"UTD.htm?15/10/15526/abstract/13,15\">",
"     13,15",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h1\">",
"     EPIDEMIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Precise data regarding the incidence of fibrosing mediastinitis are not available, but the condition appears to be rare. While it has been estimated that over 500,000 people per year in the United States are infected with Histoplasma and over 80 percent of inhabitants of endemic regions have a positive Histoplasma skin test [",
"    <a class=\"abstract\" href=\"UTD.htm?15/10/15526/abstract/16\">",
"     16",
"    </a>",
"    ], less than 1 percent of patients with histoplasmosis develop fibrosing mediastinitis (",
"    <a class=\"graphic graphic_figure graphicRef75641 \" href=\"UTD.htm?18/62/19430\">",
"     figure 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?15/10/15526/abstract/17\">",
"     17",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The largest series of fibrosing mediastinitis was from an institution in an endemic region and it described only 94 patients over a nine year period [",
"    <a class=\"abstract\" href=\"UTD.htm?15/10/15526/abstract/18\">",
"     18",
"    </a>",
"    ]. The average age at diagnosis was 33 years, 81 percent of patients were white, and there was a slight male preponderance. Similar demographics have been reported by other series [",
"    <a class=\"abstract\" href=\"UTD.htm?15/10/15526/abstract/3\">",
"     3",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H141910\">",
"    <span class=\"h1\">",
"     NATURAL HISTORY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Fibrosing mediastinitis is an insidious, progressive disease with a variable natural history. One series of 23 patients found that 10 patients (43 percent) had improvements in symptoms, 11 patients (48 percent) had no significant change, and two patients (9 percent) had progressive disease [",
"    <a class=\"abstract\" href=\"UTD.htm?15/10/15526/abstract/13\">",
"     13",
"    </a>",
"    ]. In contrast, a second series of 71 patients noted a far worse prognosis, with 21 patients (30 percent) dying during follow-up [",
"    <a class=\"abstract\" href=\"UTD.htm?15/10/15526/abstract/3\">",
"     3",
"    </a>",
"    ]. The mean interval between the development of symptoms and death was less than six years in these patients, and death resulted most frequently from cor pulmonale or relentless respiratory compromise due to recurrent infection, bronchial obstruction, or hemoptysis. Disease involving subcarinal structures conferred a worse prognosis because bilateral lung involvement was more common in these patients.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h1\">",
"     CLINICAL PRESENTATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The signs and symptoms of fibrosing mediastinitis depend upon which structures of the mediastinum are involved and the degree to which those structures are compromised. Typical complications result from compromise of the airways, heart and great vessels, or esophagus:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Airway compression can lead to postobstructive pneumonia or atelectasis, while bronchial erosion by calcific lymph nodes can lead to broncholithiasis. These complications are most common in the right upper lobe [",
"      <a class=\"abstract\" href=\"UTD.htm?15/10/15526/abstract/16\">",
"       16",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Heart and great vessel involvement can cause pulmonary artery",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      pulmonary vein obstruction, constrictive pericarditis, or superior vena cava (SVC) syndrome (",
"      <a class=\"graphic graphic_diagnosticimage graphicRef50957 \" href=\"UTD.htm?7/24/7567\">",
"       image 1",
"      </a>",
"      ). Not all patients with SVC compromise become symptomatic. SVC obstruction due to fibrosing mediastinitis typically develops slowly over a period of years, allowing the formation of an extensive collateral circulation that may be adequate to prevent both stasis and elevated pressure in the tributaries of the SVC [",
"      <a class=\"abstract\" href=\"UTD.htm?15/10/15526/abstract/3,18\">",
"       3,18",
"      </a>",
"      ]. SVC obstruction is a less common presentation of fibrosing mediastinitis than tracheobronchial narrowing [",
"      <a class=\"abstract\" href=\"UTD.htm?15/10/15526/abstract/3,19\">",
"       3,19",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Esophageal compression can lead to dysphagia",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      odynophagia. Tracheoesophageal fistula formation also may be seen.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Hemoptysis may also occur in fibrosing mediastinitis. It is a consequence of any of four possible mechanisms. Fibrous tissue can invade a bronchus and extend into the mucosa, leading to a friable intraluminal lesion. Airway obstruction may result in a postobstructive necrotizing pneumonia. Obstruction of pulmonary venous return may produce pulmonary venous hypertension (pseudo-mitral stenosis). And, finally, obstruction of pulmonary arteries can lead to extensive functional anastomoses between the intercostal or bronchial arteries and the pulmonary arteries.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h1\">",
"     DIAGNOSIS",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2489539\">",
"    <span class=\"h2\">",
"     General approach",
"    </span>",
"    &nbsp;&mdash;&nbsp;The average interval from initial symptoms to diagnosis is five years for women and 2.2 years for men [",
"    <a class=\"abstract\" href=\"UTD.htm?15/10/15526/abstract/1\">",
"     1",
"    </a>",
"    ]. Imaging studies are necessary to confirm the diagnosis of an infiltrative process in the mediastinum, to help exclude malignancy, and to assess the integrity of mediastinal structures. We feel that a biopsy should not be done if the patient has a typical clinical and radiologic presentation with associated calcification. Biopsies are difficult because of the dense fibrosis and calcification and may be hazardous as a result of bleeding from engorged collateral vessels. Serologic studies are of limited benefit because they frequently fail to establish the diagnosis.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2489546\">",
"    <span class=\"h2\">",
"     Diagnostic studies",
"    </span>",
"    &nbsp;&mdash;&nbsp;Diagnostic studies performed on patients with suspected fibrosing mediastinitis may include chest radiography, computed tomography (CT), CT angiography,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    magnetic resonance imaging (MRI).",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Chest radiographs &ndash; The findings of fibrosing mediastinitis on chest radiographs are nonspecific, with common findings including hilar or mediastinal adenopathy, lobar or segmental consolidation or atelectasis, a unilateral small pulmonary artery, septal lines, pleural effusion, or cardiomegaly. The extent of disease is often underestimated, with the chest radiograph appearing relatively normal even in patients with extensive disease (ie, disease causing major central airway obstruction and vascular occlusion) [",
"      <a class=\"abstract\" href=\"UTD.htm?15/10/15526/abstract/3,13\">",
"       3,13",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Computed tomography &ndash; CT can reveal an infiltrative mediastinal process that obliterates fat planes, with or without a discrete mass [",
"      <a class=\"abstract\" href=\"UTD.htm?15/10/15526/abstract/3,20,21\">",
"       3,20,21",
"      </a>",
"      ]. It often demonstrates calcifications within the mediastinal process, which are not evident on the chest radiograph but suggest nonmalignant disease. In one series, 86 percent of patients had calcification on their CT scan, approximately 50 percent of which were not visible on the chest radiograph alone [",
"      <a class=\"abstract\" href=\"UTD.htm?15/10/15526/abstract/22\">",
"       22",
"      </a>",
"      ]. CT may also reveal evidence of prior Histoplasma infection, such as calcified lymph nodes and splenic calcifications.",
"     </li>",
"     <li>",
"      CT angiography &ndash; CT angiography is useful in assessing the degree of vascular occlusion and demonstrating collateral blood flow around obstructed vessels [",
"      <a class=\"abstract\" href=\"UTD.htm?15/10/15526/abstract/19,21\">",
"       19,21",
"      </a>",
"      ]. Increased lung attenuation, thickened interlobular septa, and peribronchial cuffing are usually seen with pulmonary venous obstruction. When these findings are combined with an area of tracheobronchial narrowing, the diagnosis of fibrosing mediastinitis is favored over lymphoma [",
"      <a class=\"abstract\" href=\"UTD.htm?15/10/15526/abstract/22\">",
"       22",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Magnetic resonance imaging &ndash; MRI of fibrosing mediastinitis typically reveals a mass of heterogeneous signal intensity [",
"      <a class=\"abstract\" href=\"UTD.htm?15/10/15526/abstract/23,24\">",
"       23,24",
"      </a>",
"      ]. Decreased signal intensity on T2-weighted images is suggestive of fibrosis. MRI may be superior at defining the extent of disease (particularly the degree of vascular involvement) compared to CT, but is less useful for demonstrating intralesional calcifications [",
"      <a class=\"abstract\" href=\"UTD.htm?15/10/15526/abstract/21,24\">",
"       21,24",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Generally speaking, invasive procedures may be hazardous because of pulmonary hypertension",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    the potential for pulmonary hemorrhage. This was demonstrated by a case series of 71 patients, which reported two deaths from hemorrhage complicating bronchoscopy and two deaths complicating cardiac catheterization [",
"    <a class=\"abstract\" href=\"UTD.htm?15/10/15526/abstract/3\">",
"     3",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h1\">",
"     TREATMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;There is no curative therapy for fibrosing mediastinitis. Antifungal agents are generally ineffective, although several case reports have suggested a potential benefit [",
"    <a class=\"abstract\" href=\"UTD.htm?15/10/15526/abstract/3,18,20,25\">",
"     3,18,20,25",
"    </a>",
"    ]. Glucocorticoids also do not appear to be beneficial, although controlled trials have not been performed [",
"    <a class=\"abstract\" href=\"UTD.htm?15/10/15526/abstract/3,26\">",
"     3,26",
"    </a>",
"    ]. A possible exception is autoimmune fibrosing mediastinitis, which may respond more favorably to glucocorticoid therapy, although these cases are difficult to identify prospectively [",
"    <a class=\"abstract\" href=\"UTD.htm?15/10/15526/abstract/13\">",
"     13",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Surgery has been performed to palliate symptoms by relieving airway, vascular, and esophageal obstruction, as well as managing tracheoesophageal fistulas [",
"    <a class=\"abstract\" href=\"UTD.htm?15/10/15526/abstract/18,26\">",
"     18,26",
"    </a>",
"    ]. However, its success has been variable. Extensive fibrosis, calcification, and collateral vessels limit the benefits of surgery and are responsible for substantial morbidity and mortality [",
"    <a class=\"abstract\" href=\"UTD.htm?15/10/15526/abstract/3,18,26\">",
"     3,18,26",
"    </a>",
"    ]. This was illustrated by a series of 18 patients with fibrosing mediastinitis secondary to histoplasmosis, which reported three deaths (19 percent) during the early postoperative period [",
"    <a class=\"abstract\" href=\"UTD.htm?15/10/15526/abstract/26\">",
"     26",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Resection of the stenotic airway",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      the distal lung parenchyma is usually required in cases of fibrosing mediastinitis complicated by recurrent postobstructive infection or poor gas exchange secondary to shunt physiology. Sleeve lobectomy, carinal resection, or pneumonectomy may be required [",
"      <a class=\"abstract\" href=\"UTD.htm?15/10/15526/abstract/26\">",
"       26",
"      </a>",
"      ]. Airway surgery is technically difficult and associated with significant mortality; despite this, early surgical intervention is generally advocated for patients with airway involvement because fibrosis is progressive and delay may lead to more complicated surgery [",
"      <a class=\"abstract\" href=\"UTD.htm?15/10/15526/abstract/26\">",
"       26",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Superior vena cava (SVC) bypass surgery with a spiral vein graft has been used for symptomatic relief in some patients with SVC obstruction. The saphenous vein is harvested and then opened longitudinally through its entire length. It is then wrapped around a stent in a spiral manner and sutured together to create a bioprosthesis of the desired length and diameter. The stent is then removed and the graft is placed in the mediastinum anterior to the aorta. The largest series of patients treated in this fashion included four individuals with SVC syndrome due to fibrosing mediastinitis; all were symptom-free two years after the operation [",
"      <a class=\"abstract\" href=\"UTD.htm?15/10/15526/abstract/27,28\">",
"       27,28",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Bronchoscopically placed airway stents and percutaneously placed vascular stents have been used to treat airway obstruction and SVC obstruction, respectively [",
"    <a class=\"abstract\" href=\"UTD.htm?15/10/15526/abstract/29,30\">",
"     29,30",
"    </a>",
"    ]. While such stents are effective in the short-term, there is a frequent need for reintervention. Thus, surgery is generally preferred, although stenting is a reasonable primary intervention for selected patients. A series of four patients with fibrosing mediastinitis described the use of pulmonary artery and pulmonary vein stents to relieve vascular obstruction [",
"    <a class=\"abstract\" href=\"UTD.htm?15/10/15526/abstract/29\">",
"     29",
"    </a>",
"    ]. All patients derived hemodynamic and symptomatic improvement following the procedure, and the only reported complication was self-limited pulmonary hemorrhage in one patient.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H141956\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Fibrosing mediastinitis is a rare disorder characterized by an excessive fibrotic reaction in the mediastinum. (See",
"      <a class=\"local\" href=\"#H1\">",
"       'Introduction'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H6\">",
"       'Epidemiology'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Fibrosing mediastinitis usually results from an excessive host response to a prior infection that involved the mediastinal lymph nodes. The vast majority of cases are thought to be sequelae of Histoplasma capsulatum infection. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Etiology'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Fibrosing mediastinitis is an insidious, progressive disease with a variable natural history. Morbidity is directly related to the location and extent of the fibrosis. (See",
"      <a class=\"local\" href=\"#H141910\">",
"       'Natural history'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The signs and symptoms of fibrosing mediastinitis depend upon the structures of the mediastinum that are involved and the extent to which they are compromised. Typical complications result from compression and obstruction of the airways, heart and great vessels, or esophagus. Hemoptysis may also occur. (See",
"      <a class=\"local\" href=\"#H7\">",
"       'Clinical presentation'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Imaging studies are necessary to confirm the presence of an infiltrative process in the mediastinum, to help exclude malignancy, and to assess the integrity of mediastinal structures. A biopsy should not be done if the patient has a typical clinical and radiologic presentation with associated calcification. Biopsies may also be hazardous because of a significant risk of bleeding. (See",
"      <a class=\"local\" href=\"#H12\">",
"       'Diagnosis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      There is no curative therapy for fibrosing mediastinitis. Surgery has been performed to palliate symptoms by relieving airway, vascular, and esophageal obstruction, but its success has been variable. Bronchoscopically placed airway stents and percutaneously placed vascular stents may be reasonable alternatives to surgery for selected patients. (See",
"      <a class=\"local\" href=\"#H18\">",
"       'Treatment'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/10/15526/abstract/1\">",
"      Goodwin RA, Nickell JA, Des Prez RM. Mediastinal fibrosis complicating healed primary histoplasmosis and tuberculosis. Medicine (Baltimore) 1972; 51:227.",
"     </a>",
"    </li>",
"    <li>",
"     file://www.idsociety.org/Content.aspx?id=9088 (Accessed on December 12, 2011).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/10/15526/abstract/3\">",
"      Loyd JE, Tillman BF, Atkinson JB, Des Prez RM. Mediastinal fibrosis complicating histoplasmosis. Medicine (Baltimore) 1988; 67:295.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/10/15526/abstract/4\">",
"      Peebles RS, Carpenter CT, Dupont WD, Loyd JE. Mediastinal fibrosis is associated with human leukocyte antigen-A2. Chest 2000; 117:482.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/10/15526/abstract/5\">",
"      Dines DE, Payne WS, Bernatz PE, Pairolero PC. Mediastinal granuloma and fibrosing mediastinitis. Chest 1979; 75:320.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/10/15526/abstract/6\">",
"      SALYER JM, HARRISON HN, WINN DF Jr, TAYLOR RR. Chronic fibrous mediastinitis and superior vena caval obstruction due to histoplasmosis. Dis Chest 1959; 35:364.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/10/15526/abstract/7\">",
"      Morrone N, Gama e Silva Volpe VL, Dourado AM, et al. Bilateral pleural effusion due to mediastinal fibrosis induced by radiotherapy. Chest 1993; 104:1276.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/10/15526/abstract/8\">",
"      Puri S, Factor SM, Farmer P. Sclerosing mediastinitis. Presumed to be due to primary aspergillosis. N Y State J Med 1977; 77:1774.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/10/15526/abstract/9\">",
"      Ahmad M, Weinstein AJ, Hughes JA, Cosgrove DE. Granulomatous mediastinitis due to Aspergillus flavus in a nonimmunosuppressed patient. Am J Med 1981; 70:887.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/10/15526/abstract/10\">",
"      Schowengerdt CG, Suyemoto R, Main FB. Granulomatous and fibrous mediastinitis. A review and analysis of 180 cases. J Thorac Cardiovasc Surg 1969; 57:365.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/10/15526/abstract/11\">",
"      Gilbert HM, Hartman BJ. Short report: a case of fibrosing mediastinitis caused by Wuchereria bancrofti. Am J Trop Med Hyg 1996; 54:596.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/10/15526/abstract/12\">",
"      Lagerstrom CF, Mitchell HG, Graham BS, Hammon JW Jr. Chronic fibrosing mediastinitis and superior vena caval obstruction from blastomycosis. Ann Thorac Surg 1992; 54:764.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/10/15526/abstract/13\">",
"      Sherrick AD, Brown LR, Harms GF, Myers JL. The radiographic findings of fibrosing mediastinitis. Chest 1994; 106:484.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/10/15526/abstract/14\">",
"      Worrell JA, Donnelly EF, Martin JB, et al. Computed tomography and the idiopathic form of proliferative fibrosing mediastinitis. J Thorac Imaging 2007; 22:235.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/10/15526/abstract/15\">",
"      Mitchell IM, Saunders NR, Maher O, et al. Surgical treatment of idiopathic mediastinal fibrosis: report of five cases. Thorax 1986; 41:210.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/10/15526/abstract/16\">",
"      Wheat LJ, Slama TG, Eitzen HE, et al. A large urban outbreak of histoplasmosis: clinical features. Ann Intern Med 1981; 94:331.",
"     </a>",
"    </li>",
"    <li>",
"     Wheat LJ. Histoplasmosis susceptibility in humans. In: Fungal Disease, Jacobs PH, Nall L (Eds), Marcel Dekker, New York 1997. p.239.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/10/15526/abstract/18\">",
"      Garrett HE Jr, Roper CL. Surgical intervention in histoplasmosis. Ann Thorac Surg 1986; 42:711.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/10/15526/abstract/19\">",
"      Feigin DS, Eggleston JC, Siegelman SS. The multiple roentgen manifestations of sclerosing mediastinitis. Johns Hopkins Med J 1979; 144:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/10/15526/abstract/20\">",
"      Peikert T, Colby TV, Midthun DE, et al. Fibrosing mediastinitis: clinical presentation, therapeutic outcomes, and adaptive immune response. Medicine (Baltimore) 2011; 90:412.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/10/15526/abstract/21\">",
"      McNeeley MF, Chung JH, Bhalla S, Godwin JD. Imaging of granulomatous fibrosing mediastinitis. AJR Am J Roentgenol 2012; 199:319.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/10/15526/abstract/22\">",
"      Weinstein JB, Aronberg DJ, Sagel SS. CT of fibrosing mediastinitis: findings and their utility. AJR Am J Roentgenol 1983; 141:247.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/10/15526/abstract/23\">",
"      Farmer DW, Moore E, Amparo E, et al. Calcific fibrosing mediastinitis: demonstration of pulmonary vascular obstruction by magnetic resonance imaging. AJR Am J Roentgenol 1984; 143:1189.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/10/15526/abstract/24\">",
"      Rholl KS, Levitt RG, Glazer HS. Magnetic resonance imaging of fibrosing mediastinitis. AJR Am J Roentgenol 1985; 145:255.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/10/15526/abstract/25\">",
"      Urschel HC Jr, Razzuk MA, Netto GJ, et al. Sclerosing mediastinitis: improved management with histoplasmosis titer and ketoconazole. Ann Thorac Surg 1990; 50:215.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/10/15526/abstract/26\">",
"      Mathisen DJ, Grillo HC. Clinical manifestation of mediastinal fibrosis and histoplasmosis. Ann Thorac Surg 1992; 54:1053.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/10/15526/abstract/27\">",
"      Doty DB. Bypass of superior vena cava: Six years' experience with spiral vein graft for obstruction of superior vena cava due to benign and malignant disease. J Thorac Cardiovasc Surg 1982; 83:326.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/10/15526/abstract/28\">",
"      Doty JR, Flores JH, Doty DB. Superior vena cava obstruction: bypass using spiral vein graft. Ann Thorac Surg 1999; 67:1111.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/10/15526/abstract/29\">",
"      Qanadli SD, El Hajjam M, Mignon F, et al. Subacute and chronic benign superior vena cava obstructions: endovascular treatment with self-expanding metallic stents. AJR Am J Roentgenol 1999; 173:159.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/10/15526/abstract/30\">",
"      Kalra M, Gloviczki P, Andrews JC, et al. Open surgical and endovascular treatment of superior vena cava syndrome caused by nonmalignant disease. J Vasc Surg 2003; 38:215.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 4397 Version 8.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0604-203.80.222.8-3384FBAA07-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f15_10_15526=[""].join("\n");
var outline_f15_10_15526=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H141956\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      ETIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H141984\">",
"      Histoplasmosis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Other precipitants",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      EPIDEMIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H141910\">",
"      NATURAL HISTORY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      CLINICAL PRESENTATION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H2489539\">",
"      General approach",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H2489546\">",
"      Diagnostic studies",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      TREATMENT",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H141956\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"PULM/4397\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PULM/4397|DiagnosticImage\">",
"      <a href=\"#\" title=\"DIAGNOSTIC IMAGES\">",
"       DIAGNOSTIC IMAGES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?7/24/7567\" title=\"diagnostic image 1\">",
"      Fibrosing mediastinitis PAgram",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PULM/4397|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?18/62/19430\" title=\"figure 1\">",
"      Histoplasma clinical syndromes",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?21/23/21881?source=related_link\">",
"      Diagnosis and treatment of pulmonary histoplasmosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?23/38/24167?source=related_link\">",
"      Human leukocyte antigens (HLA): A roadmap",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?41/24/42376?source=related_link\">",
"      Pathogenesis and clinical features of pulmonary histoplasmosis",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f15_10_15527="Cold agglutinin";
var content_f15_10_15527=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=HEME%2F50522&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=3\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=HEME%2F50522&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=3\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic2\" style=\"width: 1040px;\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Red blood cell agglutination due to a cold agglutinin",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 360px; height: 235px; background-image: url(data:image/jpeg;base64,/9j/4AAQSkZJRgABAQAAAQABAAD/2wBDAAYEBQYFBAYGBQYHBwYIChAKCgkJChQODwwQFxQYGBcUFhYaHSUfGhsjHBYWICwgIyYnKSopGR8tMC0oMCUoKSj/2wBDAQcHBwoIChMKChMoGhYaKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCj/wAARCADrAWgDASIAAhEBAxEB/8QAHwAAAQUBAQEBAQEAAAAAAAAAAAECAwQFBgcICQoL/8QAtRAAAgEDAwIEAwUFBAQAAAF9AQIDAAQRBRIhMUEGE1FhByJxFDKBkaEII0KxwRVS0fAkM2JyggkKFhcYGRolJicoKSo0NTY3ODk6Q0RFRkdISUpTVFVWV1hZWmNkZWZnaGlqc3R1dnd4eXqDhIWGh4iJipKTlJWWl5iZmqKjpKWmp6ipqrKztLW2t7i5usLDxMXGx8jJytLT1NXW19jZ2uHi4+Tl5ufo6erx8vP09fb3+Pn6/8QAHwEAAwEBAQEBAQEBAQAAAAAAAAECAwQFBgcICQoL/8QAtREAAgECBAQDBAcFBAQAAQJ3AAECAxEEBSExBhJBUQdhcRMiMoEIFEKRobHBCSMzUvAVYnLRChYkNOEl8RcYGRomJygpKjU2Nzg5OkNERUZHSElKU1RVVldYWVpjZGVmZ2hpanN0dXZ3eHl6goOEhYaHiImKkpOUlZaXmJmaoqOkpaanqKmqsrO0tba3uLm6wsPExcbHyMnK0tPU1dbX2Nna4uPk5ebn6Onq8vP09fb3+Pn6/9oADAMBAAIRAxEAPwDj7/ULm/uTLcvvmbq2OtdN4R0G+v7pJkjdYVIYyEYGAegri41kmmVI1yScYA7mvfvDUDadoVlbzcSIg3j0zzWbXU/S8XWdKCUd2b+mqUhUNwV4H+FaQbKrn0rmB4k0uK4MMl7AJM4IBzit23nSaMSROGVh1XnNJx5dz56tTkneSLgA7HH40mMjnoRwOlIjEYHpSucA+uMCjc5uom4Drkj3p6uDu7ew4Neb+K/Et9LqTafpLmPZw8q9SfQUvhbWdSt9UjtdSleZHOMMfunpxV+zsrna8DLk5769j00Hg49epHFOGM4JHHTNQxnPHGcY9alzyOmPz5qLHnNDh0rJ8Q3D22k3M0W4MqH6jtmtRjjPGc1Tu40uLeSKVdyOpVgfQ00XSspJs8avWLvuclt3+c1VtbJry/SCNQxk+VRnr/hXUan4P1GK6YWSrcxE5Vg4BUfQ1Z8NeFr5NTin1GIQLC27bn5m9MYrS6ve59E8TTULqSOl8NaP/YulC1Vg0pfe7AcEk9B+FM8TeGbDxBCq3askqH5JU6j2x3FdAB945z0/Cq19OILWacglY0ZiO5wCaNb36nixrTdTnT1PGtS+HWuW90y2EcV1b9pBIF/MGtfwZ4EurHWIb3XJrWJYGDrCJQzMR0z6DpXGa14g1TW9TleS5mRWbCRI5VVHpxW74bsmUiWR3c8EsxJ/X0p1E4t3a+7/AIJ701W9nacl8l/wf0O78e62UgWxsZD+8G6SWM9Bn7ufWuIikaJ1O/nqQDV+/eKGQhhuB6nOB+NRw6XPfxb9NVrgZwyDl4z6keh9alvRJGVGEaMLdCGCRZXkZsZHOPc1uWSHb3Y9gD/OuRtZ2hmZZwRk4Ydxg9Pwr0Cy024is4JZYnVZgGXI5pcjW5VdqBf0QtFeQc8k4NTavNJ9vlBJ4Yirej2TSXCSYIRDkk/0q7q2km5YvEQrtjINVseTKtBVdexzUV2yDluAePyrrNHuWnsVZskjIz6iudl0d4C091hIowSSD1psNxeXkOLWUwW6/dSMdB9aHG5VaEa0fdfzOxJBJHHTHNVprVJ+J1SRCeFKZA+ua5a11G907U4re8kaa3kbZ83VM967Fenv9aLNHDUpSota7la0sre1ULbwxxITnaiYBPrT3KxIzvjCAsfUDFTFgATxUM5RgY2Zct8u0tjIPWj1ITcnqeL694hvb3UHkeQ7DwqDooqpY6vcWV6kocqVIbIPp61Z8ZaXNpWqyKVG0jchHG5fWsK2jkuLqOOMb5XYBYwc5Pqa1b1utj6qmoOmuVaH0HYzi5toJQR+8jVxg+o6VheMfDkOv2arK3lzx58uQdvqK3NIgNvp1tA/JRFUn8KszJgdOM1i5W2PmY1HSq3h0PG7H4aS/a86hdxtAO0QOW/TivR7a2S3hSOJAqKAqr6AVovHggYPP6fWonQk5Bx6+9OU3Lc66mKnW+Jldhwe4HJrzLxhpGow31zMInlSdjsdAWAHvXqLjGPQ+tZmq6/ZaUsgnuEEwUkRA8nHStqcmtlcvD1JQleCueLTW08WEnjaMtztYEEVNawF5QFwOc56AD3q7qfiK6v7qSS8jilyTgMvKilg1FRbyRJDGgYD7o/lStaWh7fNLl1R00njC8ntmto1RYQu3cRy2P5VpeFdThhtpjcRJuB5IHWuEsobm4mEdtE8kjNgBRXqml+FYDo0MV4GWfbltp6E9qbVlqcGJ9jRjZ9Tkb66W+8QQG0Xbhwfk5J79BXq8G4RqCfQHPP1rK0jw1YaZKJYIyZf+ejnJA9q2wmBg9KmUlZJHlYvEQqWjDZENzF50exgSr5VvQDBoqZwAc4GT3H+frRQr9DmhUlFe6zzvTPCek6ZcLNb2ymbsznOCPSofGMs0ViscTFTK20sOOOtdLazRzQK8TmRCOD1rO1/TF1KzeAELJklD6HtWK0d2evTqv2idQ4b/hF9OtbL7dczs28ZOOm70rT+G+qu+oXNhvLxbN6ZPTFc/d+GvEjMIBC7RA8EOMHnr14rufAnhY6FbM9w6veTDkjkIPTNXN6NNnXiKkFSalK7Z2g3MFAIAyCflzx6fX3p0i5GM/TFNQgNgnp2p5b5fTHpWSR4L3PJtatbjSNfu5pY2ZJXLI6j1/qK1dG8y71CC/1Jo7S1i5RpSFMh9s9f6V3Nyq7SWVWwCcEZr5w8T6lfanrFw920hIdlVP4UGTgAela35tT3MM3iotbW6n0nb3CSruhdJFPRkOQRXP3XjrR01abR7W5WXVUyoh2tt3/3N2MZrxXSNZv7CBoLe6lSJiCArnGa6TwNb6ZP4ujvr6GU3jPviYHCCT+8Rjk/U1tQjR1dS+2lv1MZ5cqacm72O71vxXc2umwBYFjvZcjBJwB6iuPl8RavAx3XsxdxgjdwR7V1HxB0yW4aC8iUyKnyuBnIA5ziuH1EPMFYRsSBk/X0FTdbxW5thYU3BNJampJp2oDT11RLiTym+YsJDkHNdx4C1OfUtOZbsl5YG2hj1YH1PqK4mHULs6JDpIQsFOMKvzHJzj9a9C8F6M+k6YVmUiedvMcf3cDgf59aiV+X3jHGySpNT3vp6GvPKkEDSynCKpJ9sVxmrahrN/byvpqhIWBGzAJkX05rqvEEEk+k3EcX32UbR6nriuFsPE32GIwtES44x6GhJ2ulc5sJDmi5xV2cPBo851JVghLOZM+Vj5h6iu107S57RHa9/wBHRT/HxVK41FbnVIb26TyVSRX+VfnIB9PX9K9KR7XWNPEihZrWcfxj9PrSlvdndisROCV1ozxbVr1JJ3jjUEKxAPtWp8OpbgeLbYW7EqyskgHQrjn+ldHd/DaB5y1rfvHGTnDpuI+h711XhjwzY+H4mNtukuHGGnfGSPQegpvl6ak18dR9k4x1bRotpVhLci4extnnBB8xohmpri7gtwFmcA9duMmpnYgE4ww5Az1964K6vWa5kMhP3ucnrUqN9zyaFJ137z0R3dtdwTALE2CeNuMVZY8ZrgbS9AcZJyP85rZu/ED23lkwq2VzyTzRy9h1MFJS9w09dtWutMuIEJ3unBFcXourHTv3NwmxxkYIIxXZ6fqEGoW6zQsP9pM/MDUzQRNLueONnPUlQapPTlaClV9lF06iOXs7e41XVI7lo2S2iO7cw+8c9AK6e6uorS2knuH2RRjcWPp/jU+0LjAA54A4ri/iXcvFZWlupPlyEswz1wRQld2HB/WqkYbIpan4/kWR1tbRFXGFLkk/XFcBr+t3V/etKJpVIxg7iMe4qy0W/eTjhcZPPU/pWZNAwd+3Jxt5AHbNCq8ux79DD0qXwo63RfGVpHo1xF4ogW9SGP8Ac+Yu52P9wk9veuDfxrNbag9xpen2loQxKBVLFPxNOvYVMTROAQxDBsnI7YFYrWADhum3jA5pRlFfM2p4enFtpb/d9x7p8JvFd/4mtLttRiH7hlUSjoSc8fWvQDliDj73FcD8ISY/DRttsa7JScKADg9670Hrj6UTS5nZHzOOSVeSirIjZPmGOnXAqFo85JGR6jirWRkD16moJHwpJ+XaDknsKlI54tlCdWEZZfvAHnHI968e16CQ3sz3DEuW5Ldc13mpeONMtb3yVWaXacM6jAzVtBo3iSDzhHHN2JAwwPoa3i3BarQ9bDueH96cXZnjzxB12RxsXzxjkt7Cu98K+BhmK61VycgFYFHT/erSv4PD/hK3+33MPl5fah272LH0H9a6jS7yG+tIbm3O6KRdyn2qmpKPOlo+priMXNwvTTS7lyxsba2z5FvDEeh2IB+FaAXge9VUcA4JqdZcjgHjv7Vi9Tw58zd2S45J79qUDAwP/wBdM3ggAHANPzk9PxpGTI5h+7bHp+NFSHv6kfWimnY0hPlPFfDt9Jo2uXNozlrVVYsCegHOa1/B3j/S/FOqXGn2kc8NzECyiQD51B9u9O8J6BO99JqGpJtLqQI2757mug0bwxpOjTST6bYRQzuNpdRzjOT+FXzUuWSknfoe1iqlNy03NNIgOO3WnnbGrO2MKCx9sc1IePu8HsT/AFrnfEnimx0NQs26WX/nmpGRn3rnjG7OOEZVXaKuR+EPG+m+Jbi5t7FZY54RuKyKOVzjcP8ACnDWdYk8atpkenj+yI4RJJduCDux0U9DzgY+tZXhbxDoEl5L9lsotOublsu+0DzPYkf/AKq7RJo5Y8xOrp/snNdU50ozbhHRrr08zWrD2Un7tr9zjfiXrTWWnfZLeQJc3GN2DyqV5GLUP8z5L+9dn8UbaZfEIkYHy5IxsOOOOD+Ncso2AHBOBkAHr9K56miSR7ODioUly9SKS32INuQeM45NbPha+srDWLe51MssUbbiEGTntWczMImwduOpHX8Kyrtn80sx69c+tTDc6JR54tM+mLGeG8t457aUSQyDhgRg1JFplmJPMW1hD567QefauO+DvnnwsfMyIxO3l56Y716BGABkcVT0dj5XEJ0akoRexDFZwRuXjhjRj/GFANWcfLxSjggD/wDVS/gOKk5HJvcidcgkDBxXnnitVn8URWiLHACimSRQAWz616QRxgnqOe1ct4q8NnVpI7m2lEV0nGW6MB06dKuFr6nXgqsYVPeZja9p+naTphjgTfcSYG4nLVwmqXly4jto53W3h4CISAGPUn15rtb/AMP3tpplzfajdLM9vC2yNMnHuT+NcCZM7gT8pwSM8VSbitHc9vCWaunzeZ0PgbXryw1W1tJZWls7ltm1jnaT0I/HFdxrniyy05p7aAme8Qbdqj5Vb3Pt7V5/oELJLLdN8nlANGCeh9atWsGnpHcNfSEyvyuOpb39qq6bu0Z18PTqVOdr/glKa6u7y7M0l1K8ud2d2MY6fStq1kN8FaX5Z1XBLdzWNpxLXYYozLkYx3rstJs7m/cFIDFADkyMMD8Perld6sutNQXoQxWzWzIZysaHkN6isrWNR8/eYuAmVGeOlbXxQuBpnhiJkTIEoTI6jjrmvKLfXC6bHJBPHOOlTyu3MThYutH2pJd301tfb4JXjK8ghsEetex/D/XZta0QSXR3XELmN2xjeMZBxXl8HhfU9VgS7sYVmjZsbkYHB9DXqvgrQW0DRUtpWV52bzJSp4B9Pfiqk046meYzpOly394u+JNettCshLc5Z5MqkanBYj37CuDuvE6+JQltcQJC28eUR1GaqfFaaX+2wkmfKSNfLz29f1rmdHuUtryCd8nY4OR29/eomlGK7jweEgqSqW943dQms7Mz2tuhkJ485uMEHnA9KxPM3gjGX549atajEy3Mqk5Byy8dQe9ZlxIfPYJj72DzXO0ehBaDpWDghSCM5HHOarXWdnYhe/Tn1pG4OVwcHvW74e8OXuvxyvaqpWIY3Mcc9gKqMblSlGmuaT0JvAN9Na+IrJI22pMdjr2Oa9tDduw4+vvXEeDfBLaVeJe6i6POg+RI+Qp9Se9du6/Llu3OexreVm0fPZhWp1ai5CrfX0NpAZrqVY4xnJY4yPb3ryXxD4ou9Vup0hmeO0XhUU449Wp3xMnuYtfkiMrlMDYD0APpXMW785QDoeCeKqygtOp6GCwkYRVR6tjpI8gFiTg8t6V0nw3kkh1K5GdtuIS0mTgJjvUGg6PNrN0kaoyw7gzykcBfXNdZ4m0qHRtAeDTxt+0SATOerAVOr919TavWj/B6sg1rVdB1aNbe+jlmtwwJO07TjvXT6RLbPaRfYiotlUKgUcKPT/61c+un6WNCQKkZYIMt/FuxWR4Du5IdeltImJgkRm25yBjqfyq780bJuyOOdKMqb5b6dz0O8u0s7WSeTcUQHO0dD7/y/KvLtV8Vate3TPDK8MKn5Vj4FbniXxQLiOazsYvMQ/K7nv8AT2rA0e9twTDcw9OjA4+vWhXir2LwuH5Iuco3Z1ngLxNc39z9hvj5koXMcnQt6g16DG+eRg9a8p8EWDXHiI3cKFbeEk5x1NepRn5R+tRUWuh5+YQgqnuk3rySKKaT1/p2oqDz0jJUc4PJxz704sFz1I6ViW91cWHh+CXUyrXqQr5u3o0mOR+dcjLrGv39wz2iyRxIeAo4x7mp9nvrsetTwzqXd9DqvGOqtpmlNJCcTO21favH7xpbm4aSV2LM3LHue9eiSmfxLoc9s6/6dancFxjzB349a4aS0kEwSRCjghcEY/Oh3tZHp4OMacXHqUvs3lEEOSOAc9B9AK6Tw5qd1p2rwGORnjk2xuvYg9f51N/wi18tkLqOBpATlVHJ+pq/4Q8M3k+qRXd9A8VtGd+JBjcQeBTjdLVl1a1Nwbbudh4r0+3vdFujcQiUxxs8ZPVSBwa8ckh27SAcAZ47V7/JCsqsJQGV8gg9CDXnOseDL2K4f7En2iBvukYBX6ikldWOHAYmMU4yZ57cAjkrjHBzwDU3h3SZ9Z1iC2hjLqWBdscKueWrtrDwuliG1HxLCkNjCMmJiC0p6ADFLb+K7qH5dE0e1srXPUJkn61UY/yr/I7pYhyTVJX8+h6bp1pBZW6W9rGIoYxwqjjFXlHHHArlPCPiUauzW9yiwXgGQoPDD2rq4zuAbHHaocWtGfNYiE4SanuO9x9OKMYxRz19T19qCR68e9Sc4oGT+vFRTMArEkDaKfuXnn3rmfHd1JBpCpGSvnSbGI44q4xu7GtGm6k1HuRaj4o0gebA7NOjfJIEXj3rlJPBTXsyXGjXlvPYyHcGZsGMehrZ07w9ZNoxuJ2JmZT8x42/40zwSyQajfrG+LRRl5GOFVu341eiTcT14tUYSdFu679TX03wraW+l/Z7nM87D5pl+U/Qf/XrLm8ARNPuXUHEP90plvpmuxtLuC4B+zzRS4OD5bA49+KtDB54NJSlE4frdeEnruZuk6Ta6ZbC3tYwFI+YsMs1aO0nr0p/TpnNLjkj05wKjd3OWU5Sd2YnifT7PUtDubbU2KWzjLSd0PZh/hXgt14cjindbfU7SWMPhSxKHH0Ne7+MI2fS+p8pJAZAvp7+1cpq1poUdqZfJiMjABVUZLVrB2Vj2MuqunDq7s0fhvpEem6KXhvVu2mIL+UfkTj7vqT712Sr8uepxXmXhHVbbQFuIroSHz3DBIRkRivS7S4iuoEngcPG44I7UTve7OTHQmqjm9U+pznjfw7HrOmSSImb6GM+Xj+Lvt/nXh0qyQTeVIrK6kqVYYPvX00RnP61n3Gi6ddXAnuLC2knJ++0YLU4zVrSNMHmPsIuM1dHl9nE48ES3N7bkmLakUjDBHI5B9K4KeZhOzEE7j+VfRmtaVFqWkz2LkRxyJtBVeFIPGBXlX/CvNUivdskKyQbv9cjAg0oxi09bHfhMdTlzObs7nEWpM9zHDGWJkcKoUdSTgV794U0KHQNPFtCzO7HfKzcFm/pXlOneDfEMniS9gNklvbW7horoHaMZGMf3jj06Yr2+2QpCis29gACx/iOOtXVpeySimYZniFOKjB6df0JkTHtgUj4HXinAgAn9apapqEGnWjz3DYReAB1Y+grJJvQ8WKcnZHP+M/CsevxI8cghu4xhWIyHHoa4nQPBMlzfSBr21aC3l8uYxNuYMOox2NdR/wmkrssg05xCDgMWyT/AErU8HaZplvHd3mk+Yft0xmm3tnaxzkY7Ac/nXQk4QfN8j1Y1a+GpNS+XU2bO0itbeOGBAkSjAAqHVtNi1CwktZuFccN/dPqK0wOPwqG6kSGGSSRsRoNxJ7AVzrR6HmxqS5rrc8u1Hw1rlsXit1E0XUMjdfqKveH/DF9p9tfXVydt7LA0caLyVB56+pqzd+NGMrCysfMiViNzE5Nb3h3W4dZiO1fLnU/NGT0HqPatZudtUetUq4iNO8krdTzPQ7qCyZvtEQdsYw3Wrvh+wi1TWo9sRMWcyAZwFGf510PiCfwyl8/2mwM854Yw5UE/wBa1fC2oaVKDBYQC0frsb7ze+e9OT6pM1qYh8jnGLuzbs7WG2iCQKI4wBhR0/Ki91G2sVD3Mqx84G7v9Ktfwjpn1rgJIDrniSWO6kZY0bbt9AKmMU7tnl0aarNub0R2dhqlpfA/ZplkxyQOoorhoIxpniL9xJ+6iYl8dGHcCinKNvhNKuFs04apm34lR5dIuBEMuq7seoFcno/imC3t/s00J3oCV2455711uvavbaTbb5+XfhUAzu46Vw8d7ot7ds8+nzRKzZLRPx+VYR21R6GHjzU3zRujoPBG661K7u9uIwMfmf8ACuvls7dyHkgidx/EUGfzqppYs7fTI2sgqWwXeD/U+9Ys/jS3W62W8Ekqg4Lk4otfU5Zqdeo3BHR317bWMPmXc6Qx5wCxxUem6vYai+2zuo5mB4UdT+FeR+K9Rl1LVZ5ptwjB2xxnsOx+tZVlI9tcJLAzJKmCCvGKtQjt1OqOXJwu3qfQyjcAM9eP8aeUy2cA/hWd4fu3v9JtbmTIkkTLADjPfitUdOBUPex4s04SaZyXxAs3m8PTGISOUcSEZJ47/gKp+Cp7ObRxHiMSISJFIGce9drJGHUggc8Edq5a58FWMkzPbyzW28ksqHI+g9KpOMo8sjso14On7Obt5nPWcSf8JxCNPA2CTJ9AO9enJ3z9PrWPouhWukgmBWeRhhpGwTj0+lbKnHXGRyeaU5XaMcXWVVrl2SFY9B69/wClchrvjOCwuXgtIhcSqfmZjhQe+PWuk1FZHsp0gOJjGwQ56EivFHjaNmMqshViCrdc+/pVRirOTNsBhoVbufTod9pfjqK4uI476EW6kkb4zkfiK6PWbBNVsXt2bG7DK3YHtXjG9vMG0fN14XivSvDfieKbS86kyW7QYUuRhSO34/Sh2WsToxWE9k1Uooy5tI1rctsYCYUOS+/gj/CodOs11PNtI2xE+Xy14A9/c+9d1ZX9pfxM9nOk6Dg7GyR9a81uTeeG9dlDKSrOWQ/wspzj+dXG8rpblUKs6t4vSSLVxp9x4d1GG5t5CADggcAjPQ16gjbo1JGAQD9K8+0z7V4mvULREWsZBeTp06j616Ii9AOnapqtu19zjx8vhUviW4o9D+GKOwxxnNOI5Oe3WsrX79rDTzNHtMhIC7ug96ySu7HBCLnJRXU0ZAJEYFQyEbSCOD7GuH8UaXZW8yjT7ZjeNyfmwkY9eelZt3rl+0m83UuSc7VOKZFqSanI1vrFyPs5yVkb7yMPQj+taRTjrc9ahhalF819PL+tRI7Cx0/SppZJEuLngsynKxj0/Or+h+ILfQNO8vUvMa5nfzlhQfcQjjPpnriqA0B4WFxdzwroUR855423eZg8KB3JrkryZry6lnOSZGJGev0/KmpJ7u52qlCunFu6/rQ9l0LX9P1rP2KU715aNxhh/jW2gzjjpXhXhaaaDXrF4j83mKvH8QJ56V7lC24EHqPeicUtUePj8MqEly7MkK8Hpj1ppjBx/L+tOZ1yc/lTgcqcZ5NZnBdoh8sHn3prcDp71OQMe2ap6nG8tlcpEf3jRMF9jimi4u7sznrzxhp0F09uglmKcEoOAe9Y/i6+j1Wytbi0YtAhIdSMbW7VjaQllb+cL8YcE8nsc1d8KMtx4geFUD2rIxdG5BHaulpQd49D3Fh6dF88V8P4lu41Wwk0gRKo8zaFC46Vr+BbSWDTZXkyqyybkU9h/wDrq/H4c0uObeLYbgc4JJH5VsRoF+VcAKOAKxcla0epxVsTBwcIJ69x4Gfp3rM8RW8lxo13FFzIY8ADvz0rU9CPWo3A+tSnZ3OKEuWSl2PN/CWoabaQXVvqJWOXdn5kJyO/45pvh9o21rULu2G2zihckjsT0FX/ABBcaLNfFPsX2idch2Rtoz6cdTViwvdPubCXSLeH7DLIpEYPRz16+taz6tJ6ntSleLmov3t/LzOJyUmJbDcZ5GTVzSjK+s2xjG2QSr044qlcxyW07xzoUZTypFdL4Bs5HvHunUlFXhiMAn2pu6bZ1VZqMHI9ATA2569etczrHh+4+3td6bIA7H5lY4/KunQjYCP4u2KkwuTms4ya2PAhWlSleJw7aBc22k3k8jCS7IyFB6Dvz3ortj8yArg56n2oq1PujphjpRvzK55X8RIZGu7WRsmAjH49asaBaWdzo6loAJCmWywO38v6V12pWEF/bNDOoKkZJ7r71hWnhy7s3MdrdKITxuYcisHql5HbDERdNRbs0Zckz2/hTUo4ydvnCNfYd/5VzNlcxQxsHwx6A9K9Yt9KtobJ7VkEiOMOX/iNecaxpthF40ttAshOZrhC8kh+7DwSPduntitIU3Vuora7NcPiIScl8zKurhri586U7nwF9Biqw2Hbyobp14re8TaA+iNAqyebG8f3gMDd3Fc3JOrxL5abX4O5uP0qUtUzupyU4qUdj2vwlcC48P2MhCghdrbTwSK3l689T19a8y+Fd3O11c2pz5GwOF7Bs9a9Nj7Y/A0pRs7HzeNp+zqtAcdyOvH1oIGR0FGR2xxzx2oYnjIIzUnIIG9O386Tdldo6V574z8aXNjqclhpwVDDxJIwyS2M4A9KoxePr9tOYGOL7apH77GRj6flWnI1uehDLqsoqS6no95ewW0ZkuZ0hjzjLsF59q5/WrPTfEOlXEtpNDLNF84kiYE8eo715j4h1e81e4Wa7fcFUKqAYAHsKXwtqUmj6zBcqxEOQsgPRkPGDQ0ls9Ttp5fKnHnjL3l/Vh48z5lj/dqOABwT9TTLrzGg2s7HByO+K1vFen/2TrckaHNtLiWJieqnp+R4qk37yMIibpGJAHfP071DdneJ6EZKUVJbMb4UvptO160kjbCM4Rx2Kk4xXtjQxygLKiuuf4lB/nXjljCbKeK9uIwFiIZFc8yOO30r0zwr4gj1uBiUEU8eN65657inJuWvY8vMoOVqkVtub8UaxqAqqqr2AwBUoGOO4HX3pqk4B96cTx+nWpPDbuQ3cgiglkxkRIWx9BnivKI9Un1G7uUuZdzzcoT2Ydh7Y4r1iZkKEtjYRg5PBFeV+IPDVza3DzachurNskND8xT/AGSK1hazXU9TLXBXUtGyi7EMVYYdVPXqDjv71izuzStzhs9T/Wu88GWF5cX4mv7XEMakM8yctxjHNYnijwtJpdyZkmjazkJMYzh1/wBnHfHrTtZ2e56kMRBVPZt6mLDLINPe13sIGfzPLJ4yB1wKjaMoBwWHbHWrMakYAwo6deppLWRZgr7JFO4qFYYJwcZPtUN9zov1NLQL1PD8UupXEHnTygx2ynjBz8z+w7VvaN8QfMvEi1G2WONm/wBZF/D9R6VxuqzG6dSRgooQDsAPQVmGHDj0H8Q71cXF6SMZ4WnWu6i1Z9DxsrqGzkHnPYj2qQZ2jH5nmsrQZFbSbIq+9fJUBh9BWoCcDI5rFny9SHLJodnnrz601++BwaUjr7/rSHg9D/jQQjA1bwxp+o3BmkV45W6mM43fXNT6LoVlo6yfYozufG52bLGtkjg/5xTTg/yq+eTVrm/1io48jegzhR1wMVwNz8RYrTxne6Je6fNBb2qFjctnJAXJbbj7uM45z09a79jk8ke5rP1Q20drNNdpG0aIVYsoJI/u+4PpW1CVNN+0je/naxVBx5rTje4zQtZtNb0+K+sJHkt5CcbhtYEHnIq85DcdyOMVwljrs5k8jSLCC1tVJIjjQYGe5x0JroNH1kXsht508q6HO3PBoqQSbcdvxN6uFlBuSWn4nI20X9la3MLxSVDHBPcHvUeogX2tQx6ejeYWB+Xt71seNp9bXV9Lt9I0iG9tJeZ5JEJxz0LD7oA5zXV2mn2toS1vAkbHgkDkirmnFRqPr/Wp1yxKhGNRrVrv+Y2a0huFBuII5WHQuoNZ+s6nb6NbL8oLt/q404/yK22GF75zjmvNPHc0ia8xOQke3bnp+FY04puxy4WHtp8r2Nq28U3azQm6sykEvAZeo/OuiuNWtLaNXuJ0TcMjucfSuJTX21C0WBIh5saZ/wD1CsjUJC+FYszgdSc/nVKKe6sdjwcZvVWPSk1zT3t2m+1R7B97n9KK8vbC2/lBPmJB35/SinaK0Gsvp92bWs+KbqS9e10pCGRtu/bknHXFVrPxPqdjOv29fNhJwVIwfwNZGn3Z0fWJjcRb2VimD1HPap9c1WG5Tf5eXkbCqOMD1NRJWdraHWqEfg5dO56hbTx3FtHNEdySLuX6VwXjLxEIdQeLTVjWaMFHusDev+yDTtC8Rz2NlClxAGtgT90cgd/rWJr+gXPmyXFoGuILg+bHIg9ecH3oguVsww+HVOo+f5FWw8T3W7yb4C+ticNFcEnPuPQ1pWGg6Vr9y40m4mspl5eCYbxj/ZNckYmhIEilcfmDXR6JN/wjVqNWuF3X1wrJbW54wvd2/oKVpLU7qsbK9PRvY9J8MaDb6HaNHExkkk5eUjGfQD0FbN1dRWttLcXDiOCJC8knJ2qBkmvGoPGmuJceabkNkZ2FRtrrtY1n/hJPh7rf2RH+2/Y3DRRjLZxyRnt1q4U+eaUnu0eRiMJVUlOo73PHviB8bNX1O6ktfDpbTrNcrujb95IAeGLdR9B+tcHb+OfFkcpdNe1HcfmI+0sP61zARlldDwckMDxzUjDaoc4HoTzmveUYwvGKsl/Wvf5nje3qS1vZdl/X5nuGna9L4qt0v7hAL0IBKVGNxHG7+Wfxq3CriRgVIbGCRzisH4YW00OgSTy/6qTKxgj7+T1+nAroLm5Mah42CyDhTivIzGMY1moeX5H1+Fk5Uot9kT+WHAUghf72O39arm2PmEDseg60RX90WYNKWRgBgn7uPSrCEugOPvDr/OvPd4s31R1+o+VrPgSzvHJNxZSCGTIyduR1/Q1zVvKEzs4k2nLkdBWz4E1G2W8l0q/UG2vAQCxPDdB+f+FFx4K1eHUZIraJZ4A2FkLAZBPBNWldcpxxnGjKVObt1V+z/wCCYk0jztlmJ45DZP4V1nw4geK/mvJSIrdU2Au2AxPb36VY1Dwla6XYC6ubqVvKRQyKow7+x9M1TttOuNTt3ndTFaIvyIp42jvVRWm+hnUrQrU2ovR6XPUI2zjBySM5pzEY471wfgjVjDY6j9slb7JaEMsh5xnjaPf2q9F42sXn2SW9xFETgSEA5+oHSh05XaR408FUU2oq9jF8UX0+qa/JYxzMtvEdoXPBOOtLpAutC8QQQmV2inYJIgJIbPer+v8Ah+W7vhqekyq6yAM2Djj+8KoW99FFqEdxcRNKsDbmcnGTWt+ZWjtY9GEoypcsNrarzPQypye5HFeWfEt518RokpIi8keVnoPX9a6DX9ciu0sDA0gs5twZwcFX9DWTMILlDo3iOVopYjutL5hkgHsT6GppxcdTLB0pUZe0l93U42KUoxHrjAzV15Ut5JFYkSqBz/T9a6fSfATpeRS313E9qpyoh5L+nPYVxXi63msPEN5DKWHzkq394HkH9aXKpbM9SnWp1Z8sXckk/eOWBJB44pBEQeOQMdD2rOtbzHyydeMAiteBTIUwOCc5Pb3NSovc2l7p1+ka/daTp9pDJGksO3O3ptB6DNd5pd7Df2kdxbklG7dwe4ryNrhHi24LHOBxkYru/ARkGkyPk7HkJX8hnFOSTV+p42OoR5Oe1mdZv64HH50qnPBHzCmKeccfSlTrweAM/SoPHaJcdR70xiR06U/1xjNNfk8E8UiUcrrPi6x066a32vNIDhgnAH/16oaxrVtrOjSR2xcTKQ7RsOcevvWe+lxWGvXD6ioaIsShPOcng1U1Y2z6lANLGXLADb6+n0rp5YprlPdpUKScXFa73NXwpf2VtpjQTusNyGYtuH389PrTdKb7X4nR7YERKWLH0Aq/N4Qt53V0mkgbALKACM+1bWjaRb6VCUgBZn+87dW/wqeaOrT3MqleklKUXds0kU45X86fjGM5+tCnAU9gOO9DH5Tj6VkeVuzL1bVbXTUVrqTBb7qjkt+FcxcXOieJ3WKfzILjojEY3f41HrMazeKpFvSfKBBUH04xVPxTDY24i+xkLKP7vat1FJpdT16FGMVG1+Z9Tp9H8O2OnByiGSRhgu3UZ7CuV17Sl0ecS+ar723IpXkCu50t5Dp9u0/3zGC2fpXm/ijXmv8AUCEVRFFlUPtnrTp3ctQwrqzqu7uupWYFyM4GeeOOKKjjnXy13Egkc55opySbPS1O317SNJvGEl+yRSD+MMFauQ8Q6HFpqxXdoWuLTGCwO7aR64rmNSvJ9SvHllkcs5Pyt0/CtPwdqlzp2rxQMxe2lcRyRHkYNY2ts7kwoVKUbqV7dCebVftccVvBHkDhFQcmvSPCtjJZaJbxTDD43FfTParVrpVlBMZre0gSQc7gg4FS393HZ2clxOcRoMkjrSbUtInnV8R7ZKEEJLY2sjmSW3ieQfxMgJrjvG/he81XUoruxMbDYEcM2CAO/wBKZH43mAeaSBPKycRjjjtzWZY+OdRk1IeaYjBJwEC4C/Q1VnF3NqOHxFOXMuhNYeCHBQ3Zyx5GDgV2Hhzw5b6RJLPFvDkbQN3AFS2N4s6iXcpLc8HitU3CYJJBwOgrP2jehhiK9WXus8f+Kvw58JT3LX0tzc6bfXPzbbdQ6u2clip6fnXFaT4I8KWOJLya/wBYuF+aOEqLeEf72CSfwxXoPxOlNxr0DhWESQbQT0JyTXNWMAaRYwQGIx8wxz6V0yxlRRScr/d+e/4nZQwNKUFUqK7ZakuXnUn5EUYCoihVUDgAAdAKqXKDG4jhvQZqzJC8ZKPG45+6VrRtLaEWk812VYv8iRg8huufauRybd2ehdRWhgwo7FAoPXk1prHhAOvFIPLjGIwAeufWplbem3Bzn/OKiWoNkvh7Tp9S1y0it0bht7tjhQDk817aOWz1J/WvE7XUrjTUm+xTvG0i7ZGB5Iz09q0fB/iy9h1WG2u52ntZnCMHOdpJ4INaqLkjzsdhqlf3l0PSvEGnHUtLkt0OHyHTPA3D1rAhe5GnSaUbaVJpBsB28dfWtLxXrv8AY1uiwqJLuYlY1Pb/AGjXJ2nifX7S5SW7Z3ib76MmAR7VpGMpQ0+RxYalUlT6W3VyDXpvs2nf2XaMEgEpkmwPmdxxyfwrFfbGqlDl/ccGt7xbps1reNewIz6feASKwBO0nkg+nNY9lGs86Ipbn5uOapbJo9Ok4uCkjuvCgnm8FXKxZBAlEPqOOn55rn9GuVgsLuO+t96lPxU1pS3NxFpdtZWSmNMklF+83saoX2mC02POWSRuWB/iFOK3XdnLCKvLm+07+ZQ0aN7y01KBFJEUXm4z6Hg1PqOsW1/ocENxHm6iUJvx2rr9PfSdD0RLyAMsdwRyTlnJ7VhT6rYzXBlfQoGVn3Fjxkep7VSfNK6Q41faSb5XZPT9Tc8CRzDw5AZ87SxMYb+5/hU/iTw1Y69Cou1aOVB8ksZ+Ye3uK09KvYL+zS4tjiNuNv8Ad9qt8Yx/k1k2+ZyWjPKnWnGq5rR3POLX4aWsUwNxfyyxg52KgXP41val4btZ7NYbE/ZWRcAgZz/vVqeINVh0ixe6lXcR8qJ/fb0rhZvFGvMDcxpGkGcbREDx71pGE5rmudtKWJxFp82xa/4RW00uE3Wt3m63TgRwggufTNWbbxckZSG200R2sYwqg/MB/LNUfEep/wBs6Rp06qI03ss6j+F+OBW5pOn2DaOspVdxBLEnoaiVkrzNp6wUq+rv9x0GmX8WoWy3FtkqeMHqp7g1eVAshYcH+dcL4RuNmuzwRn908Zyo6ZBHNdwG6VE42dkeZiaXs58q2JsjFMZxg1yXiDxaljO0FmqyyqTudvug/wBayLXxxcpLm9hjeLO3KDBHv71SpStcuGBqyjzJHV+Ibm2t7QC4hSd34SM9z61xc11qenyefBbxwIOBiMbfx9as+IL7/iprWV2/0Z4UeM9tv+c1q61qNrLZi3hYSTy4ConJNWlypaXudlGDpRirXuanhzU/7U0yOdxtlyUcAdGFaH2qFX2GaISZ+5vGa4jVpZ/DnhmG3jbZc3bsXPcD0/lXCvM7DcWYt13Z5pckXd30CGBVZuSdlfQ94Vs4FR3lylpZ3F1LuKQo0rbBkkKM8D14rhvh/rctw72Fw7PtXcjHqAO3vXfALIpVgCOcjrUtcsrM4K9B0J8sjzvwtrUHxDtbqV7OWxkt3CCRW3Ag9PmwMn1Fbdh4PgguFmu5nuCh+VT0rrIoI4owsUaRxjoqKFGfoKfge+OgrSrVTk/ZrlXbccsZLVU9F2KhRVUJnkr09QP/ANdeQeJtBvdNvZCYmkgJ3LIgyCOwr2dkBKkc4zzjsff8qwfGEWrvosy+HWhF/kFRKcbh3A7Z+tKi7y5X17mmDxLpT9e55HZwXFzOsUMLszMBjFFeueHY72PS7b+1UQX23MzJjk/hRVyqcjcTtqY9qVoo8OeMqy7ecjIrsvBHhiS4uoNQvV2wqfNUEYLtnr9Kv6P4KQpDPeysCOWiA7+ldvF5Vuir8saKuADwAOw+lct7bG+KxityUy1GODn6nFZPiu2a50O4jUEnaGwB1xzWrC4YKykNkZJB4pzqGQgDg+36VKlZ3R5EJuE1LseM38Ky2SrEAWHUd6y7XTb+7lH2O1mmZM/cUkAeua9QvfCFo949wkjxxH5mjXpjuBXB6rrd/cyPDZmS2tEyqRQkqMD1Pc1T7o96hXVVWp/ia1gNS0Sw+0amyQQ5wkTHLt6gYqneeKLyckwjyk7DqWFYWZyAszSFR90tkjNWYYhHEJpwTk/KpOAR61F9Tb2Ub80tWaWtrLfyRTyNuDRKQCflx3/WsRgEDbvvA8ZrfsNTmKrCY0KjkDZ0NN1HT0uIjMI47Y5+Ydcn2FJK+jFGXJ7rMYX07W5gDuImIypPXHFTZxDHjJDZzkfpVxfDl22lT6hatFdRQ8uqH5lxnPHU4qlYSiV0RQr7xwp5ye1Ci7XRSlF35egMfmJzycHFSKQNrbuoycU0kAl+Cc4/xqrd8DaGwpYNj070uV30KWo+4mBPGM4yP8+vtWp4M0S41LXIJBEwtoGEkkhXAwD0z6msXToJ76/ht7UM0ruFCAfrXv8AbwLDbxxIqqqqBwMCt0nBHFjsV9Xjyx3Z594vuhB40gku0PkRqp5HBFXtZv7e/W3t7LE7McZjxkCtnxbY6XcWQk1XKbMiN1++T6Cuf0i+0rSAGt7G4kRxte4lIyg74xWiScU0ndHHSkp04yjF3WnkTHUtSv7wWemTJBbW4EWSAwcgc0lydY0cGZpbfbnDeVEAT7ZxVJtP1K2Rp9HUXFq7FlmDABB/tZPFUHtHu5HS78TWccuSPKBYg/jwKXLHysbRhF7Wt6XfzLE01xJbtfWLO8UbASBfvRk+vsfWo2kv9buFijR5WPyg4yAPc9q7Pwho8ek6WVW4S5eU7nlT7pHYCugiiRVOxVUH+6MZpqolsjmqY2MJNRV7bM4PxjYSWWlaVGn7yC3BVz23cc1Xi1KxOkrHs/eY/Xua9CuII5onjmRZI24ZW5BH0rCfw3pNvK9wbUkL8xDElePahVFy2l0IpYuLhyzvddiv4Jjlj0yWRg+ySTcgPpjGa2pdQtYn8uW5gjbsruAa8c1nxNqGoXrOLh4YFJCRRsQFHbgVi3FzPLzLIzkjgsck1bheV5M63lzqS55u1z1/x1A9xpMUqDcsMnmOOuVNZaaxYLoLREDeUKBeuTSfDPUJr6wuLW5LSLCRt38kqc/LXQ/8IzpLzLI1mgYZ4GdpPuO9S3Fe5LoYOUaH7mp0fQ5/wdpSXfh28F0pEM0m6MngrtH3qjuNE1m1JgtV8+DdlWRsfmD0rvIY1RAsSoqAcADAAHYe1SYBHGMd6h1Hd9jF42XO5JaPoc34U0GTTfMuLplN3KNuF6IM9PeukdSUO0468+nvT8YJx6j8KRugx69ahycndnJUqyqy5pHjWtWs9nqEkVyNrFiT9M9RWe+QVGT9D6V3vxD0yaZEvYI94jXZJgcgZ4NedrvZ9iqxbOMDnNb6ztJH0WGqe1pqR6Tpmj2ms+HNPM7v5kaFQ6nleeQax9dvIvDchsNHX/TCB5t0/wAz/Qen4V1XhCxnsNDhiuQRKSXK+me1cd48sJIdckn/AOWcwDj1/wA5pJ3bjfQ4qElOvKDd46/mZk+p3V/DHFfSGddxKFvvLTDFEVxtHqOwNIgTaFQdOM9KbOwVWJ6Dgds1DbuegklpHQ7fwPptjDAbyB99wQUYE/6v2x7120Y9QOeOa8a8I3k9vr1t5TNiRtrL6g8civZYen64pVFZni5jTlGd273JR6jjJ60E8HI/CjpjONvpSck+nHFZnmDc8kUxzngDjuKVzwwHXODXKa94vtNOmMEam4lBwcHABHarjFy2N6NGVV2grkvjG6mg0sJatteQ7dw9KKwm8SWWu7IJ4mtpRkxyFsoT02n3orohJRVpHsUIujHlktTrp3EMUjnkKCc49q8uhF/4l1KYtcSi1jHALnpnH516hOokSRMEh1wfpivL7tL3wvqUnlofJkb5GC5DDsOPrWNLry7k4LaSXxGtpN5d6Dq0NrJK0tnLgYY9B6j3r0dSSnH4dq8o0K01HxBrcdxMjpAGDsXGAB6D69a9XUfKAOmMCoq7ruY49RUl36kN26pHK5Hyqu4ge3WvDr+U3d/NKmAHYkJngCva9VZorK6ljQMyxk4PQ8dDXiBbc7EHHPHoKj7LZ1ZWtJMdGjLyAfmOfY//AFq1byPFnamaTM23Hlgfw54OfzqDR7aO7v4YppTCkrAFj2qTxXF9i12e1wdkOFQsOduKhI9FyTmo9dyvvEYOM8/ebpT5fNMOEfcB055NVRJlCd3J9+tC38tsQ8Mm0g57c04sbi+hoeCru7g8RW0dqxdZWEcsfUMpPOR7V3934R06yN3e2ML/AGkKzxJuGxW68CjwBeQalp7XDQ2yX6ttdo0CsV7HArrtu4Y4z/KtXKz0PExeKlGrZaW38zwa7u4DLuS3werKSce+O9dL4KtLfxBezwX9qjwxx5UqNpT0FdVq3gbTb+6adTNbu5JbysYJ+hra0DRLTRbUw2athjl2c5Zj259Paqly7xNq+YU3StC/N+Qmi6Dp2kktY2scbnIMmMtg+9a+0AH9aVRzijnHOOai7vdniTqSm7ydzifGyPJq+nRyZ+z4OB23E881T8TXVra6eqBVzjAAArstW0+LUItkgIZDlXHUGvO/Hely6Xo5vXuPMcMEVQMBc9/yrohJSSR6uDqQqckG9UYuralcW3h6Gw85ESZ2keGNssB23enriuZaJnIb5iw7+lU4pS8mDn5skE/zrbXAh3Ee2f8A6wqJVHFnuRh7NaHefCq9kMFzaTSfKpDRgnoc84r0ZG4we/avnlnkt2xCxXadxOetev8AgHU5tS0COS6JM0bGMuf4vT9KmWvvHi5lhbXrLqdQeM5rmfGWsppWnFRjzpwVXI4UdzXSE459K86+KdhdzLaXtujOkIKPt52knrinSSlKzOLBQjOqlI4GeCWN2Lp97kZHY+launeD9Uv7ZZViWOJuY98g+YZ6+1T6CL/VJY7aKJiB952XAUdzmvWLOFbe3iiT7iDaM1U5OL1Wp7GKxcqKSW5k+EvD8eg6f5W4PNId0jgdcdh7Cruv6vbaHpr3t5kqDtRB1dj0ArSXnGck15B8fdYbTYtOJK+WiGQocfMS2MfpWuEpLEVlGb06/I8ql/tFa9V6bv0Q+b4jatK/mRJaQWxywUISwUe5/nxVbQPjFLNO8d/FZXMSH5vIJR8ewPBxXhreJ5ro3EUqxxW0qFcoCCp9Ae9YWi3z2OoLcFc7AQeex9K96WHwui5FZnTUxOE5oxjFOL3ezX6n3Nomq2Oq2Zm06bzkDZZW+8h9CD0qfU7+DT7OS6uDhIx07sewrxH4YeIPKv4ZrY/6HOoUqU2knHPPfFdhrniS31qA2DxNEd25JN2RkeorxMXhfYVeVaoU8vaqrl1jv8jbj8VBv3gs2MQ5JBzitLR7vTtRDTWccfmK3z5jAcVxWia3FpUUthqcBJY5Rx0Ix0qt4Su5D4uj+y5EchYOB0Ix1P8AjWHIneytY1nhFaXKrW69z1PHoMj+VebfEB5U15lYnYEUrnpjHb8a9LXJTnp9e9Zev6LbatCqXIIdOUkTGQfT6e1RCSi9TiwlZUql5bHlC3OMbgMNx710Fp4Ym1XTYriGZVZ8sFkBxjOMhv6VqWngaGO4zc3TSxg52KuMj3P+FdnbxJDCiRqFRRhR04HanKSXwu53YjGxil7Lc5rwv4Sj0mYXFzJ51yM4wPlXI9e/1rsIxgjHWmKMAY44/OpV+915rNtyd2eTXrSqvmkxSTngZ7VR1fVLTSLNrvULhILZCA0j5wMn271ePX1/nVLU7O2vbY299bw3MBIJjlUMpPY4PenDl5lzbGULcy5thsk6Nb+ckq+SU3b+wUjqK8P1Rt17KFbedxOSff1rufGPiK0t7CbTLQnf9wsvCqB2FefByDtyDwMEitV7iZ7+X0HTTk+oQ58xQuTjHzd80VoeHgn9sWvnqChcF9x+UD3opqpyo6a9b2bta503hnxZD9nhtdQJ3A7FmH6ZruQquFzgg/livC7G3kkdPLJEYYl5GPC55zz/ACFd7B42jgZLeK1kliiUJvzgnHfFc3K3sc2KwjbvSO/iQBVGAFHHpxUw4A6kHkVmaLqUGqWaz27fJxuUn7p9DVq6uUt7d5pWARRkseKXLqeRKEuble464VZI2VgCDwR6ivH/ABPosuj3rKfmt5D8jevt+FdPPrmp6nI508NDAPu4HJ/+vWaLpvEcMmm38gTVIsvbyngP/smteXlWux6uEpzoO7enXyOR80o6lTgocg9/aupW0m8Y6aJ0K/2pZ5VieBMp5Az6isRfDmsvc+V9gnDZxnbhceufSvT/AAZoX9iaZtlIa5mIaTHQegqXHl1OnF4iNOKlF+90PLNS0XVdPtnmurN44QwBJ6Vivcxo/wAwDEcgEdDX0Dq8VrJYzJqBT7KF3SFzgBRzXj93rngKCbYmiTXa5wZN5Gffk1SSavZ/IMLi5Vk7wb9P+Cxnw8vLhfFNmLdmJkfawXoVPWveExjHHHavOfhvqHhm+u7j+xdNNneKmSsh3Ern+E9q9GT1PXpmlN3ex5WZ1OerbltYkx/+ul/PnvR39qOo4qDyxBjA/p2pT1B9ueKD7/jTC4HB6Y79qQWuK3KjPesjxFpkOsaZcWdxkJKMZHVT2P4GtBLhJDhJEc+zZokbJA6g9qpNp3RtTcqck1ujwrWvB914fkjkuJEmhkYqjoCMY/velNgULEpYNk9AeOPWvQ/FniCxis5bNAlzMx2seqqR/M1wbTlG3LH8xGAWq5ty1a1PpsPVqVIXmtSrMkSuBLj3w3SvU/AF3Zz6EkdijRiEkPk5JYnO7NeUwW097eJbwKXnlcKg+vf6e9dTr3iOz+G1hDpWnwrfavOvmyu5wqHsWA/QccdetOlSlVfJDVsyxsPaxVKOsn/Wp6oX6EnH86jkwVP5V833nxS8T7mlfVTApPSOJAAfQDFaXhj413y3TRaxGmoQnPQCKRfoQMED0I/Gu2eVVoq+j+f/AADzZ4CdNpcyv2vr+J7fqV5b6ZaNNOwWMcbVGN3sK5z/AIS6QEP9hP2f+8W5x61S8YXkWp6XpGp2MjTaXJk7wOhPHPuOR7VY1Fbe38Mb8KzN075rhso25lqzWlRgoJzV23b0Ov0++hvrSO4t23I/r1B968x+P3hpNX8PLfxo5nt22yMgJG3sT7A/zqf+27jw14asooCDeXoafLc+Wp6YHvUOmeO7uJZBqka3kTg4ThSPrx+la4ecqFT2kdUvxXUqGCnGTnFXjqrd1sz58g8NA2JAmT7W7lgWztC+hqtceHr9LgomyUA/NIhyqjp+Ve+Sf8IPe3G+60ae1aTktDMdo/4CCMfgK1r3Q/DXhW0t7qytTez3K7onnfeoxyGx044r2JZhhmrKLT/rrcueDw3ux5JJ/wBebRx3hLQH0XTYLm73IgBFvG33s9N2PTrVttwJOcjParDX817I0tw5Z/4i3p2qOYqeRwOuPevIxOKlXndnpRTW523hWxttd0MpqcO4wORHJnawU9sj/PNaVmdD0Fz9kBMh+V3U7z+fpWXPPJa+DdP+yIYkn5lZf4j7/Wp9KSwaz/fAbj6n2rFNpO97HmTi5czbfLfZHTaZrNpqBK27/MvVW4Iq8XLMRgbQP1rgdFtnfxMJbUMII8lm7Yq3rfjyw028eCCNrp1OHZWwM+1DjraJzTwjc+Wkr6fcdkSM/NjBJ61Dc3cdrA01zKsUKclnOABXL2njDTb/AEqaSKcW90FIWORuc9sHpXlusatqF6XiuriSUZPG7gH+tOMbt30NKGAnUbUtLHs+neLdHvroW0F6nndg3yhj7V0kbbjx09q+YbC3lku4lgOHJ4Of1r6Tsd6QxrIcuAATnvjrSqKKtykY/BwoWcHuXuvBqrfb2tJ/L4cxsF+uKsBuM+/Y01+hJ6Y4x3qEzzI6O589Xu9bqUS5DhsnI5pEcfKckBsjAPIr1TxD4Ms9TumuI3NtM4y+FyrE98etcRrPgnVLOX/Q0a7jPRo+MY9q3lao9GfT0cZSqJa2Zl29wI1kUAlj/F1I9qKtReHNYEQeSycZ42Ac/XFFCTRtz0+6NvxxpsOnQ2SWMQhgLFXZfX61bTTtMtNFZkdDLt+Y/wCFc/Z+I52AtdSj+12zgE7x07cHsav+IE0nSba0nhjnkluBvjhd/lX6isVrZGHLNctOT1/M6L4dxTR2l3IykRvKPLJ74rX8Uz2/9lSwS3Aj85liUhS3zMcLkAHAzgFjwO5FeUt4k1NiNly0SD7scXyqo9vSobi7uZJPMkmdnOcknrVdb3M5YKU6vtG7HQ21/f6FuguLRlRzw2Mg+4NR2CEX51rUFaGztm3jjmRh0UfWoPDevT2d2kc4M1seqOM49/rVr4l36XMlrFbSL9nRd+Bxgn2qZT1tbc35X7Tktv1G3HxE1J7nzIYoY4N3Ee3PHoTXovhfWE1rTFulTY/KOg6A14IOjbjn2xXX+GPFUuiQm3SJHgJ3MSOfwqU09IojF4GMqf7qOp6h4j04axpFzZM5iWVcbl7YOa+b9Vskt76SGORXEbFcr049q9x0bxraag/k3KGEtwGU5A+o7V5l4s8M3Gj6mW3LJazsWifuQex+laqTUXFkZcpUW6dTTsV/AOqJoWvRXMiNIPuEA4GD1NfRNpMk0aSwuHjYbg4OQa+bIYFjPfP05616F8LtY8i8ktLiYiKZcIrdA+f61LfMr9ULMsN7WPtY7o9bXn+lO7NxxUaHIx3FSe3r61nc+aYjZC5xXnvxG1S5S6tdNtJGTzAHdl4z2AJr0EnIOD/9auP8b6BLqaQ3VkAbqDOBnG4f41dKSUtTswMoRqpzMiLQZ9Ps0u0uXEi4cgHGa6Ozv5b7QJZ0/wBcI2TI/vY61w+/XLrFo9tcZHyncpAA+td9oOnNp2lxQOwMv3nOeOe3vVzuleW534r3YpzabueQIhlZ42Y7i2VJ9ae2GTa4+cdmrsfEvhOZ7t7jTAGVyWaMkAqc9vapfC3h+7F15+qRIIl5CSAEk8fp9aU9feudzxdPk57/AOZQ8AWi2ceo6zcQ5jtLd3iZs8sAScflivCdX1Ge/vL3UdQlaSeZmmkY9z1x7DtX13JawyWsls0a+RKrIyAYG0ggj9a+XvGvhufQdTu9OniaSAhvIkcEBwRwfwr2MncJSmuun3GODr+3nOS+K2n9ep59qerS3yQpIkYSPIUgYJB9T3qLTrZ3uIgjlWLb9xGcAVUmBAVWAUEcDNdJokcEFukxRnaRfmycHHoP0NerBc8/ePMw0Z4qveo721Z618F5n1BtY0CYlrO4t/PB6+W6kDIHvn9BXbjwvq08ItbmaIW65+fOePUCqnwR8My6TpM+pX8YS4vgoiVgNyxdc+2SensK9JY/KfWvnMdVXt5cn9M68Ti3Cq1D+meU/ErTpLa/0+RQzW6wLEGx0K1zLRZhWQgKhGFOevrXsHiXUtLsYBHqxV0kOBEU3Ej19q8o125t5dSkNpG0dsh2xx+g7VxXvFHdgqspwSa26me0Ab7kiEjoOQSK7jxJpd6PB2jF42aS1/1gU5IB6dK8/duhO5eck55Fe0+B5XufDNoZX3Fcpk+gNLmaSZWNm6SjNdH+jPKbOKWWURQjcTwBjkk/0rrtN8G39zKhvNsEH8WSCxH0Feiw2VvE++OCKNvUIAf5VbVcZwORRz2d0jzq2ZyekFYpJYQrYpamNGgChAjDIArObw3YLIWVGAJyVB46V0GMYA44qOQAnHrRFtdTz415p6MxtTtxa6LdixiCP5TFQBznH614G6lnJOTk9TXp3jPxnc2mpSWWmBV8r5XkK5JPcVxcgS4aOUxKjvy20YGfX/61aaxWvU97AQnTg5T6lG3t9oXG4t2x/KpZLUSNuBG7qVxz9KnubVZ1eGRN8bdVyQTzkdPpV1YgbYkqC+dx+n4VjzN7na5GN5Ijwsec47HmvWvAGtx31jHaSSM13brg7v4h6j1rzaSPGSeBnJNb3gBEXxIrNKE+RgoPG4+gq4vmTTOXGU1VpO/TU9bVxgDJyeaAVGSAOTnIHX3rk/FniR9JeOC1jV7mQZ+bkAdqyrbxNq1uI7i9jR4GPPy4wO/NXGm2rniQwVSceddTvmUKqgcgAYzz+tQTbYxvd8KvUtjH40WtwtzbRSxfcdQy+4rk/iRdXEemQ29vuAnbDMDjgUoRu7E0aTnUUDQm8UaNBL5cl4gYHqASKK87utDii07z3mjLNyAGFFaOMOh6kcDSl1ZveE9Bs75HkuU3MvIAPWul1rw1Y6qkYuEPmRrtV1OCB/X6Vi+E/MTVEC5GVwfpXdgcDPGQfwrC7T0OfF1pwq3TPN5/h03mnyb0BPVl5q3a+CLW3Be4meU9cfdFd6QNuPbn6VwfxO1Ga1sILa3bZ52S7A44FWry0HRxNavJQuc74ttrSwhLaVMhIOGjDbifeuJluZJdoc9PXtRbSSLLvViG55qO4JbacDpk9hWE35nvUocis3cfEWcqMZ9cc1pWNjc3SSNFBI4QZPynCj3rKtZC88QckKWwTjp9K9W129aSws7PT3IjliDMy9WB6Cpjo0ia9RwaSW5wtppt69yi28EjuTjCryfpXpC+FLi+0eOPUZ2W5UfIuchPrXL/AGO8090mVnRlOQdx49q9V0i4N5ptvcMPmkTnHrXQ5NJM8vHYicFGUDwu6tmsLyeKVVeWGRomIOQGHUZ79R9PrTtAt7m91e2gtA29pFOfQZ659q9xutJtr9XS/tLd1DkJg7iV7HoME85HP1Oafpmk2emqRZ20UO7glByfbNLnS1W5m81jyba/gXoQQoGSSOKmI7Dr6U1AR06DincH16/lWZ4LeomMgf1phGR9e1PC8Ae2KGwM9yew60BchdQOevGAM/0pkh25yQAOpz0H1rLvfEFtDdPbxq80inDFegPse/WquqXo1DQ71LXelx5R+Rvve+KtQfU6oUJu3MtGZ974xsIJ/JgikuACQXHAI9q1dE1uz1P5YGZZRyUfGf8A69cx4OsLH7M8k4ja53HO/sPSs6d0tvFUX9mnGZVwF75ODWvLFtxW6PSlhqUrwje66nqijp6jjis7W9DsdatfI1GBZUHKnup9jWinPTg5p2ck/n9ayjOUHzRdmePGcoSvF2Z4rqvwI06e/ae11F4kZ9wR492PXuM10nhn4YaJolwtzOH1C4QYU3CjYvuF/wAa9FJxn8q4z4j6nLY6bHDbuyNcEhmHXA/xrs+vYir7jlv6HbQrVasvZxdr9kl+RsNrOmpP9na8iEp7A9Px6VyXj7xbc2N01lprhWCjzJR6nsPQVxtlZS3DBlJ45461q69pN1fIt9axPMrIA6KuWUgenpxXOlFS7npU8HSpTTk7+pzl1cT387TXUhllY8lzk/54qd18+3hOAXiG1yOp9CRUOn6fdXdwILaCQyM2NpBwDXonhTwbLY3aXOpMhdeUiQ5Gff1xSkn9o7K1aFBav5Hm0seXwOcnjPWvXPh3aXFr4eUXC+WZHMiKeoU47fhWqmhaas/mrZQCXOc7O/rWrCoVf5iobVrI8nF45VockUSrz7+maUn/ABzTQxC++PWs/VNShsdPnu3dWWNcbVbkntUo8uMHJ2RcnnjhQNI6Ivq7AVWa9tiFdZkK9Mg9a8ivdSutWuzNdSF/m4H8IH0FbVt5iWgjRiMc884z61rypLc9T+zuRLmepm+KtFY63cXEGXilO5OPXms1IAiAscEHPv64rr7e58uNkkDOnII96zRp0WqfaFsQVu0XzFiJzv8AUD3pTlzbnoQquKtLZGMWjj69jn/9XvU1m5neVIQdwU5Xue/HrWe8bplXBDg4OeoNaPhO2nn8QWX2dWyr73bHAHepULm07KLZTCK5+Vue+PWpdPSQXlr5KnzPMGAPTNel6h4R0+9laZEeB2yWMZwCfp0qzo3hmy0yYSxh5JhwHc9MjnA/rVRcVqcMsxp8t1ucz49spkv4tREZaIoEYgZ2keo9Kz5tZa8tI7K3hDSHhcDj6+1envErqVYAgjBB71yPjKKO0t4Y7aJIo5id7Iu3OO3FVBp2TWqObDYlT5abWq2J9J1WxtbGC2ebc0UYDsgyoP17is34iXUcujW/kkPFIxO8Hp7VZ0iwtTbKSF3KM59DjrUENtBfT3OkznMMn7xGXqjD/GqVk7lqMI1PaK+mrPL5Xk2ldxK9gT2ortpPh9c/aAFuojBu5ODnFFXePVnofXKK+0dvoulJp6ZJzKRgt0x3PFS6nq9ppqZuZQCRgIOSauBdkbAFiWJfLNnrzj6CvJPGc8smv3AfJ2thewAwK542e55WHpfWqj52dDqPjiUzlbGJQoPBcZOfWmXUkfjXRWCBI9Sg+ZRnhx61xaEAknggjH/6q2/BkV1JrkT2u7y4zmVj0Vfc/wBKd+q0selPDwpR54aNHHS2lxany7iJ42DYO5cYI/nVRhhySOOu73r3/UtLstUg2ToksfUH0PsayLDwRpVtN5hjMx7LJyB+FQ0nqEMyha8lZnjFhazXd2lvbxM0znAVFyc16dqWnXGlWunPjzFhiCOV5w3U121ho9nZMWtraKFz1ZUANaP2ZHQq6grtwQRkUk0mc1fM1KSstEeb3V9c61LDbWkZJPHA7+/+NelaXb/ZbOGAEERrj6mktbO3gB8mKOPjJ2qBVocADHP51UpJ6I83E4hVUoxVkh/qec0dSDUMlwkbAuyqvqTjilSVWTKkMOxXnNQcnK9yYjI9xzmlGSO/09ai39cnnrSpJuIYEH3HNBNmSDA7Z7iorvIhk2/eCnH1xUmfTqeaVgBwKATszz3wu0STzvcn98G6sfzrQaYT6/bLbIcgkNjuPcVf1Lw5FPO89u5hlY5bAyD71Wn0yLSNOurmWd2l8sxmQ5BXPHGOhrZtSd77nr+2p1HzJ6vSxm6/odjC4nXUPsKyEgrjcCfap/C+hWEMhvoroXko4DgYVT9PWvPNk8W6Oa+e7BOA8hJJHvmtTQdYuNHuixJMbDLqTww/xq6iabipXO2eHqez5VO7/r5nr68Ac45xTs49iDwKz57+3trIXUkipCwBDMcA57VkjxfozTeWLscn7xU9a57N6o8ONCc9Yps6MbUXA6Dtmud8X6L/AGxYqsbKtxFkx/1B9qTWfFumaYo8+5VmY8JHyay7Px1pFxIFeSSIlsZkGevuO1VC695I6KFCvFqpGLOY1IXPh6wjj2FbyY43sPugf3R7+tYlvreq2Vz5kF3IHx/E+c+vHSup+Jd5DcRWkcGyWTlvMByAD0FeebCuSerHLE9+P/rVSs0nbc93Dr2lPmmtWe6eFb46ppcV1LGiTHKsQMAkd63AvB5x2P8A9auQ+GLyP4aRXHCyMEPqP85rslHyjBwPyqGuVtHz+KShVlFbXGScdznPasC98U6Xa3Rge7BZTg7AWUe2aseL7iS08O3s0OQ4TaCO2Tg14tGN8/zkgkZPFXGCtdnVgsHGtFyk9D1jxTqpNnbi0k/dy/MWH8q4m6Z2SVSSQRkqc81vSuk+mWqxhhtGMH1x1/8A11jTx/Lz97pgmpT0sjtw8FTjyozNPUpMMjBbkY6muk8vyoUmchYto3MxwB+NW9D8IieKK7uZ2CPgiNBjj3NddLp1t5QhNsJFYbSuBgLjBB/z3puxniMZBSstTzy9mCBl5HrWWk7pcGWMt/wE4IFdPqfhG+NwTaSJJEezHG32pB4Lm+ygpcR/bF/g7Y9M1TUe5rHEUUvi3MW1txdh5p13Rx53Njk/T1rqfAZSRbn7OoEKkAsByT2/Gsq18KanI6pM6QRZ5+bdx3rutH06HTrRIIM7RyWPVj6mk9tzmxleHI4p3uaAUAc4696kHQH2pvdeOO9OYHvWZ4rYmOT3zzmsnXtLXUrFoS21xzGT2NbB54bjHTimsoIP65qlK2qKpzcGpI8yex1i1JhSCUpnHyDINbnhXR7i3le5vNwncYVc9B1rrWQHPuKTZgcDnrVurdWsds8bKceW1rkLDC8Y47CinS4QFicAd/50UjnjqV3ZVU8gAD8q4rVrex13VZYonRZwMeYvc1oeObiWHR5jE5UsACR6V5loVzMmoRukjBt2c0ktLnrYPDtxdRPU7zT/AAPBEM3s7OAOAvH61hXy3t/etpulAWtlEcfKdpfHG5j3NemxMWgjdvvGNST9RXnPif8A0a/l+zkx7ic4PWrpajw1adWT5nqReHr+40TWobaSUyRM211zkV6zGML7gfhmvE/DX+k67amfLkvzk+h4r2wcbsegpVVqYZlFKS7kuAM8dPUU7+Z9aav3sdsUL90nvWJ5ViTr64Hr2qC5m8uOR2GAoLAj2FSucdO/+FQXYDRurcqQcimggtVc8+33OsXTPLKwVm+UDOB1OB6dDVu3vJ9G1JIXLPExCsp75pvh12W9mRThQwAFVNXleW/tTIckuB0/2hWjleTie61zS9m1oWNbvrrVNbks7aV44UITCnHPqaVJ7rQ50YSs0ZOChPBqlqDGDxNcGE7CWzx9Kr6zNJNIglcsCAD2p31UehUaa5YxtpY9QtZxM0TLnayBl9gat56fmKqWChLOFVGAsQx+VWh0P0rG58/UtfQU+/APQ/zrI8S2L6hpcsEZw5wy56Ejsa1z/rcdsZqOTkMD6gU07PQKcnCSkjxPUrK6sZvLuYXRxyMjjr6/nTNKhN7qdvb7DLukAYL2Gf8A9dexXdvDcDZPGsiHswzVex0+0s2b7NbxxEk5Kjmr5k35ntLMk4ax1PMPHt5eNqsljO22ODCIiEhduOv1rldjM4YN0OfTNeo/ES0gktre4aMGYMy7+hxivNCPkYemR/Kqkmopo78HNSpJpWIL6MzjLv8AN9e31qokGWwGyAeSPSlmYmRgTwDT7Mnc6/wlCCPwzWfPJHalY1E1Bbu2iinDL5f3XAySPenL9hG0yGeRM8rgLmstACT9KeCTHk+hP60k2pEuCWx7p4XnsbjSLd9MQR2yrgJj7p9D61tA+uCf51598KXY2N6CxIDrj2zmvQV6kds1UlZnyuMp+zqyiVNStY72zlt5/wDVyKVavKNZ8O3WjyNuXdAT8kq9D7Y7GvX5CQhPtmsC/P2y3u4bkLJEFyFKjg0KbSt0NsFXnT0WxwunXcS2c8dw7bTjbt52n3PpW74YtbLVZnimMjFBuGeAa5H/AJa47Yrsfhsi+ZdNj5toGfzo5d2enivcpyktzvIEVEVVACqMAAdqc2cHHPtS9I8jrjNRTkhHwcfKak+c3Zz/AIv1VtPtkihOJZjw390d65O4sry3t47xZ5FcneCGrS+JnC2Td9xH4cVzrXlw1msTSsU+bg1ulypW6nuYSnalFx67nb2OvhfD8F5dAGdsrsJwWI9+eafZeKreaQRyRvb7vuscECuV1FQNO0NMDbsJx7lua0tYgiXS4nVFDlOSBz2oSiZyw1Lqt2/kd4jlghUgoc5yMkjHGP0qY8Akev51z/hGR5NEtjIxYgYya3weh71lJcrseTVhyTcewoHb0/SkPQjuf50EnfTST+tSZpAcEc4I96aSduBw1R7jk89qQMTkE8Zp2L5Rk+8xSAMCxUheMc0U6QnKj1oq02jaE+VH/9k=);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Peripheral blood smear from a patient with cold agglutinin hemolytic anemia shows marked red blood cell agglutination into irregular clumps.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Carola von Kapff, SH (ASCP).",
"    </div>",
"   </div>",
"  </div>",
"  <div class=\"figure\" style=\"width: 450px\">",
"   <div class=\"ttl\">",
"    Normal peripheral blood smear",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 393px; height: 257px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    High power view of a normal peripheral blood smear. Several platelets (black arrows) and a normal lymphocyte (blue arrow) can also be seen. The red cells are of relatively uniform size and shape. The diameter of the normal red cell should approximate that of the nucleus of the small lymphocyte; central pallor (red arrow) should equal one-third of its diameter.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Carola von Kapff, SH (ASCP).",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f15_10_15527=[""].join("\n");
var outline_f15_10_15527=null;
var title_f15_10_15528="Contact thermal devices, endoscopic hemoclips, and epinephrine injection for ulcer hemostasis";
var content_f15_10_15528=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"   </img>",
"  </div>",
"  <div id=\"printHeaderText\">",
"   Official reprint from  UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"   <a href=\"file://www.uptodate.com\">",
"    www.uptodate.com",
"   </a>",
"   <br>",
"    &copy;2013 UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"   </br>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Contact thermal devices, endoscopic hemoclips, and epinephrine injection for ulcer hemostasis",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?15/10/15528/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?15/10/15528/contributors\">",
"     John R Saltzman, MD, FACP, FACG, FASGE",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?15/10/15528/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?15/10/15528/contributors\">",
"     Douglas A Howell, MD, FASGE, FACG",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?15/10/15528/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?15/10/15528/contributors\">",
"     Anne C Travis, MD, MSc, FACG",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?15/10/15528/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   May 8, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Peptic ulcer disease (PUD) is common throughout the world. Various medical initiatives such as eradication of H. pylori and preventive therapy in patients at risk for PUD have decreased the incidence of PUD bleeding in the United States and in other countries [",
"    <a class=\"abstract\" href=\"UTD.htm?15/10/15528/abstract/1-3\">",
"     1-3",
"    </a>",
"    ]. However, PUD continues to account for approximately 40 to 50 percent of patients who present to the emergency department with severe upper gastrointestinal (UGI) bleeding [",
"    <a class=\"abstract\" href=\"UTD.htm?15/10/15528/abstract/1,4,5\">",
"     1,4,5",
"    </a>",
"    ]. The outcome of bleeding PUD has improved largely due to the introduction of proton pump inhibitors (PPIs), major improvements in endoscopic diagnosis and treatment, and recognition of ulcer characteristics associated with an increased risk of continued or recurrent bleeding [",
"    <a class=\"abstract\" href=\"UTD.htm?15/10/15528/abstract/1,2,4-12\">",
"     1,2,4-12",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/15/24826?source=see_link\">",
"     \"Overview of the treatment of bleeding peptic ulcers\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    This topic will discuss the endoscopic treatment of patients with peptic ulcer bleeding, focusing primarily on contact thermal methods and endoscopic clips. An overview of the medical and surgical management of patients with UGI bleeding and general recommendations for the treatment of bleeding peptic ulcers are presented elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/55/28538?source=see_link\">",
"     \"Approach to acute upper gastrointestinal bleeding in adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/15/24826?source=see_link\">",
"     \"Overview of the treatment of bleeding peptic ulcers\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     EQUIPMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;Endoscopic diagnosis and treatment of severe UGI bleeding is best performed with therapeutic video-endoscopes that have a single large suction channel (3.7 to 6 mm diameter) or two suction channels (at least one large diameter). These endoscopes have a separate water jet for target irrigation of the bleeding site. Large diameter (3.2 mm) thermal probes (heater probe or multipolar probes), hemoclips, an injection needle, snares (for adherent clot removal after epinephrine injection), epinephrine (diluted 1:10,000 to 1:100,000 for injection), and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/32/25093?source=see_link\">",
"     glucagon",
"    </a>",
"    (for control of peristalsis) should be available.",
"   </p>",
"   <p>",
"    A number of endoscopic methods for ulcer hemostasis have been evaluated. Two thermal devices (multipolar probe and heater probe) have gained popularity in the United States (US) because of their relatively low cost, portability, easy maintenance, high efficacy, and safety. Endoscopic hemoclips have also been widely adopted following improvements in their design, particularly with the grasp-and-release and rotation capabilities of contemporary models. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?14/23/14712?source=see_link\">",
"     \"Endoclip therapy in the gastrointestinal tract: Bleeding lesions and beyond\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Any of these methods can be used with or without the prior injection of a small amount of dilute epinephrine. Epinephrine injection is often used initially (before thermal coagulation or hemoclipping) for treatment of ulcers with active bleeding to decrease bleeding so that endoscopic therapy can be accurately targeted. It is also used in patients with adherent clots to prevent rebleeding induced by clot removal or contact with accessories. (See",
"    <a class=\"local\" href=\"#H10\">",
"     'Epinephrine injection'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Doppler ultrasound probes (DUP) probes can be used to help determine the risk of continued or ongoing bleeding [",
"    <a class=\"abstract\" href=\"UTD.htm?15/10/15528/abstract/11,12\">",
"     11,12",
"    </a>",
"    ]. The probes help visualize the underlying blood flow to determine whether hemostasis is complete [",
"    <a class=\"abstract\" href=\"UTD.htm?15/10/15528/abstract/12\">",
"     12",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H7\">",
"     'Endoscopic Doppler ultrasound probe'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Contact thermal devices",
"    </span>",
"    &nbsp;&mdash;&nbsp;Two types of contact devices have gained popularity with endoscopists in the United States due to their good efficacy and safety profiles:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Multipolar probes (eg, Gold probe, Microvasive Boston Scientific, Natick, MA, or BICAP, Circon, ACMI, Stamford, CN)",
"     </li>",
"     <li>",
"      Heater probe (Olympus Corp., Lake Success, NY)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Multipolar probes",
"    </span>",
"    &nbsp;&mdash;&nbsp;Multipolar electrocautery (MPEC) probes achieve hemostasis by heating the contacted tissue with electricity that passes between the alternating arrays of positive and the negative electrodes located at the tip of the probe. Tissue coagulation occurs at the tip or sides of the multipolar probe when the tissue temperature reaches 60&ordm;C. The tissue's resistance to further coagulation increases exponentially once the tissue in contact with the MPEC probe has been completely desiccated. As a result, deep tissue coagulation is restricted. Coagulation depth can be increased by using large probes, slower coagulation for longer time, low energy, and firmer contact (tamponade).",
"   </p>",
"   <p>",
"    Coaptive coagulation is the goal of coagulation therapy of ulcers. By applying pressure directly over the vessel with the probe while applying cautery, the bleeding vessel is cauterized in a sealed state. MPEC probes can be used perpendicularly or tangentially to the lesion being treated since the electrode tip allows for therapy with any angle of surface contact.",
"   </p>",
"   <p>",
"    The standard MPEC probe allows for water irrigation at the tip of the probe, which can facilitate washing the bleeding site to allow visualization and precise application of endoscopic therapy. To prevent the probe from sticking to the area that has been treated with cautery, the area can be irrigated through the probe after each application of cautery to gently separate the probe from the underlying area.",
"   </p>",
"   <p>",
"    A catheter that combines a multipolar probe with an injection needle (the Injection-Gold probe, Microvasive Boston Scientific, Natick, MA) allows for the direct use of combination therapy of major stigmata of ulcer and other types of focal nonvariceal hemorrhage. The device has a retractable needle inside an MPEC probe and permits targeted irrigation, protraction of the needle for epinephrine injection, and subsequent (with retraction of the needle into the catheter) coagulation of the ulcer base without the need to exchange catheters.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Heater probe",
"    </span>",
"    &nbsp;&mdash;&nbsp;The heater probe has a thermocouple at the tip of the probe that can heat up quickly and achieve tissue coagulation. Because it uses heat transfer across a ceramic tip as its mode of coagulation, the penetration of tissue coagulation is not limited by tissue water, resistance, and desiccation, as it is with the multipolar probes. As a result, deep coagulation is feasible with the heater probe, but this effect can be dangerous if perforation is a concern, such as acute bleeding lesions with thin bases. Heater probes must be applied perpendicularly to the lesion being treated, which can be a limitation when treating lesions in difficult-to-access locations (such as high on the lesser curvature of the stomach).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Endoscopic hemoclips",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are different types of hemoclips with two or three prongs loaded inside a catheter, which can be advanced through the biopsy channel of the endoscope and deployed on bleeding lesions. Once extended out of the endoscope, the hemoclip can be opened and positioned on the stigma of hemorrhage in the ulcer base. The hemoclip is then closed, locked, and deployed onto the stigma in the ulcer base. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?14/23/14712?source=see_link\">",
"     \"Endoclip therapy in the gastrointestinal tract: Bleeding lesions and beyond\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Four hemoclips are commercially available:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      QuickClip2 (Olympus Corp., Lake Success, NY)",
"     </li>",
"     <li>",
"      TriClip (Wilson-Cook)",
"     </li>",
"     <li>",
"      Instinct Clip (Wilson-Cook)",
"     </li>",
"     <li>",
"      Resolution Clip (Microvasive Boston Scientific, Natick, MA)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Three of the hemoclips have two prongs (QuickClip2, Instinct Clip, and Resolution Clip), and one (TriClip) has three prongs. The hemoclips with two prongs each have different operating characteristics. The QuickClip2 can be rotated but only can be closed once. The Resolution Clip can be repeatedly opened and closed but cannot be rotated. These hemoclips are not approved for use in patients undergoing MRI procedures as they are potentially electromagnetic and may move or dislodge with an MRI. The Instinct Clip both rotates and can be opened and closed (up to five times). This hemoclip has an MRI conditional approval, meaning that the hemoclip is safe to use in patients undergoing MRI (3 Tesla or less).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Endoscopic Doppler ultrasound probe",
"    </span>",
"    &nbsp;&mdash;&nbsp;An endoscopic Doppler ultrasound probe (Vascular Technologies, Inc.) consists of a thin catheter that can be advanced through the biopsy channel of an endoscope with an ultrasound probe at the tip. It can be used to evaluate blood flow underlying the ulcer bed before and after treatment [",
"    <a class=\"abstract\" href=\"UTD.htm?15/10/15528/abstract/11,12\">",
"     11,12",
"    </a>",
"    ]. The Doppler ultrasound probe may be complementary to clinical standard endoscopic assessment of bleeding risk. The risk of recurrent or ongoing bleeding is increased when underlying blood flow can be seen beneath the ulcer, whereas recurrent bleeding is less likely when blood flow is absent upon completion of non-variceal upper GI bleed hemostasis.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h1\">",
"     ACTIVE ARTERIAL BLEEDING",
"    </span>",
"    &nbsp;&mdash;&nbsp;Active arterial bleeding is present at endoscopy in approximately 10 to 15 percent of patients with upper gastrointestinal bleeding from peptic ulcers [",
"    <a class=\"abstract\" href=\"UTD.htm?15/10/15528/abstract/1-5\">",
"     1-5",
"    </a>",
"    ]. Continued arterial-type bleeding occurs in about 80 to 90 percent of such patients who are treated with medical therapy alone (eg, with a histamine 2 receptor antagonists (H2RAs) or PPIs).",
"   </p>",
"   <p>",
"    Several studies have demonstrated the efficacy of combination endoscopic therapy (epinephrine injection followed by thermal coagulation with either a heater or multipolar probe) in the control of bleeding and reduction in rebleeding [",
"    <a class=\"abstract\" href=\"UTD.htm?15/10/15528/abstract/4,6-8,13\">",
"     4,6-8,13",
"    </a>",
"    ]. Multiple studies have also demonstrated comparable efficacy and safety with the use of one type of endoscopic hemoclip (Olympus) with or without prior epinephrine injection [",
"    <a class=\"abstract\" href=\"UTD.htm?15/10/15528/abstract/12-21\">",
"     12-21",
"    </a>",
"    ]. A prospective study of patients considered to be at high risk of bleeding who were treated with epinephrine injection and hemoclipping (Resolution Clip) had significantly better outcomes than those treated with epinephrine injection and 10 French MPEC [",
"    <a class=\"abstract\" href=\"UTD.htm?15/10/15528/abstract/22\">",
"     22",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Hemostasis techniques",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h3\">",
"     Epinephrine injection",
"    </span>",
"    &nbsp;&mdash;&nbsp;Epinephrine diluted with saline to 1:10,000 to 1:20,000 is injected in 0.5 to 2.0 mL aliquots in four quadrants within 3 mm of the bleeding site. In patients who are at increased risk of having an adverse event with epinephrine injection, such as those with significant cardiac disease or those with lesions close to the esophagogastric junction (epinephrine injected into this area may enter the systemic circulation without a first pass through the liver), a dilution of 1:100,000 can be used. A total of up to 10 mL of epinephrine solution is injected, depending upon the location and size of the ulcer, and the success in diminishing bleeding by volume tamponade",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    vasoconstriction. Larger volumes may rarely be required to achieve initial control and adequate visualization to allow for subsequent precise endoscopic therapy. Epinephrine monotherapy should not be used to control bleeding as it is inferior to other monotherapies and to combination therapy. This epinephrine injection is followed by tamponade of the bleeding site with the thermal probe and then thermal coagulation of the bleeding site (and the underlying vessel) with either a multipolar or heater probe. Alternatively, injection therapy can be followed with the placement of hemoclips.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h3\">",
"     Coaptive coagulation: MPEC or heater probe",
"    </span>",
"    &nbsp;&mdash;&nbsp;A multipolar probe is firmly applied on the bleeding point until bleeding completely stops. It is best to use the large diameter probe (3.2 mm diameter or 10 French) through a therapeutic endoscope, although the smaller probe (2.3 mm diameter or 7 French) can be used through a standard endoscope. Subsequently, thermal coagulation is applied with a power setting of 10 to 15 watts and continuous MPEC coagulation for 8 to 12 seconds in duration per tamponade pulse (ie, before moving the tip of the probe). This is repeated three to six times to achieve adequate coagulation.",
"   </p>",
"   <p>",
"    As an alternative, a 7 or 10 French heater probe can be used with a power setting of 30 joules. Four or five heater probe pulses (total 120 joules) are initially delivered before repositioning the probe and applying further coagulation, if necessary.",
"   </p>",
"   <p>",
"    Irrigation via the probe is used to wash the ulcer base, to release the probe to prevent sticking after cautery, and to facilitate repositioning of the probe for further treatment if bleeding continues. Target irrigation and suctioning of excess blood or fluid are extremely important to identify the specific bleeding site and focus the treatment upon it. This can be facilitated by using a two channel therapeutic video-endoscope that permits high volume suctioning through one channel while a probe or catheter is down the other channel. Therapeutic endoscopes have a separate water jet to allow for target jet irrigation (",
"    <a class=\"graphic graphic_picture graphicRef82331 \" href=\"UTD.htm?15/1/15382\">",
"     picture 1",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h3\">",
"     Hemoclips after epinephrine injection",
"    </span>",
"    &nbsp;&mdash;&nbsp;Hemoclips may be used in combination with epinephrine injection [",
"    <a class=\"abstract\" href=\"UTD.htm?15/10/15528/abstract/22\">",
"     22",
"    </a>",
"    ]. Once bleeding has slowed or subsided after epinephrine injection, target jet irrigation may be applied to the bleeding point to facilitate better visualization. The hemoclip is then opened, positioned directly on the bleeding site or nonbleeding visible vessel (and presumably the underlying bleeding vessel), and deployed. Typically, two or more hemoclips are placed on the bleeding point (or stigmata of major hemorrhage) to assure complete hemostasis (",
"    <a class=\"graphic graphic_picture graphicRef56986 \" href=\"UTD.htm?13/4/13383\">",
"     picture 2",
"    </a>",
"    ). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?14/23/14712?source=see_link\">",
"     \"Endoclip therapy in the gastrointestinal tract: Bleeding lesions and beyond\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Efficacy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Combination therapy (injection of epinephrine followed by thermal coagulation or hemoclips) is more effective for the treatment of active arterial bleeding from ulcers than monotherapy with epinephrine alone or with medical therapy alone [",
"    <a class=\"abstract\" href=\"UTD.htm?15/10/15528/abstract/6-8,13,23\">",
"     6-8,13,23",
"    </a>",
"    ]. As an example, the initial hemostasis rate was significantly higher in a randomized trial comparing combination therapy with endoscopic monotherapy in high-risk elderly patients with active arterial bleeding (100 versus 80 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?15/10/15528/abstract/13\">",
"     13",
"    </a>",
"    ]. The rate of recurrent bleeding in patients treated with such combination therapy and a proton pump inhibitor (PPI) was only 18 percent. This compares to a rate of recurrent or continued bleeding of 85 to 95 percent in similar patients treated in previous trials with medical therapy alone, and 25 to 40 percent in earlier trials of monotherapy (thermal or injection) plus H2 receptor antagonists [",
"    <a class=\"abstract\" href=\"UTD.htm?15/10/15528/abstract/4,7,8\">",
"     4,7,8",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Comparative trials with endoscopic hemoclips have reported similar efficacy to thermal coagulation and recurrent bleeding rates of 8 to 15 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?15/10/15528/abstract/17,21\">",
"     17,21",
"    </a>",
"    ]. However, one potential advantage with hemoclips is that they may permit effective hemostasis without increasing tissue damage, as occurs with thermal coagulation techniques.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h1\">",
"     NONBLEEDING VISIBLE VESSELS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The prevalence of nonbleeding vessels (NBVV) in patients who present with severe ulcer bleeding is 20 to 25 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?15/10/15528/abstract/4,6,8\">",
"     4,6,8",
"    </a>",
"    ]. The rebleeding rates for these patients in most reports have been 40 to 50 percent with medical therapy alone. Endoscopic therapy with thermal coagulation or endoscopic hemoclips significantly reduces the rebleeding rate to 10 to 15 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?15/10/15528/abstract/4,6-8,13\">",
"     4,6-8,13",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Technique",
"    </span>",
"    &nbsp;&mdash;&nbsp;For thermal coagulation of NBVV, it is best to use the large diameter probe (3.2 mm diameter or 10 French) through a therapeutic endoscope, although the smaller probe (2.3 mm diameter or 7 French) can be used through a standard endoscope. Epinephrine injections can be used around the vessel before coagulation or after coagulation, should bleeding occur. Epinephrine injection prior to thermal coagulation may be particularly helpful for large ulcers in patients with severe comorbidities or coagulopathies who are at increased risk for rebleeding or for adverse events should bleeding recur. (See",
"    <a class=\"local\" href=\"#H10\">",
"     'Epinephrine injection'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    Firm tamponade is applied directly on the visible vessel with the side or tip of the MPEC probe. Subsequently, coagulation is performed with 10 to 15 watts and 8 to 12 second pulses for multipolar probes. This is repeated three to six times to achieve adequate coagulation. Heater probe coagulation is achieved using four to five pulses at a power setting of 30 joules (eg, 100 to 200 joules). Good coagulation and complete flattening of the vessel should be the visual endpoints with either probe (",
"    <a class=\"graphic graphic_picture graphicRef79058 graphicRef70660 \" href=\"UTD.htm?13/11/13496\">",
"     picture 3A-B",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    Using a similar approach, endoscopic hemoclips are placed directly on the visible vessel in the base of the ulcer (",
"    <a class=\"graphic graphic_picture graphicRef82331 \" href=\"UTD.htm?15/1/15382\">",
"     picture 1",
"    </a>",
"    ). Epinephrine may be injected before placement of the hemoclips because bleeding can develop when they are placed, or it can be injected following hemoclip placement if bleeding occurs. Typically, two or more hemoclips are placed across the visible vessel to assure good hemostasis and entrapment of the underlying vessel [",
"    <a class=\"abstract\" href=\"UTD.htm?15/10/15528/abstract/7,22\">",
"     7,22",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?14/23/14712?source=see_link\">",
"     \"Endoclip therapy in the gastrointestinal tract: Bleeding lesions and beyond\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     Efficacy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Rebleeding rates after endoscopic thermal treatment (with multipolar or heater probes) combined with standard doses of PPIs are less than 15 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?15/10/15528/abstract/1-4,6-8\">",
"     1-4,6-8",
"    </a>",
"    ]. Similarly, after endoscopic hemoclip treatment of nonbleeding visible vessels, the recurrent bleeding rates of ulcers are markedly reduced [",
"    <a class=\"abstract\" href=\"UTD.htm?15/10/15528/abstract/12-22\">",
"     12-22",
"    </a>",
"    ], particularly with larger hemoclips.",
"   </p>",
"   <p>",
"    For high risk stigmata of hemorrhage requiring endoscopic hemostasis in patients with ulcer hemorrhage, intravenous proton pump inhibitors (typically",
"    <a class=\"drug drug_general\" href=\"UTD.htm?15/39/15993?source=see_link\">",
"     esomeprazole",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/16/32009?source=see_link\">",
"     pantoprazole",
"    </a>",
"    ) should be continued for 72 hours following endoscopic treatment. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/55/28538?source=see_link&amp;anchor=H5079756#H5079756\">",
"     \"Approach to acute upper gastrointestinal bleeding in adults\", section on 'Acid suppression'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h1\">",
"     NONBLEEDING ADHERENT CLOTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;A nonbleeding adherent clot is defined as a clot attached to an ulcer base that cannot be washed off with targeted irrigation, which obscures what is underneath but lacks active bleeding from underneath [",
"    <a class=\"abstract\" href=\"UTD.htm?15/10/15528/abstract/6,8,24\">",
"     6,8,24",
"    </a>",
"    ]. The prevalence of nonbleeding adherent clots in patients with clinically severe ulcer hemorrhage is approximately 10 percent. The rebleeding rate in elderly patients with comorbid conditions on medical therapy alone and adherent clots on chronic-appearing ulcers was 25 to 35 percent in several prospective studies and a meta-analysis [",
"    <a class=\"abstract\" href=\"UTD.htm?15/10/15528/abstract/24-26\">",
"     24-26",
"    </a>",
"    ]. By comparison, the rebleeding rate in young patients without comorbid conditions was 8 to 12 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?15/10/15528/abstract/4,27\">",
"     4,27",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    One of the problems in assessing the risk for rebleeding in patients with an adherent clot is that the clot obscures the underlying ulcer stigmata. Nonbleeding vessels may be present underneath and are associated with a significantly higher rebleeding rate than minor stigmata such as flat spots [",
"    <a class=\"abstract\" href=\"UTD.htm?15/10/15528/abstract/6-8,24-28\">",
"     6-8,24-28",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/15/24826?source=see_link&amp;anchor=H64438587#H64438587\">",
"     \"Overview of the treatment of bleeding peptic ulcers\", section on 'Stigmata of recent hemorrhage'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h2\">",
"     Technique",
"    </span>",
"    &nbsp;&mdash;&nbsp;We use the following approach for patients with nonbleeding adherent clots in ulcers and on other nonvariceal lesions [",
"    <a class=\"abstract\" href=\"UTD.htm?15/10/15528/abstract/24\">",
"     24",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Targeted jet irrigation is used to try to wash off parts of the clot. Dilute epinephrine (1:10,000 to 1:20,000 in saline) is injected in four quadrants at the pedicle of the clot. The clot is then cold guillotined with a polypectomy snare (without electrocoagulation) to shave it down (avoiding shearing of the clot) to reveal any underlying stigmata. If there is underlying significant stigmata of hemorrhage, the underlying visible vessel (or other stigmata) is coagulated (with MPEC or heater probe) using the same parameters as discussed above for nonbleeding visible vessels, or endoscopic hemoclips are applied. The technique of cold guillotine after epinephrine injection has been shown to be safe and has not induced the bleeding that occurred when clots were forcibly removed by other techniques in earlier studies [",
"    <a class=\"abstract\" href=\"UTD.htm?15/10/15528/abstract/6,8,24\">",
"     6,8,24",
"    </a>",
"    ]. Furthermore, it permits exposure and precise targeted treatment of the underlying ulcer stigmata, which often is a non-bleeding visible vessel (NBVV).",
"   </p>",
"   <p>",
"    An alternative to mechanically removing the clot is to irrigate the clot with 3 percent",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?40/41/41617?source=see_link\">",
"     hydrogen peroxide",
"    </a>",
"    using a spray catheter. Hydrogen peroxide acts by oxidizing hemoglobin, which makes the clot translucent and aids with its dissolution. While this technique has been shown to effectively remove the clot [",
"    <a class=\"abstract\" href=\"UTD.htm?15/10/15528/abstract/29-31\">",
"     29-31",
"    </a>",
"    ], it can be associated with patient discomfort and a significant amount of foaming, requiring washing before endoscopic therapy can be applied. Because of these limitations, removing clots using the cold guillotine method described above is preferred.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h2\">",
"     Efficacy",
"    </span>",
"    &nbsp;&mdash;&nbsp;While multiple studies suggest that removal of adherent clots followed by endoscopic therapy (thermal coagulation or hemoclip placement) is beneficial, meta-analyses have reached variable results. One meta-analysis of six studies with a total of 240 patients concluded that endoscopic therapy was associated with a significantly lower rate of recurrent hemorrhage in patients with bleeding peptic ulcers and adherent clots (8 versus 25 percent with medical therapy alone) [",
"    <a class=\"abstract\" href=\"UTD.htm?15/10/15528/abstract/27\">",
"     27",
"    </a>",
"    ]. On the other hand, a later meta-analysis found no clear evidence supporting specific endoscopic interventions in patients with an adherent clot [",
"    <a class=\"abstract\" href=\"UTD.htm?15/10/15528/abstract/32\">",
"     32",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Given the significant risk of recurrent bleeding in patients with adherent clots, we suggest that gentle attempts be made to remove the clot so that endoscopic treatment can be applied if needed (provided the ulcer is in a location that is amenable to endoscopic therapy should bleeding start), that additional surgical",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    interventional radiology support is available, and that the endoscopist performing the procedure is comfortable with the techniques involved with clot removal. If these conditions are not met and the patient is not actively bleeding, high dose IV PPI treatment alone is a reasonable alternative.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h1\">",
"     OOZING BLEEDING WITHOUT OTHER STIGMATA",
"    </span>",
"    &nbsp;&mdash;&nbsp;The prevalence of oozing ulcers (without other stigmata such as NBVV or adherent clots) was about 14 percent in most series [",
"    <a class=\"abstract\" href=\"UTD.htm?15/10/15528/abstract/4,5\">",
"     4,5",
"    </a>",
"    ]. The rate of rebleeding from these lesions treated with medical therapy alone has ranged from 10 to 27 percent in different reports [",
"    <a class=\"abstract\" href=\"UTD.htm?15/10/15528/abstract/6,13\">",
"     6,13",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Oozing ulcers without other stigmata can be treated easily with endoscopic monotherapy (such as heater probe, multipolar coagulation, or hemoclipping alone) if bleeding persists despite target irrigation and observation. The rebleeding rate on medical therapy is negligible after such endoscopic treatments [",
"    <a class=\"abstract\" href=\"UTD.htm?15/10/15528/abstract/6-8,13\">",
"     6-8,13",
"    </a>",
"    ]. Combination therapy does not add significantly to favorable results of monotherapy for oozing bleeding [",
"    <a class=\"abstract\" href=\"UTD.htm?15/10/15528/abstract/13\">",
"     13",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Patients with oozing ulcers (without other stigmata) who are treated with successful endoscopic hemostasis can also be considered for early discharge and outpatient follow-up, depending upon their reliability, comorbidities, and home support. Most patients with oozing bleeding alone and no other stigmata or hemorrhage do not benefit from high dose IV PPIs after successful endoscopic hemostasis [",
"    <a class=\"abstract\" href=\"UTD.htm?15/10/15528/abstract/24\">",
"     24",
"    </a>",
"    ]. Oral PPIs are sufficient in this subgroup of oozing ulcers without other stigmata.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h1\">",
"     MINOR STIGMATA OF ULCER HEMORRHAGE AND CLEAN ULCER BASE",
"    </span>",
"    &nbsp;&mdash;&nbsp;Approximately one-third of patients with severe ulcer hemorrhage have a clean ulcer base at endoscopy [",
"    <a class=\"abstract\" href=\"UTD.htm?15/10/15528/abstract/6-8\">",
"     6-8",
"    </a>",
"    ]. With current medical therapy, rebleeding rates for clean ulcers are less than 3 percent. Flat spots (usually red, black, or gray) are found in approximately 10 percent of patients with severe ulcer hemorrhage. Patients with a flat spot in an ulcer have rebleeding rates on medical therapy of less than 10 percent.",
"   </p>",
"   <p>",
"    Patients with ulcers that have a clean ulcer base or flat spots should be considered for same-day discharge from the hospital and outpatient follow-up, provided that they are reliable, do not have severe comorbidities, are not on anti-coagulant medications, and have support at home [",
"    <a class=\"abstract\" href=\"UTD.htm?15/10/15528/abstract/14-16,33-35\">",
"     14-16,33-35",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/15/24826?source=see_link&amp;anchor=H97408859#H97408859\">",
"     \"Overview of the treatment of bleeding peptic ulcers\", section on 'Inpatient versus outpatient management'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h1\">",
"     ENDOSCOPIC DOPPLER ULTRASOUND PROBE",
"    </span>",
"    &nbsp;&mdash;&nbsp;As noted above, a Doppler ultrasound probe can locate the blood supply beneath a bleeding lesion, thereby helping predict its likelihood of continued bleeding or rebleeding following therapy. The Doppler ultrasound probe was evaluated in a prospective trial in 79 patients (53 with peptic ulcers) who presented with upper GI bleeding [",
"    <a class=\"abstract\" href=\"UTD.htm?15/10/15528/abstract/12\">",
"     12",
"    </a>",
"    ]. Of the 53 patients bleeding from ulcers, 49 percent had a positive Doppler at baseline. These patients underwent endoscopic treatment. Of the 19 patients whose Doppler was positive at baseline but became negative after endoscopic treatment, only one rebled (5 percent).",
"   </p>",
"   <p>",
"    By contrast, for a cohort of 38 patients whose endoscopic treatment was not based on Doppler findings, the 30-day rebleed rate was 30 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?15/10/15528/abstract/12\">",
"     12",
"    </a>",
"    ]. None of the patients whose initial Doppler study was negative at baseline had rebleeding.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H27\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;An overall approach to treatment of bleeding peptic ulcers is presented separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/15/24826?source=see_link\">",
"     \"Overview of the treatment of bleeding peptic ulcers\"",
"    </a>",
"    .) The following pertain to our recommendations regarding specific endoscopic methods.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      For patients with active arterial bleeding or a nonbleeding visible vessel, we recommend combination endoscopic therapy (injection of epinephrine followed by thermal coaptive coagulation or endoscopic hemoclips) rather than medical therapy alone (",
"      <a class=\"grade\" href=\"._grade_1?title=Grade 1A\">",
"       Grade 1A",
"      </a>",
"      ). We also suggest combination endoscopic therapy rather than endoscopic monotherapy (",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H8\">",
"       'Active arterial bleeding'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?14/23/14712?source=see_link\">",
"       \"Endoclip therapy in the gastrointestinal tract: Bleeding lesions and beyond\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      For patients with a nonbleeding adherent clot, we suggest combination endoscopic therapy rather than medical therapy alone (",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      ) or endoscopic monotherapy (",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H14\">",
"       'Nonbleeding visible vessels'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H17\">",
"       'Nonbleeding adherent clots'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For high risk patients with nonbleeding visible vessels, we recommend endoscopic therapy rather than medical therapy alone (",
"      <a class=\"grade\" href=\"._grade_2?title=Grade 1B\">",
"       Grade 1B",
"      </a>",
"      ). We suggest thermal coagulation or hemoclips alone in average risk patients with easily accessible lesions rather than combination endoscopic therapy (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). Monotherapy in such situations is generally sufficient. (See",
"      <a class=\"local\" href=\"#H14\">",
"       'Nonbleeding visible vessels'",
"      </a>",
"      above.) For patients with ulcers that have persistent oozing bleeding without other stigmata (such as a clot or a nonbleeding visible vessel), we suggest endoscopic thermal therapy or hemoclipping alone followed by an oral PPI rather than endoscopic combination therapy or an oral PPI alone (",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      For patients whose ulcers contain flat spots or a clean ulcer base, we recommend medical therapy alone rather than endoscopic therapy (",
"      <a class=\"grade\" href=\"._grade_2?title=Grade 1B\">",
"       Grade 1B",
"      </a>",
"      ).",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2271967621\">",
"    <span class=\"h1\">",
"     ACKNOWLEDGMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;The author and UpToDate would like to thank Drs. Dennis Jensen and Gustavo Machicado, who contributed to earlier versions of this topic review.",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     Kovacs TOG, Jensen DM. Risk Factors and Recurrence of Ulcer Hemorrhage: Recommendations for Primary and Secondary Prevention. In: Gut-Brain Peptides in the New Millennium: A Tribute to John Walsh by his collaborators, Tache Y (Ed), CURE Foundation, 2002. p.473.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/10/15528/abstract/2\">",
"      Kovacs TO, Jensen DM. The short-term medical management of non-variceal upper gastrointestinal bleeding. Drugs 2008; 68:2105.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/10/15528/abstract/3\">",
"      Jensen DM, Mawas I, Lousuebsakul V, et al. Changes in the prevalence of different diagnoses for UGI hemorrhage in the last two decades (abstract). Gastrointest Endosc 2003; 57:AB147:M1796.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/10/15528/abstract/4\">",
"      Laine L, Peterson WL. Bleeding peptic ulcer. N Engl J Med 1994; 331:717.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/10/15528/abstract/5\">",
"      Savides TJ, Jensen DM, Cohen J, et al. Severe upper gastrointestinal tumor bleeding: endoscopic findings, treatment, and outcome. Endoscopy 1996; 28:244.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/10/15528/abstract/6\">",
"      Jensen DM. Thermal probe or combination therapy for non-variceal UGI hemorrhage. Techniques in Gastrointestinal Endoscopy 1999; 1:107.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/10/15528/abstract/7\">",
"      Jensen DM. Where next with endoscopic ulcer hemostasis? Am J Gastroenterol 2002; 97:2161.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/10/15528/abstract/8\">",
"      Jensen DM, Machicado GA. Endoscopic Hemostasis of Ulcer Hemorrhage with Injection, Thermal, or Combination Methods. Techniques in Gastrointestinal Endoscopy 2005; 7:124.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/10/15528/abstract/9\">",
"      Swain P. Perception and interpretation: the problem of the visible vessel. Endoscopy 1998; 30:570.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/10/15528/abstract/10\">",
"      Griffiths WJ, Neumann DA, Welsh JD. The visible vessel as an indicator of uncontrolled or recurrent gastrointestinal hemorrhage. N Engl J Med 1979; 300:1411.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/10/15528/abstract/11\">",
"      Wong RC. Endoscopic Doppler US probe for acute peptic ulcer hemorrhage. Gastrointest Endosc 2004; 60:804.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/10/15528/abstract/12\">",
"      Jensen D, Ohning G, Singh B, et al. For severe UGI hemorrhage doppler ultrasound probe is more accurate for risk stratification and helpful for complete endoscopic hemostasis than lesion stigmata alone. Gastrointest Endosc 2008; 67:AB81:264.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/10/15528/abstract/13\">",
"      Chung SS, Lau JY, Sung JJ, et al. Randomised comparison between adrenaline injection alone and adrenaline injection plus heat probe treatment for actively bleeding ulcers. BMJ 1997; 314:1307.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/10/15528/abstract/14\">",
"      Longstreth GF, Feitelberg SP. Outpatient care of selected patients with acute non-variceal upper gastrointestinal haemorrhage. Lancet 1995; 345:108.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/10/15528/abstract/15\">",
"      Lai KC, Hui WM, Wong BC, et al. A retrospective and prospective study on the safety of discharging selected patients with duodenal ulcer bleeding on the same day as endoscopy. Gastrointest Endosc 1997; 45:26.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/10/15528/abstract/16\">",
"      Lee JG, Turnipseed S, Romano PS, et al. Endoscopy-based triage significantly reduces hospitalization rates and costs of treating upper GI bleeding: a randomized controlled trial. Gastrointest Endosc 1999; 50:755.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/10/15528/abstract/17\">",
"      Lai YC, Yang SS, Wu CH, Chen TK. Endoscopic hemoclip treatment for bleeding peptic ulcer. World J Gastroenterol 2000; 6:53.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/10/15528/abstract/18\">",
"      Lin HJ, Hsieh YH, Tseng GY, et al. A prospective, randomized trial of endoscopic hemoclip versus heater probe thermocoagulation for peptic ulcer bleeding. Am J Gastroenterol 2002; 97:2250.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/10/15528/abstract/19\">",
"      Cipolletta L, Bianco MA, Marmo R, et al. Endoclips versus heater probe in preventing early recurrent bleeding from peptic ulcer: a prospective and randomized trial. Gastrointest Endosc 2001; 53:147.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/10/15528/abstract/20\">",
"      Park CH, Joo YE, Kim HS, et al. A prospective, randomized trial comparing mechanical methods of hemostasis plus epinephrine injection to epinephrine injection alone for bleeding peptic ulcer. Gastrointest Endosc 2004; 60:173.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/10/15528/abstract/21\">",
"      Saltzman JR, Strate LL, Di Sena V, et al. Prospective trial of endoscopic clips versus combination therapy in upper GI bleeding (PROTECCT--UGI bleeding). Am J Gastroenterol 2005; 100:1503.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/10/15528/abstract/22\">",
"      Jensen DM, Kovacs TOG, Ohning GV, et al. Hemostasis of very high risk patients with severe non-variceal UGI hemorrhage comparing injection-hemoclipping with injection-MPEC (abstract). Gastrointest Endosc 2008; 67:AB106:882.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/10/15528/abstract/23\">",
"      Lin HJ, Tseng GY, Perng CL, et al. Comparison of adrenaline injection and bipolar electrocoagulation for the arrest of peptic ulcer bleeding. Gut 1999; 44:715.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/10/15528/abstract/24\">",
"      Sung JJ, Barkun A, Kuipers EJ, et al. Intravenous esomeprazole for prevention of recurrent peptic ulcer bleeding: a randomized trial. Ann Intern Med 2009; 150:455.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/10/15528/abstract/25\">",
"      Jensen DM, Kovacs TO, Jutabha R, et al. Randomized trial of medical or endoscopic therapy to prevent recurrent ulcer hemorrhage in patients with adherent clots. Gastroenterology 2002; 123:407.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/10/15528/abstract/26\">",
"      Bleau BL, Gostout CJ, Sherman KE, et al. Recurrent bleeding from peptic ulcer associated with adherent clot: a randomized study comparing endoscopic treatment with medical therapy. Gastrointest Endosc 2002; 56:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/10/15528/abstract/27\">",
"      Kahi CJ, Jensen DM, Sung JJ, et al. Endoscopic therapy versus medical therapy for bleeding peptic ulcer with adherent clot: a meta-analysis. Gastroenterology 2005; 129:855.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/10/15528/abstract/28\">",
"      Laine L, Stein C, Sharma V. A prospective outcome study of patients with clot in an ulcer and the effect of irrigation. Gastrointest Endosc 1996; 43:107.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/10/15528/abstract/29\">",
"      Kalloo AN, Canto MI, Wadwa KS, et al. Clinical usefulness of 3% hydrogen peroxide in acute upper GI bleeding: a pilot study. Gastrointest Endosc 1999; 49:518.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/10/15528/abstract/30\">",
"      Wu DC, Lu CY, Lu CH, et al. Endoscopic hydrogen peroxide spray may facilitate localization of the bleeding site in acute upper gastrointestinal bleeding. Endoscopy 1999; 31:237.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/10/15528/abstract/31\">",
"      Sridhar S, Chamberlain S, Thiruvaiyaru D, et al. Hydrogen peroxide improves the visibility of ulcer bases in acute non-variceal upper gastrointestinal bleeding: a single-center prospective study. Dig Dis Sci 2009; 54:2427.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/10/15528/abstract/32\">",
"      Laine L, McQuaid KR. Endoscopic therapy for bleeding ulcers: an evidence-based approach based on meta-analyses of randomized controlled trials. Clin Gastroenterol Hepatol 2009; 7:33.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/10/15528/abstract/33\">",
"      Rockall TA, Logan RF, Devlin HB, Northfield TC. Selection of patients for early discharge or outpatient care after acute upper gastrointestinal haemorrhage. National Audit of Acute Upper Gastrointestinal Haemorrhage. Lancet 1996; 347:1138.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/10/15528/abstract/34\">",
"      Saeed ZA, Ramirez FC, Hepps KS, et al. Prospective validation of the Baylor bleeding score for predicting the likelihood of rebleeding after endoscopic hemostasis of peptic ulcers. Gastrointest Endosc 1995; 41:561.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/10/15528/abstract/35\">",
"      Blatchford O, Murray WR, Blatchford M. A risk score to predict need for treatment for upper-gastrointestinal haemorrhage. Lancet 2000; 356:1318.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 2589 Version 5.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.3 - C21.34",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Morehouse School of Medicine",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0605-93.125.6.160-7DBF348CA4-S473950.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f15_10_15528=[""].join("\n");
var outline_f15_10_15528=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H27\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      EQUIPMENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Contact thermal devices",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Multipolar probes",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Heater probe",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Endoscopic hemoclips",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Endoscopic Doppler ultrasound probe",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      ACTIVE ARTERIAL BLEEDING",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Hemostasis techniques",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      - Epinephrine injection",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      - Coaptive coagulation: MPEC or heater probe",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      - Hemoclips after epinephrine injection",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Efficacy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      NONBLEEDING VISIBLE VESSELS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Technique",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      Efficacy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      NONBLEEDING ADHERENT CLOTS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      Technique",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      Efficacy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      OOZING BLEEDING WITHOUT OTHER STIGMATA",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      MINOR STIGMATA OF ULCER HEMORRHAGE AND CLEAN ULCER BASE",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      ENDOSCOPIC DOPPLER ULTRASOUND PROBE",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H27\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2271967621\">",
"      ACKNOWLEDGMENT",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"GAST/2589\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"GAST/2589|PIC\">",
"      <a href=\"#\" title=\"PICTURES\">",
"       PICTURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?15/1/15382\" title=\"picture 1\">",
"      Epi injection hemoclipping",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?13/4/13383\" title=\"picture 2\">",
"      Epi MPEC hemostasis NBVV",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?27/62/28643\" title=\"picture 3A\">",
"      Visible vessel DU Endosc",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?31/15/31986\" title=\"picture 3B\">",
"      Duodenal vessel after Rx Endosc",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?27/55/28538?source=related_link\">",
"      Approach to acute upper gastrointestinal bleeding in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?14/23/14712?source=related_link\">",
"      Endoclip therapy in the gastrointestinal tract: Bleeding lesions and beyond",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?24/15/24826?source=related_link\">",
"      Overview of the treatment of bleeding peptic ulcers",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f15_10_15529="Evaluation of vaginal bleeding in children and adolescents";
var content_f15_10_15529=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"   </img>",
"  </div>",
"  <div id=\"printHeaderText\">",
"   Official reprint from  UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"   <a href=\"file://www.uptodate.com\">",
"    www.uptodate.com",
"   </a>",
"   <br>",
"    &copy;2013 UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"   </br>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"6\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Evaluation of vaginal bleeding in children and adolescents",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?15/10/15529/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?15/10/15529/contributors\">",
"     Jan Paradise, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?15/10/15529/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?15/10/15529/contributors\">",
"     Stephen J Teach, MD, MPH",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?15/10/15529/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?15/10/15529/contributors\">",
"     James F Wiley, II, MD, MPH",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?15/10/15529/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Apr 6, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H11716878\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The causes of vaginal bleeding in children differ substantially from the causes in adolescents. During childhood, vaginal bleeding after the first week or so of life but before menarche is always abnormal and warrants diagnostic evaluation. After menarche, pregnancy is a consideration; abnormal vaginal bleeding must be differentiated from menstruation; and menstrual bleeding must be categorized as either normal or excessive.",
"   </p>",
"   <p>",
"    This topic offers an approach to the evaluation of vaginal bleeding in children and adolescents. The evaluation of the specific condition dysfunctional uterine bleeding in adolescents and the differential diagnosis of vaginal bleeding in adult women are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?25/23/25975?source=see_link\">",
"     \"Definition and evaluation of abnormal uterine bleeding in adolescents\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/18/35113?source=see_link\">",
"     \"Overview of causes of genital tract bleeding in women\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11716885\">",
"    <span class=\"h1\">",
"     CAUSES",
"    </span>",
"    &nbsp;&mdash;&nbsp;The causes of vaginal bleeding in children and adolescents organized by patients&rsquo; menarcheal status are presented in the table (",
"    <a class=\"graphic graphic_table graphicRef64659 \" href=\"UTD.htm?19/55/20348\">",
"     table 1",
"    </a>",
"    ). Trauma as a cause of vaginal bleeding is discussed below (see",
"    <a class=\"local\" href=\"#H330649\">",
"     'Trauma'",
"    </a>",
"    below). In non-injured children, the clinician should first consider the patient&rsquo;s chronological age and stage in puberty (Tanner or sexual maturity stage) (",
"    <a class=\"graphic graphic_picture graphicRef72038 \" href=\"UTD.htm?10/43/10932\">",
"     picture 1",
"    </a>",
"    and",
"    <a class=\"graphic graphic_picture graphicRef79782 \" href=\"UTD.htm?29/33/30227\">",
"     picture 2",
"    </a>",
"    ). When evaluating adolescents who have passed menarche, the clinician must first establish whether or not the patient is pregnant. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?43/48/44808?source=see_link\">",
"     \"Clinical manifestations and diagnosis of early pregnancy\"",
"    </a>",
"    .) In adolescents who are not pregnant, the clinician will need to distinguish abnormal vaginal bleeding from normal menstruation. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?25/23/25975?source=see_link&amp;anchor=H4#H4\">",
"     \"Definition and evaluation of abnormal uterine bleeding in adolescents\", section on 'Definition'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11716893\">",
"    <span class=\"h2\">",
"     Trauma",
"    </span>",
"    &nbsp;&mdash;&nbsp;The home, and especially the bathroom, is a common location for both blunt and penetrating vaginal injuries in girls [",
"    <a class=\"abstract\" href=\"UTD.htm?15/10/15529/abstract/1\">",
"     1",
"    </a>",
"    ]. Bed frames, falls onto narrow objects like pencils, and protruding bathtub fixtures can pose hazards to girls who jump, fall, or slip on wet surfaces. Although sexual assault is an important consideration in children and adolescents with genital trauma, most injuries that cause vaginal bleeding are unintentional. Conversely, most sexual assault of children does not produce any genital trauma [",
"    <a class=\"abstract\" href=\"UTD.htm?15/10/15529/abstract/2\">",
"     2",
"    </a>",
"    ]. A discussion of how to distinguish between unintentional genital injury and sexual assault is presented separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/27/35258?source=see_link&amp;anchor=H28#H28\">",
"     \"Evaluation of sexual abuse in children and adolescents\", section on 'Differential diagnosis'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/53/35669?source=see_link&amp;anchor=H2#H2\">",
"     \"Straddle injuries\", section on 'Differentiating straddle injury from sexual abuse'",
"    </a>",
"    .) &nbsp;",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11716901\">",
"    <span class=\"h3\">",
"     Life-threatening vaginal trauma",
"    </span>",
"    &nbsp;&mdash;&nbsp;Penetrating injuries that lacerate the vaginal wall can cause life-threatening hemorrhage and can be associated with concomitant rectal injury or peritonitis. Mechanisms reported to produce major vaginal trauma include coitus [",
"    <a class=\"abstract\" href=\"UTD.htm?15/10/15529/abstract/3,4\">",
"     3,4",
"    </a>",
"    ] and recreational misadventures involving high-pressure water jets from fountains or water slides [",
"    <a class=\"abstract\" href=\"UTD.htm?15/10/15529/abstract/5\">",
"     5",
"    </a>",
"    ], and during water or jet skiing [",
"    <a class=\"abstract\" href=\"UTD.htm?15/10/15529/abstract/6,7\">",
"     6,7",
"    </a>",
"    ]. In patients whose visible perineal injuries are minor, a history of impalement or water jet injury should alert the clinician to the possibility of inapparent but severe vaginorectal trauma [",
"    <a class=\"abstract\" href=\"UTD.htm?15/10/15529/abstract/8\">",
"     8",
"    </a>",
"    ]. &nbsp;",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11716908\">",
"    <span class=\"h3\">",
"     Vulvar and vaginal trauma",
"    </span>",
"    &nbsp;&mdash;&nbsp;Most genital trauma in girls is blunt, non-penetrating, and produces relatively minor injury. As an example, an observational study of 4450 girls from birth to 16 years of age found that the most common causes of blunt perineal injury were motor vehicle collisions (63 percent), falls (16 percent), assaults (9 percent), playground and pool accidents (7 percent), and bicycles (5 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?15/10/15529/abstract/9\">",
"     9",
"    </a>",
"    ]. Only 9 percent of injuries required surgical repair. Evaluation and management of superficial vulvar and vaginal wounds are discussed in greater detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/53/35669?source=see_link&amp;anchor=H6#H6\">",
"     \"Straddle injuries\", section on 'Vulvar lacerations'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/53/35669?source=see_link&amp;anchor=H7#H7\">",
"     \"Straddle injuries\", section on 'Vaginal injuries'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11716915\">",
"    <span class=\"h2\">",
"     Vaginal bleeding before normal menarche",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11716922\">",
"    <span class=\"h3\">",
"     Life-threatening conditions",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <strong>",
"       Genital tract malignancies &ndash;",
"      </strong>",
"      Endodermal sinus tumors and rhabdomyosarcomas (including sarcoma botryoides) of the vagina are rare, accounting for about 8 percent of all pediatric germ cell tumors and about 0.3 percent of all childhood malignancies [",
"      <a class=\"abstract\" href=\"UTD.htm?15/10/15529/abstract/10,11\">",
"       10,11",
"      </a>",
"      ]. They present almost exclusively in girls under the age of three years with vaginal bleeding [",
"      <a class=\"abstract\" href=\"UTD.htm?15/10/15529/abstract/12\">",
"       12",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?15/63/16377?source=see_link\">",
"       \"Rhabdomyosarcoma and undifferentiated sarcoma in childhood and adolescence: Epidemiology, pathology, and molecular pathogenesis\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?30/30/31208?source=see_link&amp;anchor=H8#H8\">",
"       \"Vaginal cancer\", section on 'Sarcoma'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11716946\">",
"    <span class=\"h3\">",
"     Common conditions before normal menarche",
"    </span>",
"    &nbsp;&mdash;&nbsp;Among prepubertal girls referred to subspecialists, the most commonly reported causes of vaginal bleeding have been precocious puberty, foreign bodies, sexual abuse, and genital tumors [",
"    <a class=\"abstract\" href=\"UTD.htm?15/10/15529/abstract/13-15\">",
"     13-15",
"    </a>",
"    ]. However, these series likely reflect referral bias. In primary care practice, precocious puberty is uncommon, and genital tumors are rare. In the author&rsquo;s experience, the most common causes of actual or apparent vaginal bleeding in prepubertal girls are neonatal withdrawal bleeding, trauma, foreign bodies, infections, lichen sclerosus, and urethral prolapse. In addition, in some cases, a specific etiology cannot be identified despite complete evaluation [",
"    <a class=\"abstract\" href=\"UTD.htm?15/10/15529/abstract/14-16\">",
"     14-16",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <strong>",
"       Neonatal withdrawal bleeding &ndash;",
"      </strong>",
"      During intrauterine life, maternal estrogen crosses the placenta and stimulates growth of the female fetus&rsquo; endometrial lining. As this hormonal support wanes during the first few weeks after birth, some babies have an endometrial slough that results in a few days of bloody mucoid discharge or light vaginal bleeding. The bleeding is self-limited and requires no treatment.",
"     </li>",
"     <li>",
"      <strong>",
"       Vaginal foreign bodies &ndash;",
"      </strong>",
"      Vaginal bleeding with or without associated discharge is the most common symptom of prepubertal girls who have vaginal foreign bodies [",
"      <a class=\"abstract\" href=\"UTD.htm?15/10/15529/abstract/17\">",
"       17",
"      </a>",
"      ]. Conversely, vaginal foreign body is a likely diagnosis in girls who present with vaginal bleeding but no history of trauma [",
"      <a class=\"abstract\" href=\"UTD.htm?15/10/15529/abstract/18\">",
"       18",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?25/29/26072?source=see_link&amp;anchor=H13#H13\">",
"       \"Vulvovaginal complaints in the prepubertal child\", section on 'Foreign body'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      <strong>",
"       Infections &ndash;",
"      </strong>",
"      Of the bacteria that cause vaginitis in girls and women, two are particularly associated with bleeding: Streptococcus pyogenes (group A beta-hemolytic streptococci) and Shigella species. Infections with group A streptococci occur mainly in prepubertal girls. Similarly, Shigella vaginitis has not been reported in girls over the age of 10 years. Lack of estrogen, which results in a thin vaginal mucosa, an alkaline pH, and a relative paucity of protective microorganisms, is a risk factor for these and other vaginal infections [",
"      <a class=\"abstract\" href=\"UTD.htm?15/10/15529/abstract/19\">",
"       19",
"      </a>",
"      ]. All of these changes favor bacterial overgrowth.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      <strong>",
"       Group A streptococcal vaginitis &ndash;",
"      </strong>",
"      This infection",
"      <strong>",
"      </strong>",
"      is characterized by purulent vaginal discharge that is blood-tinged in about half of the cases [",
"      <a class=\"abstract\" href=\"UTD.htm?15/10/15529/abstract/20\">",
"       20",
"      </a>",
"      ]. A clinical hallmark of group A streptococcal perineal infection is a fiery or beefy red appearance of the perineal skin, often with a sharp margin (",
"      <a class=\"graphic graphic_picture graphicRef61877 \" href=\"UTD.htm?17/30/17889\">",
"       picture 3",
"      </a>",
"      ) [",
"      <a class=\"abstract\" href=\"UTD.htm?15/10/15529/abstract/21\">",
"       21",
"      </a>",
"      ]. Perineal streptococcal infection most often produces vulvar",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      perineal inflammation; true vaginitis with discharge is less common [",
"      <a class=\"abstract\" href=\"UTD.htm?15/10/15529/abstract/22\">",
"       22",
"      </a>",
"      ]. Most patients with perineal streptococcal infection do not have symptomatic pharyngitis, but throat cultures are positive in about 75 percent of cases [",
"      <a class=\"abstract\" href=\"UTD.htm?15/10/15529/abstract/20\">",
"       20",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      <strong>",
"       Shigella vaginitis &ndash;",
"      </strong>",
"      Shigella infection",
"      <strong>",
"      </strong>",
"      produces vaginal discharge that is bloody or serosanguineous in about half of the cases and often produces concomitant vulvitis [",
"      <a class=\"abstract\" href=\"UTD.htm?15/10/15529/abstract/23,24\">",
"       23,24",
"      </a>",
"      ]. Only about one-third of patients have a history of recent or concurrent diarrhea. Nearly all reported cases of this uncommon infection have been caused by Shigella flexneri. Stool cultures are generally negative [",
"      <a class=\"abstract\" href=\"UTD.htm?15/10/15529/abstract/23,25\">",
"       23,25",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?37/40/38535?source=see_link&amp;anchor=H996709308#H996709308\">",
"       \"Clinical manifestations and diagnosis of Shigella infection\", section on 'Other manifestations'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <strong>",
"       Lichen sclerosus &ndash;",
"      </strong>",
"      Although bleeding per se is not common, purpura, telangiectasias, and hematomas occur in 20 to 60 percent of girls with lichen sclerosus (",
"      <a class=\"graphic graphic_picture graphicRef75883 \" href=\"UTD.htm?40/9/41108\">",
"       picture 4",
"      </a>",
"      and",
"      <a class=\"graphic graphic_picture graphicRef80900 \" href=\"UTD.htm?9/12/9411\">",
"       picture 5",
"      </a>",
"      ) [",
"      <a class=\"abstract\" href=\"UTD.htm?15/10/15529/abstract/26\">",
"       26",
"      </a>",
"      ]. This condition (previously known as lichen sclerosus et atrophicus) is a chronic, mucocutaneous inflammatory disorder of unknown etiology that principally affects the vulva and perineum. Ninety percent of cases are in females, and of those, about 7 to 15 percent are in prepubertal girls. Misdiagnosis of lichen sclerosus as sexual abuse is a recognized cause of intense distress to patients and families [",
"      <a class=\"abstract\" href=\"UTD.htm?15/10/15529/abstract/27-29\">",
"       27-29",
"      </a>",
"      ].",
"      <br/>",
"      <br/>",
"      The most common presenting symptoms are vulvar and perineal itching, soreness, and pain with defecation. The perineal discomfort can lead to constipation in severe or undiagnosed cases [",
"      <a class=\"abstract\" href=\"UTD.htm?15/10/15529/abstract/27\">",
"       27",
"      </a>",
"      ]. On examination, the labia majora and minora, clitoris, introitus, and perineal skin show to varying extents the characteristic white, atrophic, &ldquo;cigarette-paper&rdquo; appearance (",
"      <a class=\"graphic graphic_picture graphicRef59461 \" href=\"UTD.htm?16/4/16449\">",
"       picture 6",
"      </a>",
"      ). Perineal hypopigmentation in a figure-of-eight pattern is a pathognomonic finding (",
"      <a class=\"graphic graphic_picture graphicRef57910 \" href=\"UTD.htm?39/18/40224\">",
"       picture 7",
"      </a>",
"      ).",
"      <br/>",
"      <br/>",
"      Treatment consists of topical application of superpotent steroid ointments [",
"      <a class=\"abstract\" href=\"UTD.htm?15/10/15529/abstract/30-32\">",
"       30-32",
"      </a>",
"      ] or calcineurin inhibitors (eg,",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?33/53/34640?source=see_link\">",
"       tacrolimus",
"      </a>",
"      ,",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?18/11/18612?source=see_link\">",
"       pimecrolimus",
"      </a>",
"      ) [",
"      <a class=\"abstract\" href=\"UTD.htm?15/10/15529/abstract/33\">",
"       33",
"      </a>",
"      ].",
"      <br/>",
"      <br/>",
"      Diagnosis and treatment of lichen sclerosus in adult women is discussed separately. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?6/45/6874?source=see_link\">",
"       \"Vulvar lichen sclerosus\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      <strong>",
"       Urethral prolapse &ndash;",
"      </strong>",
"      Although this condition does not actually involve the vagina, the typical presentation is a girl 2 to 10 years old with a history of &ldquo;vaginal&rdquo; bleeding and with a dusky red or purplish annular mass between the labia majora upon examination [",
"      <a class=\"abstract\" href=\"UTD.htm?15/10/15529/abstract/34-36\">",
"       34-36",
"      </a>",
"      ]. Some patients complain of dysuria or urinary frequency, but most have bleeding as their only symptom. Most children with urethral prolapse are of African ethnicity. Although the vaginal orifice can be obscured by the mass, and although clinicians often worry that it is malignant, gentle caudolateral retraction of the labia majora will generally reveal the diagnostic appearance of a prolapse: a smooth, doughnut shape with a central urethral dimple (",
"      <a class=\"graphic graphic_figure graphicRef74850 \" href=\"UTD.htm?41/19/42290\">",
"       figure 1",
"      </a>",
"      ).",
"      <br/>",
"      <br/>",
"      Treatment of urethral prolapse is discussed in more detail separately. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?25/29/26072?source=see_link&amp;anchor=H19#H19\">",
"       \"Vulvovaginal complaints in the prepubertal child\", section on 'Urethral prolapse'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11716993\">",
"    <span class=\"h3\">",
"     Uncommon conditions before menarche",
"    </span>",
"    &nbsp;&mdash;&nbsp;A variety of uncommon conditions can cause vaginal bleeding in children and premenarcheal adolescents.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <strong>",
"       Precocious puberty &ndash;",
"      </strong>",
"      Experts differ on the precise age that should mark the separation between abnormally early puberty and early but physiologic puberty in girls. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?19/5/19546?source=see_link&amp;anchor=H4#H4\">",
"       \"Definition, etiology, and evaluation of precocious puberty\", section on 'Threshold for evaluation'",
"      </a>",
"      .)",
"      <br/>",
"      <br/>",
"      In a girl who has already begun puberty, the clinician must assess whether bleeding that is presumed to be menstrual is in fact consistent with the patient&rsquo;s pubertal progression. On average, menarche occurs about two and a half years after the onset of breast development and most commonly when a girl is at sexual maturity rating stage 4 or 5 for breast development (",
"      <a class=\"graphic graphic_picture graphicRef72038 \" href=\"UTD.htm?10/43/10932\">",
"       picture 1",
"      </a>",
"      ). Bleeding out of synchrony with other signs of pubertal development (",
"      <a class=\"graphic graphic_figure graphicRef82350 \" href=\"UTD.htm?23/47/24317\">",
"       figure 2",
"      </a>",
"      ) or in a girl under the age of eight years warrants evaluation. The evaluation of girls with precocious puberty is discussed separately. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?19/5/19546?source=see_link\">",
"       \"Definition, etiology, and evaluation of precocious puberty\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      <strong>",
"       Hypothyroidism &ndash;",
"      </strong>",
"      Hypothyroidism can produce premature menstruation in association with growth delay, premature thelarche, galactorrhea, and ovarian cysts, in varying combinations (Van Wyk-Grumbach syndrome) [",
"      <a class=\"abstract\" href=\"UTD.htm?15/10/15529/abstract/37\">",
"       37",
"      </a>",
"      ]. Notably, in some cases, the massive size of the associated multicystic ovaries has distracted clinicians&rsquo; attention away from the underlying, causal hypothyroidism [",
"      <a class=\"abstract\" href=\"UTD.htm?15/10/15529/abstract/38\">",
"       38",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?19/5/19546?source=see_link&amp;anchor=H8#H8\">",
"       \"Definition, etiology, and evaluation of precocious puberty\", section on 'Causes of gonadotropin dependent precocious puberty (GDPP)'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      <strong>",
"       Hemangiomas",
"      </strong>",
"      &ndash; Infantile hemangiomas are typically small at birth, then proliferate for several months, and ultimately involute. Intravaginal hemangiomas can produce vaginal bleeding in infancy or childhood [",
"      <a class=\"abstract\" href=\"UTD.htm?15/10/15529/abstract/39\">",
"       39",
"      </a>",
"      ] and should not be mistaken for sexual abuse [",
"      <a class=\"abstract\" href=\"UTD.htm?15/10/15529/abstract/40\">",
"       40",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?43/39/44665?source=see_link\">",
"       \"Epidemiology; pathogenesis; clinical features; and complications of infantile hemangiomas\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      <strong>",
"       Genital warts &ndash;",
"      </strong>",
"      Genital warts can produce bleeding when they are located on the mucosal surface of the introitus or just inside the hymenal ring. Children acquire genital warts by vertical transmission (birth through an infected lower genital tract), autoinoculation of common warts, non-abusive contact, or sexual contact. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?34/27/35258?source=see_link&amp;anchor=H27#H27\">",
"       \"Evaluation of sexual abuse in children and adolescents\", section on 'STIs'",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?25/29/26072?source=see_link&amp;anchor=H12#H12\">",
"       \"Vulvovaginal complaints in the prepubertal child\", section on 'Condylomata acuminata'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      <strong>",
"       Estrogen exposure",
"      </strong>",
"      &ndash; The possibility that a child with vaginal bleeding has been exposed chronically to exogenous estrogen in a cream, food, or alternative therapy should be explored. Evidence-based summaries of many dietary supplements and herbal remedies can be found on websites provided by the National Library of Medicine: (",
"      <a class=\"external\" href=\"file://www.nlm.nih.gov/medlineplus/druginfo/herb_All.html\">",
"       www.nlm.nih.gov/medlineplus/druginfo/herb_All.html",
"      </a>",
"      ) and the National Institutes of Health (",
"      <a class=\"external\" href=\"file://ods.od.nih.gov/\">",
"       ods.od.nih.gov",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      <strong>",
"       Female genital cutting",
"      </strong>",
"      &ndash; Hemorrhage is a recognized complication of female genital cutting, which is practiced mainly by individuals from parts of East Africa, the Middle East, and Southeast Asia. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?33/21/34133?source=see_link\">",
"       \"Female genital cutting (circumcision)\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      <strong>",
"       Isolated menses",
"      </strong>",
"      &ndash; Bleeding that appears to be menstrual has been reported in girls who have no other signs of precocious puberty [",
"      <a class=\"abstract\" href=\"UTD.htm?15/10/15529/abstract/41,42\">",
"       41,42",
"      </a>",
"      ]. All other causes of bleeding, especially intravaginal foreign body and tumor, should be excluded before settling on this diagnosis.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26169070\">",
"    <span class=\"h2\">",
"     Vaginal bleeding during adolescence",
"    </span>",
"    &nbsp;&mdash;&nbsp;Because bleeding during pregnancy can indicate a life-threatening condition, the clinician&rsquo;s first task for the postmenarcheal adolescent with abnormal bleeding is to establish whether or not she is pregnant. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?43/48/44808?source=see_link&amp;anchor=H12#H12\">",
"     \"Clinical manifestations and diagnosis of early pregnancy\", section on 'Detection of hCG'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In non-pregnant adolescents, abnormal vaginal bleeding usually indicates anovulation. In that case, the clinician&rsquo;s task is to identify the cause of the anovulation. &nbsp;",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11717060\">",
"    <span class=\"h3\">",
"     Life-threatening conditions during adolescence",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <strong>",
"       Ectopic pregnancy &ndash;",
"      </strong>",
"      Vaginal bleeding and abdominal pain preceded by an interval of amenorrhea are the classic symptoms of ectopic pregnancy. Although ectopic pregnancy is more common in adult women than in adolescents, the diagnosis should be considered in an adolescent who presents with vaginal bleeding and abdominal pain following a missed period. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?1/9/1178?source=see_link&amp;anchor=H2#H2\">",
"       \"Clinical manifestations, diagnosis, and management of ectopic pregnancy\", section on 'Clinical manifestations'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      <strong>",
"       Placenta previa",
"      </strong>",
"      &ndash; During the second or third trimester of pregnancy, vaginal bleeding can indicate placental tissue overlying the internal cervical os. This condition is uncommon in pregnant adolescents since they lack the interrelated risk factors of increasing age, increasing parity, and previous cesarean delivery. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?34/13/35032?source=see_link\">",
"       \"Clinical features, diagnosis, and course of placenta previa\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      <strong>",
"       Placental abruption &ndash;",
"      </strong>",
"      Placental abruption refers to a separation of the placenta from the uterine wall before normal delivery of the fetus. Abruption should be considered in pregnant patients who present during the second or third trimester with one or more of the following: vaginal bleeding, abdominal pain, preterm labor,",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      abdominal trauma. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?28/46/29417?source=see_link\">",
"       \"Placental abruption: Clinical features and diagnosis\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11717099\">",
"    <span class=\"h3\">",
"     Common conditions related to pregnancy during adolescence",
"    </span>",
"    &nbsp;&mdash;&nbsp;Among clinically recognized pregnancies, approximately 8 to 20 percent end in spontaneous abortion, which nearly always occurs during the first trimester. Vaginal bleeding also is common during the second and third trimesters of pregnancy. The causes of vaginal bleeding during pregnancy are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?15/6/15465?source=see_link\">",
"     \"Overview of the etiology and evaluation of vaginal bleeding in pregnant women\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?19/23/19834?source=see_link\">",
"     \"Spontaneous abortion: Risk factors, etiology, clinical manifestations, and diagnostic evaluation\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Vaginal bleeding can also indicate a complication following spontaneous or therapeutic abortion. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?19/23/19834?source=see_link\">",
"     \"Spontaneous abortion: Risk factors, etiology, clinical manifestations, and diagnostic evaluation\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/29/39384?source=see_link\">",
"     \"Retained products of conception\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11717106\">",
"    <span class=\"h3\">",
"     Common conditions in non-pregnant adolescents",
"    </span>",
"    &nbsp;&mdash;&nbsp;In most non-pregnant adolescent patients, the source of abnormal vaginal bleeding is the uterus. When it occurs in association with anovulation, the general term for this bleeding is dysfunctional uterine bleeding (DUB). The most common causes of DUB in adolescence are delayed pubertal maturation, polycystic ovary syndrome, and side-effects of hormonal contraceptive agents. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?25/23/25975?source=see_link&amp;anchor=H3#H3\">",
"     \"Definition and evaluation of abnormal uterine bleeding in adolescents\", section on 'Abnormal uterine bleeding (AUB) in adolescents'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/10/22698?source=see_link\">",
"     \"Management of unscheduled bleeding in women using contraception\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11717113\">",
"    <span class=\"h3\">",
"     Uncommon conditions during adolescence",
"    </span>",
"    &nbsp;&mdash;&nbsp;Vaginal foreign bodies, cervicitis, genital warts, and infections (eg, pelvic inflammatory disease, endometritis), can uncommonly produce irregular or very light bleeding in adolescents [",
"    <a class=\"abstract\" href=\"UTD.htm?15/10/15529/abstract/43\">",
"     43",
"    </a>",
"    ]. Vulvar endometriosis is a rare cause of vaginal bleeding [",
"    <a class=\"abstract\" href=\"UTD.htm?15/10/15529/abstract/44\">",
"     44",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/38/23144?source=see_link\">",
"     \"Condylomata acuminata (anogenital warts)\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/18/35113?source=see_link\">",
"     \"Overview of causes of genital tract bleeding in women\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?0/4/64?source=see_link\">",
"     \"Acute cervicitis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/63/37876?source=see_link\">",
"     \"Desquamative inflammatory vaginitis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11717120\">",
"    <span class=\"h1\">",
"     EVALUATION",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H330649\">",
"    <span class=\"h2\">",
"     Trauma",
"    </span>",
"    &nbsp;&mdash;&nbsp;Evaluation of the seriously injured child is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?39/11/40119?source=see_link\">",
"     \"Approach to the initially stable child with blunt or penetrating injury\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Evaluation of the injured, post-pubertal patient is also presented separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?16/32/16904?source=see_link&amp;anchor=H7#H7\">",
"     \"Penetrating trauma of the upper and lower genitourinary tract\", section on 'Initial assessment'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/7/22650?source=see_link&amp;anchor=H13#H13\">",
"     \"Pelvic trauma: Initial evaluation and management\", section on 'Clinical features'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11717127\">",
"    <span class=\"h2\">",
"     Premenarcheal patients",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11717135\">",
"    <span class=\"h3\">",
"     History",
"    </span>",
"    &nbsp;&mdash;&nbsp;In prepubertal children, genitourinary symptoms have low predictive value; diagnosis will depend primarily on the patient&rsquo;s physical examination findings [",
"    <a class=\"abstract\" href=\"UTD.htm?15/10/15529/abstract/45,46\">",
"     45,46",
"    </a>",
"    ]. However, it can be helpful to elicit a history of associated vaginal discharge, recent sore throat or diarrhea, pain with defecation, previous vaginal foreign bodies, or streptococcal infection in a household member. The clinician should try to establish that the source of the bleeding is not the urinary or the gastrointestinal tract.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11717142\">",
"    <span class=\"h3\">",
"     Physical examination",
"    </span>",
"    &nbsp;&mdash;&nbsp;The clinician will tend to focus on the external genital examination, but the skin, thyroid gland, and chest also require attention. Children&rsquo;s underwear should be removed completely to facilitate careful inspection of the external genitalia and perineum. Cafe-au-lait spots can suggest neurofibromatosis or McCune-Albright syndrome (",
"    <a class=\"graphic graphic_picture graphicRef80844 \" href=\"UTD.htm?41/51/42815\">",
"     picture 8",
"    </a>",
"    ), rare causes of precocious puberty. Thyroid enlargement can suggest hypothyroidism. Breast or pubic hair development (",
"    <a class=\"graphic graphic_picture graphicRef72038 \" href=\"UTD.htm?10/43/10932\">",
"     picture 1",
"    </a>",
"    and",
"    <a class=\"graphic graphic_picture graphicRef79782 \" href=\"UTD.htm?29/33/30227\">",
"     picture 2",
"    </a>",
"    ) indicates either abnormal vaginal bleeding in a girl with normally progressing puberty or, much less commonly, precocious puberty. Lichen sclerosus (",
"    <a class=\"graphic graphic_picture graphicRef80900 \" href=\"UTD.htm?9/12/9411\">",
"     picture 5",
"    </a>",
"    and",
"    <a class=\"graphic graphic_picture graphicRef57910 \" href=\"UTD.htm?39/18/40224\">",
"     picture 7",
"    </a>",
"    ) and urethral prolapse (",
"    <a class=\"graphic graphic_figure graphicRef74850 \" href=\"UTD.htm?41/19/42290\">",
"     figure 1",
"    </a>",
"    ) usually present pathognomonic appearances.",
"   </p>",
"   <p>",
"    If the general physical examination and inspection of the external genitalia do not permit a confident diagnosis, the vaginal vault should be inspected. Although speculum examination was recommended historically, this procedure is painful and should not be used in the awake premenarcheal patient. Most children over three years of age can cooperate for prone knee-chest examination (",
"    <a class=\"graphic graphic_picture graphicRef75858 \" href=\"UTD.htm?22/58/23457\">",
"     picture 9",
"    </a>",
"    ). The keys to successful visualization of the vaginal vault using this position are adequate lateral and cephalad retraction of the child&rsquo;s buttocks and labia majora (accomplished by a parent or assistant) and adequate relaxation of the abdominal muscles to ensure that air enters the vaginal vault. &nbsp;",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11717149\">",
"    <span class=\"h3\">",
"     Diagnostic evaluation",
"    </span>",
"    &nbsp;&mdash;&nbsp;The selection of diagnostic tests should be guided by findings from the child's history and physical examination (see",
"    <a class=\"local\" href=\"#H11717156\">",
"     'Approach'",
"    </a>",
"    below). If the physical examination was not diagnostic, vaginal secretions should be obtained and sent for culture. The clinician should alert the microbiology laboratory staff in advance to use culture media appropriate for the suspected pathogens, namely group A streptococcus and shigella species. Otherwise a report of &ldquo;Group B Strep not present&rdquo; is likely to be obtained and will be useless to the clinician. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?42/19/43316?source=see_link&amp;anchor=H4#H4\">",
"     \"Gynecologic examination of the newborn and child\", section on 'How to obtain cultures from children'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    If the vaginal culture is negative and vaginal bleeding remains unexplained, vaginoscopy should be undertaken [",
"    <a class=\"abstract\" href=\"UTD.htm?15/10/15529/abstract/47\">",
"     47",
"    </a>",
"    ]. Studies suggest that vaginoscopy has considerably better diagnostic sensitivity than does non-invasive imaging (ultrasound, CT, MRI), for the diagnoses of foreign body and malignancy [",
"    <a class=\"abstract\" href=\"UTD.htm?15/10/15529/abstract/15\">",
"     15",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?21/40/22147?source=see_link\">",
"     \"Vaginoscopy\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Serum alpha-fetoprotein is a sensitive and specific marker for endodermal sinus tumors and should be obtained if there is any suspicion that a malignancy might be present. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?5/37/5721?source=see_link&amp;anchor=H7#H7\">",
"     \"Ovarian germ cell neoplasms: Pathology, clinical manifestations, and diagnosis\", section on 'Tumor markers'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The diagnostic evaluation of the child with precocious puberty is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?19/5/19546?source=see_link&amp;anchor=H14#H14\">",
"     \"Definition, etiology, and evaluation of precocious puberty\", section on 'Evaluation'",
"    </a>",
"    .).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11717156\">",
"    <span class=\"h3\">",
"     Approach",
"    </span>",
"    &nbsp;&mdash;&nbsp;The algorithm summarizes an approach to diagnosis for patients with vaginal bleeding before menarche (",
"    <a class=\"graphic graphic_algorithm graphicRef63607 \" href=\"UTD.htm?14/3/14398\">",
"     algorithm 1",
"    </a>",
"    ). In many premenarcheal children, the physical examination findings will provide or suggest a diagnosis (see",
"    <a class=\"local\" href=\"#H11717142\">",
"     'Physical examination'",
"    </a>",
"    above). If the patient has a non-diagnostic examination and no signs of puberty, then vaginal culture for bacterial infection should be obtained, followed by vaginoscopy if the culture is negative (see",
"    <a class=\"local\" href=\"#H11717149\">",
"     'Diagnostic evaluation'",
"    </a>",
"    above). Endocrinological evaluation is indicated for patients with early signs or an abnormal sequence of puberty (",
"    <a class=\"graphic graphic_figure graphicRef82350 \" href=\"UTD.htm?23/47/24317\">",
"     figure 2",
"    </a>",
"    ). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?19/5/19546?source=see_link&amp;anchor=H4#H4\">",
"     \"Definition, etiology, and evaluation of precocious puberty\", section on 'Threshold for evaluation'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11717163\">",
"    <span class=\"h2\">",
"     Postmenarcheal patients",
"    </span>",
"    &nbsp;&mdash;&nbsp;The evaluation of adolescents who could be pregnant is discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?43/48/44808?source=see_link\">",
"     \"Clinical manifestations and diagnosis of early pregnancy\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?20/27/20920?source=see_link\">",
"     \"Approach to vaginal bleeding in the emergency department\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?15/6/15465?source=see_link\">",
"     \"Overview of the etiology and evaluation of vaginal bleeding in pregnant women\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    History-taking for non-pregnant, postmenarcheal adolescents with abnormal bleeding should focus on an estimate of how much blood has been lost (",
"    <a class=\"graphic graphic_table graphicRef69390 \" href=\"UTD.htm?14/2/14379\">",
"     table 2",
"    </a>",
"    ), the menstrual history, and any history of contraceptive medications. Physical examination findings with potential diagnostic significance include pallor, abnormal bruising, severe acne, hirsutism, thyroid enlargement, and obesity. Laboratory testing should include a complete blood count to assess for anemia and thrombocytopenia and, in patients with no obvious diagnosis, evaluation for endocrinological causes of anovulation. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?20/25/20887?source=see_link\">",
"     \"Initial approach to the premenopausal woman with abnormal uterine bleeding\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?25/23/25975?source=see_link&amp;anchor=H6#H6\">",
"     \"Definition and evaluation of abnormal uterine bleeding in adolescents\", section on 'Evaluation'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11717170\">",
"    <span class=\"h3\">",
"     Approach",
"    </span>",
"    &nbsp;&mdash;&nbsp;The algorithm summarizes an approach to diagnosis for postmenarcheal adolescents with vaginal bleeding, (",
"    <a class=\"graphic graphic_algorithm graphicRef80261 \" href=\"UTD.htm?39/42/40623\">",
"     algorithm 2",
"    </a>",
"    ).Management of postmenarcheal patients with urgent or emergent vaginal bleeding is presented in detail separately (",
"    <a class=\"graphic graphic_algorithm graphicRef77923 \" href=\"UTD.htm?43/38/44640\">",
"     algorithm 3",
"    </a>",
"    ). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?20/27/20920?source=see_link\">",
"     \"Approach to vaginal bleeding in the emergency department\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    For non-pregnant adolescents, a complete blood count should be obtained to assess for significant blood loss and for thrombocytopenia. Whether and which laboratory investigations should be undertaken next will depend on the diagnoses suggested by the individual patient&rsquo;s clinical circumstances. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?25/23/25975?source=see_link&amp;anchor=H6#H6\">",
"     \"Definition and evaluation of abnormal uterine bleeding in adolescents\", section on 'Evaluation'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11717177\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The causes of vaginal bleeding in children and adolescents and the diagnostic approach organized by patients&rsquo; menarcheal status are presented in the table and the algorithms (",
"      <a class=\"graphic graphic_table graphicRef64659 \" href=\"UTD.htm?19/55/20348\">",
"       table 1",
"      </a>",
"      and",
"      <a class=\"graphic graphic_algorithm graphicRef63607 \" href=\"UTD.htm?14/3/14398\">",
"       algorithm 1",
"      </a>",
"      and",
"      <a class=\"graphic graphic_algorithm graphicRef80261 \" href=\"UTD.htm?39/42/40623\">",
"       algorithm 2",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H11716885\">",
"       'Causes'",
"      </a>",
"      above.).",
"     </li>",
"     <li>",
"      The management of postmenarcheal adolescents and women with urgent or emergent vaginal bleeding is presented in detail separately (",
"      <a class=\"graphic graphic_algorithm graphicRef77923 \" href=\"UTD.htm?43/38/44640\">",
"       algorithm 3",
"      </a>",
"      ). (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?20/27/20920?source=see_link\">",
"       \"Approach to vaginal bleeding in the emergency department\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Penetrating vaginal injuries can cause life-threatening hemorrhage, rectal injury, or peritonitis. The possibility of intravaginal injury should be considered even if a patient&rsquo;s visible perineal injuries are minor. (See",
"      <a class=\"local\" href=\"#H11716893\">",
"       'Trauma'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Although the possibility of sexual assault should be considered, most injuries that cause vaginal bleeding are unintentional. Conversely, most sexual abuse or assault of children does not produce genital trauma or bleeding. In particular, the clinician should be careful not to confuse lichen sclerosus (",
"      <a class=\"graphic graphic_picture graphicRef80900 \" href=\"UTD.htm?9/12/9411\">",
"       picture 5",
"      </a>",
"      and",
"      <a class=\"graphic graphic_picture graphicRef57910 \" href=\"UTD.htm?39/18/40224\">",
"       picture 7",
"      </a>",
"      ) with sexual abuse. (See",
"      <a class=\"local\" href=\"#H11716893\">",
"       'Trauma'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?34/27/35258?source=see_link&amp;anchor=H28#H28\">",
"       \"Evaluation of sexual abuse in children and adolescents\", section on 'Differential diagnosis'",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?34/53/35669?source=see_link&amp;anchor=H2#H2\">",
"       \"Straddle injuries\", section on 'Differentiating straddle injury from sexual abuse'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Foreign bodies, infectious vaginitis, and urethral prolapse (",
"      <a class=\"graphic graphic_figure graphicRef74850 \" href=\"UTD.htm?41/19/42290\">",
"       figure 1",
"      </a>",
"      ) are common causes of actual or apparent vaginal bleeding in premenarcheal children. Genital malignancies are rare. (See",
"      <a class=\"local\" href=\"#H11716946\">",
"       'Common conditions before normal menarche'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H11716922\">",
"       'Life-threatening conditions'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For adolescents with vaginal bleeding, the most urgent issues are to establish whether the patient is pregnant and to manage hemorrhagic shock, if it is present. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?43/48/44808?source=see_link\">",
"       \"Clinical manifestations and diagnosis of early pregnancy\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?20/27/20920?source=see_link&amp;anchor=H10#H10\">",
"       \"Approach to vaginal bleeding in the emergency department\", section on 'Diagnostic approach and disposition'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      In adolescents who are not pregnant, the clinician needs to distinguish abnormal bleeding from normal menstruation. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?25/23/25975?source=see_link&amp;anchor=H4#H4\">",
"       \"Definition and evaluation of abnormal uterine bleeding in adolescents\", section on 'Definition'",
"      </a>",
"      and",
"      <a class=\"local\" href=\"#H11717106\">",
"       'Common conditions in non-pregnant adolescents'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/10/15529/abstract/1\">",
"      Sugar NF, Feldman KW. Perineal impalements in children: distinguishing accident from abuse. Pediatr Emerg Care 2007; 23:605.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/10/15529/abstract/2\">",
"      DeLago C, Deblinger E, Schroeder C, Finkel MA. Girls who disclose sexual abuse: urogenital symptoms and signs after genital contact. Pediatrics 2008; 122:e281.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/10/15529/abstract/3\">",
"      Hoffman RJ, Ganti S. Vaginal laceration and perforation resulting from first coitus. Pediatr Emerg Care 2001; 17:113.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/10/15529/abstract/4\">",
"      Bhagat M. Coital injury presenting in a 13 year old as abdominal pain and vaginal bleeding. Pediatr Emerg Care 1996; 12:354.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/10/15529/abstract/5\">",
"      Aho T, Upadhyay V. Vaginal water-jet injuries in premenarcheal girls. N Z Med J 2005; 118:U1565.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/10/15529/abstract/6\">",
"      Perlman SE, Hertweck SP, Wolfe WM. Water-ski douche injury in a premenarcheal female. Pediatrics 1995; 96:782.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/10/15529/abstract/7\">",
"      Goldberg J, Horan C, O'Brien LM. Severe anorectal and vaginal injuries in a jet ski passenger. J Trauma 2004; 56:440.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/10/15529/abstract/8\">",
"      Grisoni ER, Hahn E, Marsh E, et al. Pediatric perineal impalement injuries. J Pediatr Surg 2000; 35:702.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/10/15529/abstract/9\">",
"      Scheidler MG, Schultz BL, Schall L, Ford HR. Mechanisms of blunt perineal injury in female pediatric patients. J Pediatr Surg 2000; 35:1317.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/10/15529/abstract/10\">",
"      Lacy J, Capra M, Allen L. Endodermal sinus tumor of the infant vagina treated exclusively with chemotherapy. J Pediatr Hematol Oncol 2006; 28:768.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/10/15529/abstract/11\">",
"      Handel LN, Scott SM, Giller RH, et al. New perspectives on therapy for vaginal endodermal sinus tumors. J Urol 2002; 168:687.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/10/15529/abstract/12\">",
"      Fernandez-Pineda I, Spunt SL, Parida L, et al. Vaginal tumors in childhood: the experience of St. Jude Children's Research Hospital. J Pediatr Surg 2011; 46:2071.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/10/15529/abstract/13\">",
"      Heller ME, Savage MO, Dewhurst J. Vaginal bleeding in childhood: a review of 51 patients. Br J Obstet Gynaecol 1978; 85:721.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/10/15529/abstract/14\">",
"      Hill NC, Oppenheimer LW, Morton KE. The aetiology of vaginal bleeding in children. A 20-year review. Br J Obstet Gynaecol 1989; 96:467.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/10/15529/abstract/15\">",
"      Striegel AM, Myers JB, Sorensen MD, et al. Vaginal discharge and bleeding in girls younger than 6 years. J Urol 2006; 176:2632.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/10/15529/abstract/16\">",
"      Perlman SE. Management quandary. Premenarchal vaginal bleeding. J Pediatr Adolesc Gynecol 2001; 14:135.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/10/15529/abstract/17\">",
"      Paradise JE, Willis ED. Probability of vaginal foreign body in girls with genital complaints. Am J Dis Child 1985; 139:472.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/10/15529/abstract/18\">",
"      Stricker T, Navratil F, Sennhauser FH. Vaginal foreign bodies. J Paediatr Child Health 2004; 40:205.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/10/15529/abstract/19\">",
"      Verstraelen H, Verhelst R, Vaneechoutte M, Temmerman M. Group A streptococcal vaginitis: an unrecognized cause of vaginal symptoms in adult women. Arch Gynecol Obstet 2011; 284:95.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/10/15529/abstract/20\">",
"      Straumanis JP, Bocchini JA Jr. Group A beta-hemolytic streptococcal vulvovaginitis in prepubertal girls: a case report and review of the past twenty years. Pediatr Infect Dis J 1990; 9:845.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/10/15529/abstract/21\">",
"      Ginsburg CM. Group A streptococcal vaginitis in children. Pediatr Infect Dis 1982; 1:36.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/10/15529/abstract/22\">",
"      Mogielnicki NP, Schwartzman JD, Elliott JA. Perineal group A streptococcal disease in a pediatric practice. Pediatrics 2000; 106:276.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/10/15529/abstract/23\">",
"      Gryngarten, MG, Turco, et al. Shigellavulvovaginitis in prepubertal girls. Adolesc Pediatr Gynecol 1994; 7:86.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/10/15529/abstract/24\">",
"      Murphy TV, Nelson JD. Shigella vaginitis: report of 38 patients and review of the literature. Pediatrics 1979; 63:511.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/10/15529/abstract/25\">",
"      Bogaerts J, Lepage P, De Clercq A, et al. Shigella and gonococcal vulvovaginitis in prepubertal central African girls. Pediatr Infect Dis J 1992; 11:890.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/10/15529/abstract/26\">",
"      Poindexter G, Morrell DS. Anogenital pruritus: lichen sclerosus in children. Pediatr Ann 2007; 36:785.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/10/15529/abstract/27\">",
"      Maronn ML, Esterly NB. Constipation as a feature of anogenital lichen sclerosus in children. Pediatrics 2005; 115:e230.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/10/15529/abstract/28\">",
"      Isaac R, Lyn M, Triggs N. Lichen sclerosus in the differential diagnosis of suspected child abuse cases. Pediatr Emerg Care 2007; 23:482.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/10/15529/abstract/29\">",
"      Wood PL, Bevan T. Lesson of the week child sexual abuse enquiries and unrecognised vulval lichen sclerosus et atrophicus. BMJ 1999; 319:899.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/10/15529/abstract/30\">",
"      Smith YR, Quint EH. Clobetasol propionate in the treatment of premenarchal vulvar lichen sclerosus. Obstet Gynecol 2001; 98:588.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/10/15529/abstract/31\">",
"      Patrizi A, Gurioli C, Medri M, Neri I. Childhood lichen sclerosus: a long-term follow-up. Pediatr Dermatol 2010; 27:101.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/10/15529/abstract/32\">",
"      Chi CC, Kirtschig G, Baldo M, et al. Topical interventions for genital lichen sclerosus. Cochrane Database Syst Rev 2011; :CD008240.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/10/15529/abstract/33\">",
"      Goldstein AT, Tha&ccedil;i D, Luger T. Topical calcineurin inhibitors for the treatment of vulvar dermatoses. Eur J Obstet Gynecol Reprod Biol 2009; 146:22.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/10/15529/abstract/34\">",
"      Anveden-Hertzberg L, Gauderer MW, Elder JS. Urethral prolapse: an often misdiagnosed cause of urogenital bleeding in girls. Pediatr Emerg Care 1995; 11:212.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/10/15529/abstract/35\">",
"      Valerie E, Gilchrist BF, Frischer J, et al. Diagnosis and treatment of urethral prolapse in children. Urology 1999; 54:1082.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/10/15529/abstract/36\">",
"      Hillyer S, Mooppan U, Kim H, Gulmi F. Diagnosis and treatment of urethral prolapse in children: experience with 34 cases. Urology 2009; 73:1008.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/10/15529/abstract/37\">",
"      Van Wyk JJ, Grumbach MM. Syndrome of precocious menstruation and galactorrhea in juvenile hypothyroidism: an example of hormonal overlap in pituitary feedback. J Pediatr 1960; 57:416.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/10/15529/abstract/38\">",
"      Sanjeevaiah AR, Sanjay S, Deepak T, et al. Precocious puberty and large multicystic ovaries in young girls with primary hypothyroidism. Endocr Pract 2007; 13:652.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/10/15529/abstract/39\">",
"      Jackson MG, Simms-Cendan J, Sims SM, et al. Vaginal bleeding due to an infantile hemangioma in a 3-year-old girl. J Pediatr Adolesc Gynecol 2009; 22:e53.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/10/15529/abstract/40\">",
"      Hostetler, BR, Jones, et al. Capillary hemangiomas of the vulva mistaken for sexual abuse. Adolesc Pediatr Gynecol 1994; 7:44.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/10/15529/abstract/41\">",
"      Murram D, Dewhurst J, Grant DB. Premature menarche: a follow-up study. Arch Dis Child 1983; 58:142.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/10/15529/abstract/42\">",
"      Blanco-Garcia M, Evain-Brion D, Roger M, Job JC. Isolated menses in prepubertal girls. Pediatrics 1985; 76:43.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/10/15529/abstract/43\">",
"      Hoffman L, Ma OJ, Gaddis G, Schwab RA. Cervical infections in emergency department patients with vaginal bleeding. Acad Emerg Med 2002; 9:781.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/10/15529/abstract/44\">",
"      Eyvazzadeh AD, Smith YR, Lieberman R, Quint EH. A rare case of vulvar endometriosis in an adolescent girl. Fertil Steril 2009; 91:929.e9.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/10/15529/abstract/45\">",
"      Paradise JE, Campos JM, Friedman HM, Frishmuth G. Vulvovaginitis in premenarcheal girls: clinical features and diagnostic evaluation. Pediatrics 1982; 70:193.",
"     </a>",
"    </li>",
"    <li>",
"     Paradise, JE. Vaginal bleeding.. In: The Textbook of Pediatric Emergency Medicine, 6th edition, Fleisher, GR, Ludwig, S (Eds), Lippincott, Williams, &amp; Wilkins, Philadelphia 2010. p.606.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/10/15529/abstract/47\">",
"      Smorgick N, Padua A, Lotan G, et al. Diagnosis and treatment of pediatric vaginal and genital tract abnormalities by small diameter hysteroscope. J Pediatr Surg 2009; 44:1506.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 15411 Version 7.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.3 - C21.34",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Morehouse School of Medicine",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1002-210.101.131.232-DE283444F4-S473950.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f15_10_15529=[""].join("\n");
var outline_f15_10_15529=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H11717177\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H11716878\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H11716885\">",
"      CAUSES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11716893\">",
"      Trauma",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H11716901\">",
"      - Life-threatening vaginal trauma",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H11716908\">",
"      - Vulvar and vaginal trauma",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11716915\">",
"      Vaginal bleeding before normal menarche",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H11716922\">",
"      - Life-threatening conditions",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H11716946\">",
"      - Common conditions before normal menarche",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H11716993\">",
"      - Uncommon conditions before menarche",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H26169070\">",
"      Vaginal bleeding during adolescence",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H11717060\">",
"      - Life-threatening conditions during adolescence",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H11717099\">",
"      - Common conditions related to pregnancy during adolescence",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H11717106\">",
"      - Common conditions in non-pregnant adolescents",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H11717113\">",
"      - Uncommon conditions during adolescence",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H11717120\">",
"      EVALUATION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H330649\">",
"      Trauma",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11717127\">",
"      Premenarcheal patients",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H11717135\">",
"      - History",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H11717142\">",
"      - Physical examination",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H11717149\">",
"      - Diagnostic evaluation",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H11717156\">",
"      - Approach",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11717163\">",
"      Postmenarcheal patients",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H11717170\">",
"      - Approach",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H11717177\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"EM/15411\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"EM/15411|ALG\">",
"      <a href=\"#\" title=\"ALGORITHMS\">",
"       ALGORITHMS",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_algorithm\" href=\"UTD.htm?14/3/14398\" title=\"algorithm 1\">",
"      Approach to premenarcheal vaginal bleeding",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_algorithm\" href=\"UTD.htm?39/42/40623\" title=\"algorithm 2\">",
"      Approach to postmenarcheal bleeding",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_algorithm\" href=\"UTD.htm?43/38/44640\" title=\"algorithm 3\">",
"      Approach to vaginal bleeding in the emergency department",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"EM/15411|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?41/19/42290\" title=\"figure 1\">",
"      Urethral prolapse",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?23/47/24317\" title=\"figure 2\">",
"      Normal puberty in girls",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"EM/15411|PIC\">",
"      <a href=\"#\" title=\"PICTURES\">",
"       PICTURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?10/43/10932\" title=\"picture 1\">",
"      Sexual maturity rating of breast development in girls",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?29/33/30227\" title=\"picture 2\">",
"      Sexual maturity rating of pubic hair in girls",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?17/30/17889\" title=\"picture 3\">",
"      Perineal group A streptococcal disease",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?40/9/41108\" title=\"picture 4\">",
"      Lichen sclerosis with ecchymosis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?9/12/9411\" title=\"picture 5\">",
"      Vulvar lichen sclerosis with purpura 1",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?16/4/16449\" title=\"picture 6\">",
"      Vulvar lichen sclerosis with purpura 2",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?39/18/40224\" title=\"picture 7\">",
"      Lichen sclerosus in a 10 year old prepubertal girl",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?41/51/42815\" title=\"picture 8\">",
"      Cafe au lait spots",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?22/58/23457\" title=\"picture 9\">",
"      Prone knee-chest position",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"EM/15411|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?19/55/20348\" title=\"table 1\">",
"      Causes of vaginal bleeding",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?14/2/14379\" title=\"table 2\">",
"      Assessing menstrual blood loss",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?0/4/64?source=related_link\">",
"      Acute cervicitis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?39/11/40119?source=related_link\">",
"      Approach to the initially stable child with blunt or penetrating injury",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?20/27/20920?source=related_link\">",
"      Approach to vaginal bleeding in the emergency department",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?34/13/35032?source=related_link\">",
"      Clinical features, diagnosis, and course of placenta previa",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?37/40/38535?source=related_link\">",
"      Clinical manifestations and diagnosis of Shigella infection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?43/48/44808?source=related_link\">",
"      Clinical manifestations and diagnosis of early pregnancy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?1/9/1178?source=related_link\">",
"      Clinical manifestations, diagnosis, and management of ectopic pregnancy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?22/38/23144?source=related_link\">",
"      Condylomata acuminata (anogenital warts)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?25/23/25975?source=related_link\">",
"      Definition and evaluation of abnormal uterine bleeding in adolescents",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?19/5/19546?source=related_link\">",
"      Definition, etiology, and evaluation of precocious puberty",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?36/63/37876?source=related_link\">",
"      Desquamative inflammatory vaginitis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?43/39/44665?source=related_link\">",
"      Epidemiology; pathogenesis; clinical features; and complications of infantile hemangiomas",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?34/27/35258?source=related_link\">",
"      Evaluation of sexual abuse in children and adolescents",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?33/21/34133?source=related_link\">",
"      Female genital cutting (circumcision)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?42/19/43316?source=related_link\">",
"      Gynecologic examination of the newborn and child",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?20/25/20887?source=related_link\">",
"      Initial approach to the premenopausal woman with abnormal uterine bleeding",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?22/10/22698?source=related_link\">",
"      Management of unscheduled bleeding in women using contraception",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?5/37/5721?source=related_link\">",
"      Ovarian germ cell neoplasms: Pathology, clinical manifestations, and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?34/18/35113?source=related_link\">",
"      Overview of causes of genital tract bleeding in women",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?15/6/15465?source=related_link\">",
"      Overview of the etiology and evaluation of vaginal bleeding in pregnant women",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?22/7/22650?source=related_link\">",
"      Pelvic trauma: Initial evaluation and management",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?16/32/16904?source=related_link\">",
"      Penetrating trauma of the upper and lower genitourinary tract",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?28/46/29417?source=related_link\">",
"      Placental abruption: Clinical features and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?38/29/39384?source=related_link\">",
"      Retained products of conception",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?15/63/16377?source=related_link\">",
"      Rhabdomyosarcoma and undifferentiated sarcoma in childhood and adolescence: Epidemiology, pathology, and molecular pathogenesis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?19/23/19834?source=related_link\">",
"      Spontaneous abortion: Risk factors, etiology, clinical manifestations, and diagnostic evaluation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?34/53/35669?source=related_link\">",
"      Straddle injuries",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?30/30/31208?source=related_link\">",
"      Vaginal cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?21/40/22147?source=related_link\">",
"      Vaginoscopy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?6/45/6874?source=related_link\">",
"      Vulvar lichen sclerosus",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?25/29/26072?source=related_link\">",
"      Vulvovaginal complaints in the prepubertal child",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f15_10_15530="Second-generation antipsychotic medications: Pharmacology, administration, and comparative side effects";
var content_f15_10_15530=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"6\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Second-generation antipsychotic medications: Pharmacology, administration, and comparative side effects",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?15/10/15530/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?15/10/15530/contributors\">",
"     Michael D Jibson, MD, PhD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?15/10/15530/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?15/10/15530/contributors\">",
"     Stephen Marder, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?15/10/15530/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?15/10/15530/contributors\">",
"     Richard Hermann, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?15/10/15530/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Sep 7, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H76524623\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Antipsychotic medications have efficacy in the treatment of acute psychosis (irrespective of cause), chronic psychotic disorders, and other psychiatric conditions.",
"   </p>",
"   <p>",
"    First-generation antipsychotics (FGAs), also known as neuroleptics or conventional antipsychotics, cause extrapyramidal side effects, including rigidity, bradykinesia, tremor, and akathisia (restlessness). They also frequently lead to tardive dyskinesia&mdash;hyperkinetic, involuntary movements most readily observed in the face and extremities.",
"   </p>",
"   <p>",
"    Second-generation antipsychotics (SGAs), also known as atypical antipsychotics, generally have lower risks of extrapyramidal side effects and tardive dyskinesia compared to FGAs. However, these medications generally cause higher rates of weight gain and metabolic side effects, although the side effect profiles of individual drugs vary. One SGA,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?34/21/35161?source=see_link\">",
"     clozapine",
"    </a>",
"    , has sufficiently unique properties to justify separate consideration.",
"   </p>",
"   <p>",
"    The pharmacology,",
"    <strong>",
"    </strong>",
"    administration, and comparative side effects of second-generation antipsychotics available in the US are discussed here. First-generation antipsychotics and antipsychotics in the treatment of schizophrenia and bipolar disorder are discussed separately, as are antipsychotic poisoning, tardive dyskinesia, and neuroleptic malignant syndrome (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/35/29241?source=see_link\">",
"     \"Pharmacotherapy for schizophrenia: Acute and maintenance phase treatment\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?43/45/44760?source=see_link\">",
"     \"Pharmacotherapy for schizophrenia: Side effect management\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?4/31/4600?source=see_link\">",
"     \"First generation (Typical) antipsychotic medication poisoning\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?42/19/43320?source=see_link\">",
"     \"Second generation (atypical) antipsychotic medication poisoning\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?20/4/20553?source=see_link\">",
"     \"Neuroleptic malignant syndrome\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/26/36264?source=see_link\">",
"     \"Tardive dyskinesia: Etiology and epidemiology\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/8/38026?source=see_link\">",
"     \"Bipolar disorder in adults: Pharmacotherapy for acute mania, mixed episodes, and hypomania\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?6/40/6793?source=see_link\">",
"     \"Guidelines for prescribing clozapine in schizophrenia\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H76524630\">",
"    <span class=\"h1\">",
"     TERMINOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Second-generation antipsychotic medications are also referred to as &ldquo;atypical antipsychotics&rdquo;. First-generation antipsychotics may be referred to as &ldquo;conventional antipsychotics&rdquo; or &ldquo;neuroleptics&rdquo;. The older term \"major tranquilizer\" does not accurately describe the action of these medications, and is no longer encouraged.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H76524637\">",
"    <span class=\"h1\">",
"     PHARMACOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;The common activity of both first-generation antipsychotics (FGAs) and second-generation antipsychotics (SGAs) appears to be post-synaptic blockade of brain dopamine D2 receptors. The exception,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?42/11/43193?source=see_link\">",
"     aripiprazole",
"    </a>",
"    , is a D2 partial agonist. Several lines of evidence support the role of these receptors in the activity of antipsychotics, including a correlation between receptor binding and clinical potency [",
"    <a class=\"abstract\" href=\"UTD.htm?15/10/15530/abstract/1\">",
"     1",
"    </a>",
"    ]. Functional imaging studies show a consistent requirement of 60 to 65 percent D2 receptor occupancy for medications to show antipsychotic efficacy [",
"    <a class=\"abstract\" href=\"UTD.htm?15/10/15530/abstract/2\">",
"     2",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    SGAs differ from older medications in that serotonin 5HT2 receptor binding can exceed their affinity for dopamine D2 receptors, whereas first-generation generally do not. Largely for that reason, 5HT2 activity has been suggested as one basis for the lower risk of extrapyramidal side effects of many of the atypical drugs compared to FGAs, particularly the high-potency agents [",
"    <a class=\"abstract\" href=\"UTD.htm?15/10/15530/abstract/3\">",
"     3",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The drugs differ as to how tightly they bind D2 receptors. Two of the atypical drugs,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?34/21/35161?source=see_link\">",
"     clozapine",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?19/56/20361?source=see_link\">",
"     quetiapine",
"    </a>",
"    , bind loosely and turn over after only a few minutes, in contrast to all other antipsychotics, which bind tightly and turn over after several hours. The exceptionally low risk of EPS with clozapine and quetiapine may be related to that binding characteristic. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?6/40/6793?source=see_link\">",
"     \"Guidelines for prescribing clozapine in schizophrenia\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The drugs differ in other aspects of their pharmacology, making each medication unique in its side effect profile, dosing pattern, rate of absorption, clearance time, drug-drug interactions, and susceptibility to changes in hepatic and renal function (",
"    <a class=\"graphic graphic_table graphicRef82533 \" href=\"UTD.htm?32/57/33694\">",
"     table 1",
"    </a>",
"    and",
"    <a class=\"graphic graphic_table graphicRef60624 \" href=\"UTD.htm?30/58/31663\">",
"     table 2",
"    </a>",
"    ). The decision as to whether a rapid or slow rate of absorption or a long versus short clearance time is preferable will be determined by the individual clinical situation. As examples, a drug with rapid absorption would be preferred in an urgent situation, whereas one with slower uptake might be better tolerated. Alternatively, a patient with less than optimal treatment adherence would benefit from a longer-acting drug, but a shorter-acting medication would be advantageous if rapid dose adjustments are anticipated. (See",
"    <a class=\"local\" href=\"#H76524672\">",
"     'Individual medications'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H90780126\">",
"    <span class=\"h1\">",
"     INDICATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Initially shown to provide efficacious treatment for schizophrenia, antipsychotic medications are effective in reducing acute and chronic psychosis regardless of cause, and have shown efficacy for other psychiatric disorders. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/35/29241?source=see_link\">",
"     \"Pharmacotherapy for schizophrenia: Acute and maintenance phase treatment\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?43/45/44760?source=see_link\">",
"     \"Pharmacotherapy for schizophrenia: Side effect management\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/8/38026?source=see_link\">",
"     \"Bipolar disorder in adults: Pharmacotherapy for acute mania, mixed episodes, and hypomania\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/48/27402?source=see_link\">",
"     \"Treatment of behavioral symptoms related to dementia\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/62/29670?source=see_link\">",
"     \"Treatment of postpartum psychosis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/33/28185?source=see_link\">",
"     \"Prevention and treatment of delirium and confusional states\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H76524651\">",
"    <span class=\"h1\">",
"     SIDE EFFECTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Side effects associated with second-generation antipsychotics (SGAs) include weight gain, diabetes, hyperlipidemia, hyperprolactinemia, neuroleptic malignant syndrome, sudden death, and an increased risk of mortality when used to treat psychiatric symptoms associated with dementia in elderly patients (",
"    <a class=\"graphic graphic_table graphicRef82533 \" href=\"UTD.htm?32/57/33694\">",
"     table 1",
"    </a>",
"    ). Extrapyramidal symptoms (EPS) and tardive dyskinesia can also occur with SGAs, but at lower rates than with first-generation agents. These side effects and their management are described separately. Some side effects occur at a rate and severity that varies across individual SGAs; they are described in a table (",
"    <a class=\"graphic graphic_table graphicRef82533 \" href=\"UTD.htm?32/57/33694\">",
"     table 1",
"    </a>",
"    ) and under individual medications below. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?43/45/44760?source=see_link\">",
"     \"Pharmacotherapy for schizophrenia: Side effect management\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/40/27269?source=see_link\">",
"     \"Tardive dyskinesia: Clinical features and diagnosis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/8/34952?source=see_link\">",
"     \"Tardive dyskinesia: Prevention and treatment\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?20/4/20553?source=see_link\">",
"     \"Neuroleptic malignant syndrome\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/55/23418?source=see_link\">",
"     \"Acquired long QT syndrome\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?21/41/22167?source=see_link\">",
"     \"Causes of hyperprolactinemia\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H76524658\">",
"    <span class=\"h1\">",
"     COST",
"    </span>",
"    &nbsp;&mdash;&nbsp;Second-generation antipsychotic drugs are more expensive than first-generation agents. Generic formulations of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?11/33/11802?source=see_link\">",
"     risperidone",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?36/36/37449?source=see_link\">",
"     olanzapine",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?19/56/20361?source=see_link\">",
"     quetiapine",
"    </a>",
"    , and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?4/39/4728?source=see_link\">",
"     ziprasidone",
"    </a>",
"    are available in the US and many other countries. A table provides relative costs of antipsychotic drugs (",
"    <a class=\"graphic graphic_table graphicRef51828 \" href=\"UTD.htm?23/6/23662\">",
"     table 3",
"    </a>",
"    ). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?7/24/7562?source=see_link&amp;anchor=H272233801#H272233801\">",
"     \"First-generation antipsychotic medications: Pharmacology, administration, and comparative side effects\", section on 'Cost'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H76524665\">",
"    <span class=\"h1\">",
"     FORMULATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Several antipsychotic medications are available in other formulations in addition to a standard oral tablet (",
"    <a class=\"graphic graphic_table graphicRef60624 \" href=\"UTD.htm?30/58/31663\">",
"     table 2",
"    </a>",
"    ). Rapid-disintegrating tablets and liquid formulations for oral or intramuscular administration can be used in emergent situations or for patients who have difficulty swallowing pills. As an example, an agitated, acutely psychotic patient can be treated by intramuscular injection of a sterile solution. Rapid-disintegrating formulations can also be useful for patients who are suspected of \"cheeking\" or concealing tablets in their mouths and disposing of them. These tablets dissolve rapidly in a minimal amount of saliva, making this form of non-adherence nearly impossible. A table summarizes antipsychotic drug doses for treating acute agitation (",
"    <a class=\"graphic graphic_table graphicRef60846 \" href=\"UTD.htm?32/7/32893\">",
"     table 4",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    Depot or long-acting, injectable antipsychotics are used to treat patients unable to adhere to daily regimens. These agents are administered by injection at two to four week intervals. Administration of long-acting antipsychotics is described in a table (",
"    <a class=\"graphic graphic_table graphicRef59201 \" href=\"UTD.htm?9/36/9806\">",
"     table 5",
"    </a>",
"    ) and discussed further separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/9/30871?source=see_link\">",
"     \"Pharmacotherapy for schizophrenia: Long-acting injectable antipsychotic drugs\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H76524672\">",
"    <span class=\"h1\">",
"     INDIVIDUAL MEDICATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Pharmacology and side effect profiles unique to individual second-generation antipsychotics (SGA) are described below, along with information on available formulations and recommended dosing for each.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H76524679\">",
"    <span class=\"h2\">",
"     Risperidone",
"    </span>",
"    &nbsp;&mdash;&nbsp;Generic",
"    <a class=\"drug drug_general\" href=\"UTD.htm?11/33/11802?source=see_link\">",
"     risperidone",
"    </a>",
"    is widely available in standard tablets, rapid-disintegrated tablets, and oral solution. Proprietary risperidone is additionally available in an injectable, depot formulation. Neither the oral solution nor the rapid-disintegrating formulations of risperidone are absorbed across the oral mucosa. Time to peak concentration is the same as for the standard tablets.",
"   </p>",
"   <p>",
"    The pharmacokinetics of the oral formulations are all equivalent, with rapid absorption and 20-hour elimination half life (",
"    <a class=\"graphic graphic_table graphicRef60624 \" href=\"UTD.htm?30/58/31663\">",
"     table 2",
"    </a>",
"    ).",
"    <a class=\"drug drug_general\" href=\"UTD.htm?11/33/11802?source=see_link\">",
"     Risperidone",
"    </a>",
"    has little activity at muscarinic receptors and no anticholinergic effects. Drug-drug interactions are infrequent, but its serum levels are modestly decreased by inducers of the cytochrome P450 system, such as",
"    <a class=\"drug drug_general\" href=\"UTD.htm?25/10/25770?source=see_link\">",
"     carbamazepine",
"    </a>",
"    , and are increased by inhibitors such as",
"    <a class=\"drug drug_general\" href=\"UTD.htm?14/49/15130?source=see_link\">",
"     fluoxetine",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/34/33312?source=see_link\">",
"     ketoconazole",
"    </a>",
"    . Although it is not necessary to adjust the dose of risperidone whenever such a medication is added or withdrawn, clinicians should be aware of the potential for a change in serum level with the simultaneous use of these medications (",
"    <a class=\"graphic graphic_table graphicRef60624 \" href=\"UTD.htm?30/58/31663\">",
"     table 2",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    The drug is typically dosed once daily. Starting doses for adults are 1 to 2",
"    <span class=\"nowrap\">",
"     mg/day,",
"    </span>",
"    and maintenance doses are typically in the 2 to 6",
"    <span class=\"nowrap\">",
"     mg/day",
"    </span>",
"    range, with 4",
"    <span class=\"nowrap\">",
"     mg/day",
"    </span>",
"    the average dose in the community. Doses above 6 to 8",
"    <span class=\"nowrap\">",
"     mg/day",
"    </span>",
"    are associated with higher rates of extrapyramidal symptoms. Titration should be done over the course of several days in order to minimize the emergence of extrapyramidal symptoms or akathisia. For the elderly population, doses typically start at 0.25 to 0.5",
"    <span class=\"nowrap\">",
"     mg/day,",
"    </span>",
"    average about 1",
"    <span class=\"nowrap\">",
"     mg/day,",
"    </span>",
"    and do not usually exceed 2",
"    <span class=\"nowrap\">",
"     mg/day.",
"    </span>",
"    Hepatic impairment results in increased serum levels and activity due to a 35 percent greater free fraction of the drug. Renal dysfunction reduces elimination of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?11/33/11802?source=see_link\">",
"     risperidone",
"    </a>",
"    by 60 percent. Both conditions may require dose reductions [",
"    <a class=\"abstract\" href=\"UTD.htm?15/10/15530/abstract/4\">",
"     4",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The usual dose of the oral solution and rapid-disintegrating formulation of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?11/33/11802?source=see_link\">",
"     risperidone",
"    </a>",
"    for acute agitation is 1 to 2 mg every 30 minutes to two hours, to a maximum of 4",
"    <span class=\"nowrap\">",
"     mg/day.",
"    </span>",
"    The oral medication has been found to equal injectable",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/50/32553?source=see_link\">",
"     haloperidol",
"    </a>",
"    in effectiveness and time to onset of action [",
"    <a class=\"abstract\" href=\"UTD.htm?15/10/15530/abstract/5\">",
"     5",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A depot preparation of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?11/33/11802?source=see_link\">",
"     risperidone",
"    </a>",
"    (Risperdal Consta) is available; its administration is described in a table (",
"    <a class=\"graphic graphic_table graphicRef59201 \" href=\"UTD.htm?9/36/9806\">",
"     table 5",
"    </a>",
"    ) and discussed further separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/9/30871?source=see_link\">",
"     \"Pharmacotherapy for schizophrenia: Long-acting injectable antipsychotic drugs\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The primary side effects of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?11/33/11802?source=see_link\">",
"     risperidone",
"    </a>",
"    are mild sedation, hypotension, akathisia, prolactin elevation, and weight gain [",
"    <a class=\"abstract\" href=\"UTD.htm?15/10/15530/abstract/6,7\">",
"     6,7",
"    </a>",
"    ]. Preliminary data suggest that risperidone may be associated with an increased incidence of pituitary adenomas compared to other antipsychotic agents [",
"    <a class=\"abstract\" href=\"UTD.htm?15/10/15530/abstract/8\">",
"     8",
"    </a>",
"    ]. At higher doses, the drug is associated with a somewhat greater risk of extrapyramidal symptoms than other atypicals. Risperidone&rsquo;s risk of extrapyramidal symptoms is comparable to the mid-potency FGAs, less than the high potency FGAs and more than the low potency FGAs [",
"    <a class=\"abstract\" href=\"UTD.htm?15/10/15530/abstract/3\">",
"     3",
"    </a>",
"    ]. Adverse effects are summarized in a table (",
"    <a class=\"graphic graphic_table graphicRef82533 \" href=\"UTD.htm?32/57/33694\">",
"     table 1",
"    </a>",
"    ). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?7/24/7562?source=see_link\">",
"     \"First-generation antipsychotic medications: Pharmacology, administration, and comparative side effects\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H76524686\">",
"    <span class=\"h2\">",
"     Olanzapine",
"    </span>",
"    &nbsp;&mdash;&nbsp;Generic",
"    <a class=\"drug drug_general\" href=\"UTD.htm?36/36/37449?source=see_link\">",
"     olanzapine",
"    </a>",
"    is available in standard tablets and orally disintegrating tablets in the US, Canada, Europe, and elsewhere [",
"    <a class=\"abstract\" href=\"UTD.htm?15/10/15530/abstract/9\">",
"     9",
"    </a>",
"    ]. Proprietary olanzapine is available in coated tablets, rapid-disintegrating tablets, short-acting injectable solution, a and a long-acting injectable (depot) formulation, olanzapine pamoate. The oral formulations have gradual absorption and 30-hour elimination half life. The drug is usually given once a day. The medication readily oxidizes in air [",
"    <a class=\"abstract\" href=\"UTD.htm?15/10/15530/abstract/10\">",
"     10",
"    </a>",
"    ]; if cut, the coated tablets should be used immediately to avoid loss of potency.",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?36/36/37449?source=see_link\">",
"     Olanzapine",
"    </a>",
"    has significant activity at histaminic and muscarinic receptors. Drug-drug interactions are not prominent with olanzapine, but olanzapine is dependent upon CYP 1A2 for clearance. Coadministration of medications that strongly inhibit or induce CYP 1A2 can alter olanzapine levels. Olanzapine levels are decreased somewhat by cigarette smoking (",
"    <a class=\"graphic graphic_table graphicRef60624 \" href=\"UTD.htm?30/58/31663\">",
"     table 2",
"    </a>",
"    ). This may be an issue when patients are stabilized on a specific dose of olanzapine while on a nonsmoking hospital unit and then resume smoking upon discharge, reducing serum levels of the drug.",
"    <strong>",
"    </strong>",
"    Although this does not usually require a dose adjustment, clinicians should be aware of this possibility if they observe a reduction in clinical efficacy when patients transition to the outpatient setting.",
"   </p>",
"   <p>",
"    For adults, the starting dose of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?36/36/37449?source=see_link\">",
"     olanzapine",
"    </a>",
"    is usually 5 to 10",
"    <span class=\"nowrap\">",
"     mg/day.",
"    </span>",
"    Maintenance doses of 15 to 30",
"    <span class=\"nowrap\">",
"     mg/day",
"    </span>",
"    are common and doses up to 40",
"    <span class=\"nowrap\">",
"     mg/day",
"    </span>",
"    can be useful in selected cases, though exceeding the manufacturer's recommended maximum of 20",
"    <span class=\"nowrap\">",
"     mg/day.",
"    </span>",
"    Doses for most non-treatment-refractory patients should not exceed 20",
"    <span class=\"nowrap\">",
"     mg/day,",
"    </span>",
"    as data have suggested equivalent efficacy of 10, 20 and 40",
"    <span class=\"nowrap\">",
"     mg/day,",
"    </span>",
"    but worsened tolerability at doses of 40 mg compared to 10",
"    <span class=\"nowrap\">",
"     mg/day",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?15/10/15530/abstract/11\">",
"     11",
"    </a>",
"    ]. The average dose for stable schizophrenia patients participating in an 18-month effectiveness study was about 20 mg daily [",
"    <a class=\"abstract\" href=\"UTD.htm?15/10/15530/abstract/12\">",
"     12",
"    </a>",
"    ]. For the elderly population, doses begin at 1.25 to 2.5",
"    <span class=\"nowrap\">",
"     mg/day,",
"    </span>",
"    average 5",
"    <span class=\"nowrap\">",
"     mg/day,",
"    </span>",
"    and may go up to 10",
"    <span class=\"nowrap\">",
"     mg/day",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?15/10/15530/abstract/13\">",
"     13",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The usual dose of oral",
"    <a class=\"drug drug_general\" href=\"UTD.htm?36/36/37449?source=see_link\">",
"     olanzapine",
"    </a>",
"    for acute agitation is 5 to 10 mg, repeated every 30 minutes to two hours to a maximum of 20",
"    <span class=\"nowrap\">",
"     mg/day.",
"    </span>",
"    There is no significant absorption of the rapid-disintegrating formulation of olanzapine across the oral mucosa.",
"   </p>",
"   <p>",
"    An intramuscular injectable form of the medication is available for the treatment of acute agitation. The recommended dose is 10 mg, repeated at intervals of two to four hours, up to a total of 30",
"    <span class=\"nowrap\">",
"     mg/day.",
"    </span>",
"    For agitation associated with dementia, doses of 5 mg have been found effective [",
"    <a class=\"abstract\" href=\"UTD.htm?15/10/15530/abstract/14\">",
"     14",
"    </a>",
"    ]. The drug causes less somnolence than alternative medications commonly used for agitation, including benzodiazepines and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/50/32553?source=see_link\">",
"     haloperidol",
"    </a>",
"    [14].",
"   </p>",
"   <p>",
"    The administration of the long-acting injectable (depot) formulation,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?36/36/37449?source=see_link\">",
"     olanzapine",
"    </a>",
"    pamoate, and associated monitoring requirements, are described in a table (",
"    <a class=\"graphic graphic_table graphicRef59201 \" href=\"UTD.htm?9/36/9806\">",
"     table 5",
"    </a>",
"    ) and discussed further separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/9/30871?source=see_link\">",
"     \"Pharmacotherapy for schizophrenia: Long-acting injectable antipsychotic drugs\"",
"    </a>",
"    .).",
"   </p>",
"   <p>",
"    There is controversy regarding the safety of injectable",
"    <a class=\"drug drug_general\" href=\"UTD.htm?36/36/37449?source=see_link\">",
"     olanzapine",
"    </a>",
"    in combination with a benzodiazepine. Fatalities have been reported on these medications although causality was not established. Some expert guidelines and the manufacturer have recommended against combined use, citing possible cardiovascular risk [",
"    <a class=\"abstract\" href=\"UTD.htm?15/10/15530/abstract/15\">",
"     15",
"    </a>",
"    ]. However, studies have not been done to assess the safety of the combination.",
"   </p>",
"   <p>",
"    The most common side effects of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?36/36/37449?source=see_link\">",
"     olanzapine",
"    </a>",
"    are weight gain, sedation, akathisia, hypotension, dry mouth, and constipation [",
"    <a class=\"abstract\" href=\"UTD.htm?15/10/15530/abstract/16,17\">",
"     16,17",
"    </a>",
"    ]. Weight gain, hyperglycemia, and hyperlipidemia are greater with olanzapine than with other SGAs [",
"    <a class=\"abstract\" href=\"UTD.htm?15/10/15530/abstract/18-20\">",
"     18-20",
"    </a>",
"    ], and are particularly prominent in adolescents [",
"    <a class=\"abstract\" href=\"UTD.htm?15/10/15530/abstract/21\">",
"     21",
"    </a>",
"    ]. The US FDA has recommended that olanzapine be used with caution when treating this age group [",
"    <a class=\"abstract\" href=\"UTD.htm?15/10/15530/abstract/22\">",
"     22",
"    </a>",
"    ]. No specific recommendations have been made regarding dosing changes for patients with renal or hepatic impairment [",
"    <a class=\"abstract\" href=\"UTD.htm?15/10/15530/abstract/23\">",
"     23",
"    </a>",
"    ]. Adverse effects are summarized in a table (",
"    <a class=\"graphic graphic_table graphicRef82533 \" href=\"UTD.htm?32/57/33694\">",
"     table 1",
"    </a>",
"    ). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?43/45/44760?source=see_link\">",
"     \"Pharmacotherapy for schizophrenia: Side effect management\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H76524693\">",
"    <span class=\"h2\">",
"     Quetiapine",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?19/56/20361?source=see_link\">",
"     Quetiapine",
"    </a>",
"    is available as immediate or extended release tablets. The immediate release formulation has been available as a generic for several years in Canada, the United Kingdom, Australia, and more recently in the US. It is rapidly absorbed and cleared with a six to seven hour elimination half life. The extended release tablets give a peak concentration at six hours, followed by a seven-hour clearance half life. For both formulations, an active metabolite, norquetiapine, represents about half of the active drug in circulation and has a 12 hour elimination half time.",
"   </p>",
"   <p>",
"    Although the manufacturer recommends twice daily dosing for the immediate release tables, both formulations are commonly used in the community on a once daily schedule without substantial problems. The drug has strong histaminic, cholinergic, and alpha-1-adrenergic binding, responsible for relatively high levels of sedation, anticholinergic effects, and orthostatic hypotension. Drug-drug interactions are not common with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?19/56/20361?source=see_link\">",
"     quetiapine",
"    </a>",
"    , but serum levels are affected by induction or inhibition of the cytochrome P450 system by drugs including",
"    <a class=\"drug drug_general\" href=\"UTD.htm?25/10/25770?source=see_link\">",
"     carbamazepine",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?14/49/15130?source=see_link\">",
"     fluoxetine",
"    </a>",
"    , and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/34/33312?source=see_link\">",
"     ketoconazole",
"    </a>",
"    (",
"    <a class=\"graphic graphic_table graphicRef60624 \" href=\"UTD.htm?30/58/31663\">",
"     table 2",
"    </a>",
"    ). In practice, dose adjustments with these medications are not commonly required.",
"   </p>",
"   <p>",
"    The usual adult starting dose of immediate release",
"    <a class=\"drug drug_general\" href=\"UTD.htm?19/56/20361?source=see_link\">",
"     quetiapine",
"    </a>",
"    is 25 mg twice daily, followed by a relatively slow titration at the rate of 25 to 50",
"    <span class=\"nowrap\">",
"     mg/day",
"    </span>",
"    to a total dose of 300 to 600",
"    <span class=\"nowrap\">",
"     mg/day.",
"    </span>",
"    The titration of the drug may be even slower if the patient develops hypotension or excessive sedation. The manufacturer suggests a starting dose of quetiapine extended release to be up to 300",
"    <span class=\"nowrap\">",
"     mg/day,",
"    </span>",
"    with titration to 600",
"    <span class=\"nowrap\">",
"     mg/day",
"    </span>",
"    by Day 2, and 800",
"    <span class=\"nowrap\">",
"     mg/day",
"    </span>",
"    by Day 3. Final doses of the two formulations are equivalent. The manufacturer recommends a maximum dose of 800",
"    <span class=\"nowrap\">",
"     mg/day,",
"    </span>",
"    but doses as high as 1200",
"    <span class=\"nowrap\">",
"     mg/day",
"    </span>",
"    have been used and appear to be well tolerated. For the elderly population, doses usually start at 12.5 to 25 mg twice daily and are titrated to doses substantially lower than for younger adults [",
"    <a class=\"abstract\" href=\"UTD.htm?15/10/15530/abstract/24\">",
"     24",
"    </a>",
"    ]. The drug does not require renal function for clearance, but patients with hepatic impairment may experience an increase in serum levels necessitating dose adjustment [",
"    <a class=\"abstract\" href=\"UTD.htm?15/10/15530/abstract/25\">",
"     25",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The main side effects of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?19/56/20361?source=see_link\">",
"     quetiapine",
"    </a>",
"    are sedation, orthostatic hypotension, akathisia, dry mouth, and weight gain [",
"    <a class=\"abstract\" href=\"UTD.htm?15/10/15530/abstract/26,27\">",
"     26,27",
"    </a>",
"    ]. Sedation is most often noted early in treatment and seems more closely related to treatment duration than to dose, so patients may find their sedation improving after several days, even if the medication dose is still being titrated [",
"    <a class=\"abstract\" href=\"UTD.htm?15/10/15530/abstract/28\">",
"     28",
"    </a>",
"    ]. Quetiapine causes QT prolongation in combination with other factors prolonging the QT interval; use of the drug should be avoided in conjunction with other medications that prolong the QT interval or patient risk factors for QT prolongation [",
"    <a class=\"abstract\" href=\"UTD.htm?15/10/15530/abstract/29\">",
"     29",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/55/23418?source=see_link\">",
"     \"Acquired long QT syndrome\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?19/56/20361?source=see_link\">",
"     Quetiapine",
"    </a>",
"    appears to cause less extrapyramidal symptoms than other antipsychotics, with the exception of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?34/21/35161?source=see_link\">",
"     clozapine",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?34/59/35767?source=see_link\">",
"     iloperidone",
"    </a>",
"    , and is less likely to increase prolactin levels [",
"    <a class=\"abstract\" href=\"UTD.htm?15/10/15530/abstract/30\">",
"     30",
"    </a>",
"    ]. Adverse effects are summarized in a table (",
"    <a class=\"graphic graphic_table graphicRef82533 \" href=\"UTD.htm?32/57/33694\">",
"     table 1",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H76524700\">",
"    <span class=\"h2\">",
"     Ziprasidone",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?4/39/4728?source=see_link\">",
"     Ziprasidone",
"    </a>",
"    is available in capsules and as a sterile solution for intramuscular injection. A generic preparation of the oral medication recently became available in the US. The oral formulation is absorbed slowly and cleared with an elimination half life of seven hours. The drug is approved for twice daily dosing, but once daily administration is commonly used in the community without apparent problem. Bioavailability in the absence of food is inconsistent. It has been estimated to be 50 percent lower than when ziprasidone is taken with the recommended &ge;500 calorie meal. Patients and families should be educated about the need to take the medication with an adequate meal. It is not possible to compensate for the food effect by doubling the dose because in the absence of food, the increase in plasma level by oral dose is not dose-proportional [",
"    <a class=\"abstract\" href=\"UTD.htm?15/10/15530/abstract/31\">",
"     31",
"    </a>",
"    ]. The drug has low histaminic and no appreciable muscarinic activity.",
"   </p>",
"   <p>",
"    Drug-drug interactions are of two types. First, serum levels respond modestly to concurrent treatment with inhibitors and inducers of the cytochrome P450 system, such as",
"    <a class=\"drug drug_general\" href=\"UTD.htm?25/10/25770?source=see_link\">",
"     carbamazepine",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?14/49/15130?source=see_link\">",
"     fluoxetine",
"    </a>",
"    , and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/34/33312?source=see_link\">",
"     ketoconazole",
"    </a>",
"    (",
"    <a class=\"graphic graphic_table graphicRef60624 \" href=\"UTD.htm?30/58/31663\">",
"     table 2",
"    </a>",
"    ). Second, the drug causes mild QT prolongation, not usually clinically significant in isolation, but use of the drug with other medications that prolong the QT interval is contraindicated.",
"   </p>",
"   <p>",
"    The recommended adult starting dose of oral",
"    <a class=\"drug drug_general\" href=\"UTD.htm?4/39/4728?source=see_link\">",
"     ziprasidone",
"    </a>",
"    is 20 to 40 mg twice daily, followed by titration over two to five days to the manufacturer's highest recommended dose of 80 mg twice daily. In practice, doses up to 240",
"    <span class=\"nowrap\">",
"     mg/day",
"    </span>",
"    are common and well tolerated. A dose of at least 120",
"    <span class=\"nowrap\">",
"     mg/day",
"    </span>",
"    is believed to be necessary to achieve sufficient dopamine D2 blockade for therapeutic efficacy. Pharmacokinetics and side effects in clinical-trial subjects over 65 years were comparable to those for younger patients. The oral drug is not affected by renal impairment, but a component of the intramuscular preparation is cleared through the kidney, leading to the manufacturer&rsquo;s recommendation that it be used with caution in that population. Hepatic impairment causes mild increases in serum levels and clearance time that may require dose adjustment. [",
"    <a class=\"abstract\" href=\"UTD.htm?15/10/15530/abstract/32\">",
"     32",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Injectable",
"    <a class=\"drug drug_general\" href=\"UTD.htm?4/39/4728?source=see_link\">",
"     ziprasidone",
"    </a>",
"    has been FDA-approved for acute agitation. It is recommended in 20 mg doses every four hours or 10 mg doses every two hours to a maximum of 40",
"    <span class=\"nowrap\">",
"     mg/day.",
"    </span>",
"   </p>",
"   <p>",
"    Side effects include mild sedation early in treatment, nausea, weakness, nasal congestion, and mild QT prolongation [",
"    <a class=\"abstract\" href=\"UTD.htm?15/10/15530/abstract/33\">",
"     33",
"    </a>",
"    ].",
"    <a class=\"drug drug_general\" href=\"UTD.htm?4/39/4728?source=see_link\">",
"     Ziprasidone",
"    </a>",
"    appears to cause less weight gain, hyperglycemia, and hyperlipidemia than other second-generation antipsychotics [",
"    <a class=\"abstract\" href=\"UTD.htm?15/10/15530/abstract/34,35\">",
"     34,35",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Despite the report of QT prolongation in clinical trials, this has not emerged as a clinically significant problem in post-marketing surveillance [",
"    <a class=\"abstract\" href=\"UTD.htm?15/10/15530/abstract/36\">",
"     36",
"    </a>",
"    ]. The FDA requires a warning recommending vigilance in cases of congenital QT prolongation, bradycardia, hypokalemia, and hypomagnesemia, and advises caution with the concurrent use of other medications that prolong the QT interval. The drug should either be avoided in patients with these conditions, or cardiac monitoring should be used if the condition develops during treatment. Routine cardiac monitoring has not been recommended in other patients. Adverse effects are summarized in a table (",
"    <a class=\"graphic graphic_table graphicRef82533 \" href=\"UTD.htm?32/57/33694\">",
"     table 1",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H76524707\">",
"    <span class=\"h2\">",
"     Aripiprazole",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?42/11/43193?source=see_link\">",
"     Aripiprazole",
"    </a>",
"    is unique among the SGA in its pharmacology and pharmacokinetics, but is similar in clinical efficacy [",
"    <a class=\"abstract\" href=\"UTD.htm?15/10/15530/abstract/37\">",
"     37",
"    </a>",
"    ]. Aripiprazole acts as a partial agonist at dopamine D2 receptors, activating the receptor but eliciting a reduced response compared to the natural neurotransmitter. The drug is also a partial agonist at serotonin 5HT1a receptors, but an antagonist at 5HT2a, H1, and alpha-1-adrenergic receptors.",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?42/11/43193?source=see_link\">",
"     Aripiprazole",
"    </a>",
"    is available as a standard and orally disintegrating tablet as well as a sterile solution for intramuscular injection. Oral aripiprazole is absorbed slowly and cleared with a 75-hour elimination half life. The injectable preparation shows significant clinical efficacy within 45 minutes [",
"    <a class=\"abstract\" href=\"UTD.htm?15/10/15530/abstract/38\">",
"     38",
"    </a>",
"    ], and reaches peak serum levels in one to three hours. Its long elimination half life has the advantage of creating relatively steady serum levels throughout the day, even with an occasional missed dose, but may slow the impact of a dose adjustment or transition to a different medication.",
"   </p>",
"   <p>",
"    Other drug-drug interactions have not commonly been reported with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?42/11/43193?source=see_link\">",
"     aripiprazole",
"    </a>",
"    , but it is metabolized via the cytochrome P450 system. Hence, the manufacturer recommends a two-fold increase in dosing in the presence of metabolic inducers, such as",
"    <a class=\"drug drug_general\" href=\"UTD.htm?25/10/25770?source=see_link\">",
"     carbamazepine",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?15/10/15530/abstract/39\">",
"     39",
"    </a>",
"    ], and a 50 percent reduction in dose with cytochrome P450 inhibitors, such as",
"    <a class=\"drug drug_general\" href=\"UTD.htm?14/49/15130?source=see_link\">",
"     fluoxetine",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?0/48/777?source=see_link\">",
"     quinidine",
"    </a>",
"    , or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/34/33312?source=see_link\">",
"     ketoconazole",
"    </a>",
"    (",
"    <a class=\"graphic graphic_table graphicRef60624 \" href=\"UTD.htm?30/58/31663\">",
"     table 2",
"    </a>",
"    ). Many practitioners prefer, however, to make dose adjustments solely on the basis of the patient&rsquo;s clinical response.",
"   </p>",
"   <p>",
"    Clinical trials of adults with schizophrenia started the drug at 10 to 15 mg daily, administered in a single dose. This dose proved to be adequate for many patients, but doses up to 30 mg daily have been approved. The manufacturer's clinical trials for bipolar disorder started patients at 30 mg daily and lowered the dose only for side effects. Studies in the elderly population have not been reported, but expert opinions suggest doses of 15 to 30 mg daily in elderly patients with schizophrenia [",
"    <a class=\"abstract\" href=\"UTD.htm?15/10/15530/abstract/40\">",
"     40",
"    </a>",
"    ]. The manufacturer does not recommend dose adjustment for patients with hepatic or renal insufficiency [",
"    <a class=\"abstract\" href=\"UTD.htm?15/10/15530/abstract/41\">",
"     41",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The most common side effects of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?42/11/43193?source=see_link\">",
"     aripiprazole",
"    </a>",
"    are headache, nausea, vomiting, insomnia, tremor, and constipation. Weight gain has been minimal in short and long-term trials. The drug has a lower risk of extrapyramidal symptoms, increases in lipid or prolactin levels, and sedation, compared to other atypicals in a small number of comparative trials [",
"    <a class=\"abstract\" href=\"UTD.htm?15/10/15530/abstract/42\">",
"     42",
"    </a>",
"    ]. It has not been found to cause QT prolongation. Rates of akathisia are substantially higher for patients receiving aripiprazole for major depressive disorder and bipolar disorder compared to patients receiving aripiprazole for schizophrenia. Adverse effects are summarized in a table (",
"    <a class=\"graphic graphic_table graphicRef82533 \" href=\"UTD.htm?32/57/33694\">",
"     table 1",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    The use of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?42/11/43193?source=see_link\">",
"     aripiprazole",
"    </a>",
"    in conjunction with other antipsychotic medications is not generally recommended, because the combination of a partial agonist with an antagonist leads to unpredictable levels of receptor activity. Switching patients to aripiprazole should be done slowly because of aripiprazole&rsquo;s exceptionally high affinity for dopamine D2 receptors in the face of its partial agonism at this receptor.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H76524714\">",
"    <span class=\"h2\">",
"     Paliperidone",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?43/43/44728?source=see_link\">",
"     Paliperidone",
"    </a>",
"    is available in an osmotic delivery capsule to be swallowed whole, not crushed or chewed, and requires several days to achieve steady-state kinetics. The bioavailability of paliperidone is increased by about 50 percent when taken with a high calorie meal. Once absorbed, paliperidone has a 23-hour elimination half time. About 60 percent is excreted unchanged in the urine, with the remainder metabolized by cytochrome P450 isoenzymes. The high level of urinary excretion of unmetabolized paliperidone makes it unique among antipsychotics in not requiring intact hepatic function for clearance. Thus, in contrast to other antipsychotics, paliperidone requires no dose adjustment with hepatic impairment [",
"    <a class=\"abstract\" href=\"UTD.htm?15/10/15530/abstract/43\">",
"     43",
"    </a>",
"    ]. Significant drug-drug interactions have not been identified.",
"   </p>",
"   <p>",
"    For non-elderly adults,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?43/43/44728?source=see_link\">",
"     paliperidone",
"    </a>",
"    is typically started at 6 mg once daily and, if needed, can be increased in 3",
"    <span class=\"nowrap\">",
"     mg/day",
"    </span>",
"    increments at five day intervals. For elderly patients, or those with renal impairment, 3 mg per day may be used.",
"   </p>",
"   <p>",
"    The most common side effects are extrapyramidal symptoms, including parkinsonism, dystonia, dyskinesia, and akathisia. Other side effects include prolactin elevation and tachycardia.",
"    <a class=\"drug drug_general\" href=\"UTD.htm?43/43/44728?source=see_link\">",
"     Paliperidone",
"    </a>",
"    has a mild to moderate risk of weight gain; comparative trials found that the increase in weight was less than that caused by",
"    <a class=\"drug drug_general\" href=\"UTD.htm?36/36/37449?source=see_link\">",
"     olanzapine",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?15/10/15530/abstract/44\">",
"     44",
"    </a>",
"    ]. Paliperidone can prolong the QT interval, and should not be used with other drugs with similar effects. These side effects are dose-dependent, more prominent at doses above 6 mg per day. Adverse effects are summarized in a table (",
"    <a class=\"graphic graphic_table graphicRef82533 \" href=\"UTD.htm?32/57/33694\">",
"     table 1",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    A long-acting, injectable formulation of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?43/43/44728?source=see_link\">",
"     paliperidone",
"    </a>",
"    is available; its administration is described in a table (",
"    <a class=\"graphic graphic_table graphicRef59201 \" href=\"UTD.htm?9/36/9806\">",
"     table 5",
"    </a>",
"    ) and discussed further separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/9/30871?source=see_link\">",
"     \"Pharmacotherapy for schizophrenia: Long-acting injectable antipsychotic drugs\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H76524721\">",
"    <span class=\"h2\">",
"     Iloperidone",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?34/59/35767?source=see_link\">",
"     Iloperidone",
"    </a>",
"    has antagonist activity at dopamine D2 and serotonin 5HT2a receptors, similar to other SGAs. Short-term studies of varying doses found optimal efficacy at 12 to 24 mg daily [",
"    <a class=\"abstract\" href=\"UTD.htm?15/10/15530/abstract/45\">",
"     45",
"    </a>",
"    ]. Because of the propensity for orthostatic hypotension, dosing should be initiated at 1 mg BID with gradual titration, reaching 6 mg BID by Day 4. The elimination half life is 18 to 33 hours. Plasma levels increase with CYP 2D6 and CYP3A4 inhibitors, leading to the recommendation that dose be reduced by 50 percent in the presence of medications such as",
"    <a class=\"drug drug_general\" href=\"UTD.htm?14/49/15130?source=see_link\">",
"     fluoxetine",
"    </a>",
"    (",
"    <a class=\"graphic graphic_table graphicRef60624 \" href=\"UTD.htm?30/58/31663\">",
"     table 2",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    Side effects include dizziness, orthostatic hypotension, tachycardia, weight gain, dry mouth, and sedation [",
"    <a class=\"abstract\" href=\"UTD.htm?15/10/15530/abstract/1,46\">",
"     1,46",
"    </a>",
"    ]. Compared to other antipsychotics,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?34/59/35767?source=see_link\">",
"     iloperidone",
"    </a>",
"    caused relatively few extrapyramidal symptoms, an intermediate degree of weight gain, and above average QT prolongation, though not to a degree that cardiac monitoring or avoidance of other drugs that prolong the QT interval has been recommended. Adverse effects are summarized in a table (",
"    <a class=\"graphic graphic_table graphicRef82533 \" href=\"UTD.htm?32/57/33694\">",
"     table 1",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    Few patients over 65 years of age were included in clinical trials, so specific information on dosing and side effects in the older population is not available. The known risks of hypotension and QT prolongation suggest that caution should be exercised in the use of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?34/59/35767?source=see_link\">",
"     iloperidone",
"    </a>",
"    in older patients. The drug is not affected by renal insufficiency, but no studies have been conducted involving patients with hepatic dysfunction and on that basis the manufacturer recommends against its use in that population [",
"    <a class=\"abstract\" href=\"UTD.htm?15/10/15530/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H76524728\">",
"    <span class=\"h2\">",
"     Asenapine",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?2/56/2951?source=see_link\">",
"     Asenapine",
"    </a>",
"    has a broad range of receptor activities, including antagonism of dopamine, serotonin, adrenergic, and histaminic receptors, but minimal muscarinic activity [",
"    <a class=\"abstract\" href=\"UTD.htm?15/10/15530/abstract/47\">",
"     47",
"    </a>",
"    ]. It is rapidly absorbed and has a 24-hour elimination clearance half-time. Its major route of metabolism is through CYP 1A2 and glucuronidation, with no major active metabolites. Drug interactions tend to be mild and generally do not require an adjustment in dose (",
"    <a class=\"graphic graphic_table graphicRef60624 \" href=\"UTD.htm?30/58/31663\">",
"     table 2",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?15/10/15530/abstract/48\">",
"     48",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?2/56/2951?source=see_link\">",
"     Asenapine",
"    </a>",
"    is unique among antipsychotics in its sublingual administration, necessitated by its poor GI absorption. Both the starting and maintenance doses of the medication are 5 to 10 mg BID. The maximum recommended dose is 10 mg BID. The drug dissolves and is absorbed quickly, but the patient should not eat or drink within 10 minutes of administration [",
"    <a class=\"abstract\" href=\"UTD.htm?15/10/15530/abstract/48\">",
"     48",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The most common side effects are sedation, weight gain, dizziness, EPS (especially akathisia), and oral hypoesthesia. Weight gain is intermediate among the SGAs. In short-term studies of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?2/56/2951?source=see_link\">",
"     asenapine",
"    </a>",
"    , weight gain averaged 1.2 kg, compared with 0.1 to 0.2 kg with placebo [",
"    <a class=\"abstract\" href=\"UTD.htm?15/10/15530/abstract/48\">",
"     48",
"    </a>",
"    ]. Over 52 weeks of treatment, average weight gain was 0.9 kg. The risk of patients gaining at least 7 percent of body weight was 5.8 percent at 6 weeks and 14.7 percent at 52 weeks. QT prolongation was limited to 2 to 5 milliseconds at doses as high as 20 mg BID, a level not expected to be of clinical significance [",
"    <a class=\"abstract\" href=\"UTD.htm?15/10/15530/abstract/49\">",
"     49",
"    </a>",
"    ]. Prolactin levels do not differ from those seen with placebo [",
"    <a class=\"abstract\" href=\"UTD.htm?15/10/15530/abstract/2\">",
"     2",
"    </a>",
"    ]. Rare reports of serious hypersensitivity reactions, including anaphylaxis, caused the issuance of a",
"    <a class=\"external\" href=\"file://www.fda.gov/Drugs/DrugSafety/ucm270243.htm\">",
"     safety communication",
"    </a>",
"    and product warnings by US Food &amp; Drug Administration. Eight of 52 cases described in the communication occurred after only one dose of asenapine and 19 prompted emergency intervention or hospitalization [",
"    <a class=\"abstract\" href=\"UTD.htm?15/10/15530/abstract/50\">",
"     50",
"    </a>",
"    ]. Adverse effects are summarized in a table (",
"    <a class=\"graphic graphic_table graphicRef82533 \" href=\"UTD.htm?32/57/33694\">",
"     table 1",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    Systematic studies of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?2/56/2951?source=see_link\">",
"     asenapine",
"    </a>",
"    in geriatric patients have not been reported, but caution is recommended early in treatment because of a mildly elevated risk of orthostatic hypotension and syncope. No data on use in children or adolescents have been reported. Severe hepatic dysfunction caused a 7-fold increase in serum levels of asenapine, leading the manufacturer to recommend against its use in that population [",
"    <a class=\"abstract\" href=\"UTD.htm?15/10/15530/abstract/48\">",
"     48",
"    </a>",
"    ]. Renal impairment has no impact on drug levels or clearance.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H30683618\">",
"    <span class=\"h2\">",
"     Lurasidone",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?15/1/15383?source=see_link\">",
"     Lurasidone",
"    </a>",
"    shows high affinity for dopamine D2 and serotonin 5-HT2A receptors, as is characteristic of other second-generation antipsychotics. It also has potent antagonism at 5-HT7 receptors of unclear significance, as yet [",
"    <a class=\"abstract\" href=\"UTD.htm?15/10/15530/abstract/51\">",
"     51",
"    </a>",
"    ]. It has moderate affinity for 5-HT1A and alpha2 adrenergic receptors, and minimal binding at alpha1 adrenergic, histamine H1, and muscarinic M1 receptors [",
"    <a class=\"abstract\" href=\"UTD.htm?15/10/15530/abstract/52,53\">",
"     52,53",
"    </a>",
"    ]. Absorption of the drug occurs over one to three hours, followed by a serum half-life of 18 to 37 hours [",
"    <a class=\"abstract\" href=\"UTD.htm?15/10/15530/abstract/53,54\">",
"     53,54",
"    </a>",
"    ]. Bioavailability increases two to three-fold when the drug is taken with a 350 calorie meal, but is not dependent on the fat content of the meal. Its major route of metabolism is via CYP3A4, which produces both active and inactive metabolites. Medications that are strong inhibitors or inducers of CYP3A4 substantially alter serum levels of lurasidone and their coadministration is contraindicated [",
"    <a class=\"abstract\" href=\"UTD.htm?15/10/15530/abstract/53\">",
"     53",
"    </a>",
"    ]. Dose reduction is recommended in the presence of moderate CYP3A4 inhibitors, such as",
"    <a class=\"drug drug_general\" href=\"UTD.htm?12/16/12554?source=see_link\">",
"     diltiazem",
"    </a>",
"    . A list of common medications that are significant inhibitors or inducers of CYP3A4 is provided in the table (",
"    <a class=\"graphic graphic_table graphicRef76992 \" href=\"UTD.htm?9/45/9950\">",
"     table 6",
"    </a>",
"    ). Specific drug interactions may be analyzed using the Lexi-Interact tool included with UpToDate.",
"   </p>",
"   <p>",
"    The drug is supplied as 20, 40, 80 and 120 mg tablets intended for once daily dosing with a meal. The suggested initial dose is 40 mg daily for most patients; dose titration was not employed in the efficacy studies [",
"    <a class=\"abstract\" href=\"UTD.htm?15/10/15530/abstract/53\">",
"     53",
"    </a>",
"    ]. The maximum daily dose of 160 mg received approval based upon results of a 6 week efficacy trial available only in abstract form [",
"    <a class=\"abstract\" href=\"UTD.htm?15/10/15530/abstract/55\">",
"     55",
"    </a>",
"    ]. However, results of an unpublished trial that included 120 mg daily showed no benefit over and more adverse effects than 80 mg per day [",
"    <a class=\"abstract\" href=\"UTD.htm?15/10/15530/abstract/51,56\">",
"     51,56",
"    </a>",
"    ]. Dose reduction is needed in the setting of moderate or severe renal or hepatic insufficiency. Dosing, drug interactions, metabolism, and available preparations are summarized in a table (",
"    <a class=\"graphic graphic_table graphicRef60624 \" href=\"UTD.htm?30/58/31663\">",
"     table 2",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    Common side effects include somnolence, akathisia, nausea, and parkinsonism [",
"    <a class=\"abstract\" href=\"UTD.htm?15/10/15530/abstract/52,53,57\">",
"     52,53,57",
"    </a>",
"    ]. Less commonly reported adverse effects include acute dystonia, agitation, anxiety, and dizziness. Weight gain was mild in short-term studies (mean 0.75 kg versus 0.26 kg for placebo) and was not observed in open-label extension studies of 24 to 52 weeks [",
"    <a class=\"abstract\" href=\"UTD.htm?15/10/15530/abstract/53\">",
"     53",
"    </a>",
"    ]. Fasting glucose is more likely to be elevated with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?15/1/15383?source=see_link\">",
"     lurasidone",
"    </a>",
"    (10 to 14 percent of patients compared to 8.6 percent on placebo), but lipid levels show little difference compared to placebo treatment. Prolactin elevation occurs in 8.3 percent of women and 1.9 percent of men on the drug, compared to 0.6 to 1 percent of those on placebo. The mean change in QT interval was -1.2 milliseconds in the initial clinical trial [",
"    <a class=\"abstract\" href=\"UTD.htm?15/10/15530/abstract/57\">",
"     57",
"    </a>",
"    ] and no other ECG abnormalities were reported subsequently [",
"    <a class=\"abstract\" href=\"UTD.htm?15/10/15530/abstract/53\">",
"     53",
"    </a>",
"    ]. Adverse effects are summarized in a table (",
"    <a class=\"graphic graphic_table graphicRef82533 \" href=\"UTD.htm?32/57/33694\">",
"     table 1",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    The drug has not been tested in children or adolescents. Its pharmacokinetics appear unchanged in the elderly population, but no studies of its efficacy or safety in that group are available [",
"    <a class=\"abstract\" href=\"UTD.htm?15/10/15530/abstract/58\">",
"     58",
"    </a>",
"    ]. &nbsp;",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H76524735\">",
"    <span class=\"h2\">",
"     Clozapine",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?34/21/35161?source=see_link\">",
"     Clozapine",
"    </a>",
"    is uniquely efficacious in treating certain features of schizophrenia, including clinically significant positive symptoms that have not responded to other antipsychotics and suicidality [",
"    <a class=\"abstract\" href=\"UTD.htm?15/10/15530/abstract/59,60\">",
"     59,60",
"    </a>",
"    ] (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/35/29241?source=see_link&amp;anchor=H108920615#H108920615\">",
"     \"Pharmacotherapy for schizophrenia: Acute and maintenance phase treatment\", section on 'Clozapine'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?6/40/6793?source=see_link\">",
"     \"Guidelines for prescribing clozapine in schizophrenia\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?34/21/35161?source=see_link\">",
"     Clozapine",
"    </a>",
"    is administered as tablets with an intermediate rate of absorption and elimination half life (12 hours), and as an orally disintegrating tablet with similar pharmacokinetics.",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?34/21/35161?source=see_link\">",
"     Clozapine",
"    </a>",
"    is started at a low dose (12.5 to 25",
"    <span class=\"nowrap\">",
"     mg/day)",
"    </span>",
"    and titrated up slowly. Maintenance doses of 300 to 600",
"    <span class=\"nowrap\">",
"     mg/day",
"    </span>",
"    are usually required for efficacy. A clozapine plasma level can be useful to guide dosing. Doses higher than 900",
"    <span class=\"nowrap\">",
"     mg/day",
"    </span>",
"    are not recommended. In the elderly and medically ill population, the titration may need to be slower, and maintenance doses are typically in the 100 to 150",
"    <span class=\"nowrap\">",
"     mg/day",
"    </span>",
"    range [",
"    <a class=\"abstract\" href=\"UTD.htm?15/10/15530/abstract/61\">",
"     61",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?6/40/6793?source=see_link&amp;anchor=H20931863#H20931863\">",
"     \"Guidelines for prescribing clozapine in schizophrenia\", section on 'Dosing'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?34/21/35161?source=see_link\">",
"     Clozapine",
"    </a>",
"    side effects tend to be prominent and persistent, limiting its acceptability to many patients. Most troublesome is the risk of potentially life-threatening agranulocytosis, leading to requirements in the US and other countries to monitor the white blood cell counts (WBC). Orthostatic hypotension, tachycardia, weight gain, the metabolic syndrome, sialorrhea, sedation, and constipation are among the most commonly reported problems. Other severe adverse effects include seizure, myocarditis, and pulmonary emboli. Compared with other antipsychotic drugs, clozapine is associated with reduced rates of extrapyramidal symptoms and tardive dyskinesia. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?6/40/6793?source=see_link&amp;anchor=H98147514#H98147514\">",
"     \"Guidelines for prescribing clozapine in schizophrenia\", section on 'Monitoring'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?6/40/6793?source=see_link&amp;anchor=H20932063#H20932063\">",
"     \"Guidelines for prescribing clozapine in schizophrenia\", section on 'Adverse effects'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H76524742\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The defining characteristics of second-generation antipsychotics (SGAs) are lower risks of extrapyramidal side effects and tardive dyskinesia&mdash;adverse effects that were prominent with the first generation of antipsychotics. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?7/24/7562?source=see_link&amp;anchor=H272233801#H272233801\">",
"       \"First-generation antipsychotic medications: Pharmacology, administration, and comparative side effects\", section on 'Cost'",
"      </a>",
"      and",
"      <a class=\"local\" href=\"#H76524630\">",
"       'Terminology'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      SGAs have been found to have problematic side effects as well, most notably weight gain and metabolic effects. However, the side effect profiles of individual drugs vary. Adverse effects are summarized in a table (",
"      <a class=\"graphic graphic_table graphicRef82533 \" href=\"UTD.htm?32/57/33694\">",
"       table 1",
"      </a>",
"      ). These medications also differ in their pharmacokinetics and available formulations (",
"      <a class=\"graphic graphic_table graphicRef60624 \" href=\"UTD.htm?30/58/31663\">",
"       table 2",
"      </a>",
"      ). Thus, selecting an antipsychotic requires the weighing of its benefits and disadvantages in individual clinical circumstances. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?7/24/7562?source=see_link\">",
"       \"First-generation antipsychotic medications: Pharmacology, administration, and comparative side effects\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?11/33/11802?source=see_link\">",
"       Risperidone",
"      </a>",
"      offers the advantages of extensive clinical experience, availability in multiple forms, and lower cost generic versions. It has a somewhat greater risk of extrapyramidal symptoms, weight gain, and prolactin elevation than other SGAs. (See",
"      <a class=\"local\" href=\"#H76524679\">",
"       'Risperidone'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?36/36/37449?source=see_link\">",
"       Olanzapine",
"      </a>",
"      's advantages include extensive clinical experience and multiple formulations, and it is now available as a generic. Weight gain, hyperglycemia, and hyperlipidemia are greater with olanzapine than with other SGAs. (See",
"      <a class=\"local\" href=\"#H76524686\">",
"       'Olanzapine'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?19/56/20361?source=see_link\">",
"       Quetiapine",
"      </a>",
"      has a low incidence of extrapyramidal symptoms even at higher doses. It is available in the US and other countries as generic drug. Disadvantages include sedation and hypotension, moderate risk of weight gain, QT prolongation in conjunction with other medications that prolong the QT interval or patient risk factors for QT prolongation. Twice daily dosing is recommended for the immediate release formulation. (See",
"      <a class=\"local\" href=\"#H76524693\">",
"       'Quetiapine'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?4/39/4728?source=see_link\">",
"       Ziprasidone",
"      </a>",
"      's advantages include lower risks of weight gain, diabetes, and hyperlipidemia, along with a generic formulation in the US. Disadvantages include twice daily dosing and prolonged QT interval. It should be taken in conjunction with a meal of at least 500 calories. (See",
"      <a class=\"local\" href=\"#H76524700\">",
"       'Ziprasidone'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?42/11/43193?source=see_link\">",
"       Aripiprazole",
"      </a>",
"      's advantages include a lower risk of weight gain, increased lipid or prolactin levels, extrapyramidal effects and sedation. Disadvantages include a long elimination time, and the need to avoid co-administration with other antipsychotic drugs. Akathisia is more commonly seen in patients with mood disorders. (See",
"      <a class=\"local\" href=\"#H76524707\">",
"       'Aripiprazole'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?43/43/44728?source=see_link\">",
"       Paliperidone",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?34/59/35767?source=see_link\">",
"       iloperidone",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?2/56/2951?source=see_link\">",
"       asenapine",
"      </a>",
"      , and",
"      <a class=\"drug drug_general\" href=\"UTD.htm?15/1/15383?source=see_link\">",
"       lurasidone",
"      </a>",
"      are newer antipsychotics that have been subject to fewer studies and less clinical experience than other second-generation drugs. Clinically significant findings to date include:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?43/43/44728?source=see_link\">",
"       Paliperidone",
"      </a>",
"      can be used to treat psychosis in patients with hepatic impairment. It can prolong the QT interval and should not be used with other drugs that have similar effects. It has a similar risk profile to",
"      <a class=\"drug drug_general\" href=\"UTD.htm?11/33/11802?source=see_link\">",
"       risperidone",
"      </a>",
"      , including prolactin elevation. (See",
"      <a class=\"local\" href=\"#H76524714\">",
"       'Paliperidone'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?34/59/35767?source=see_link\">",
"       Iloperidone",
"      </a>",
"      has not been extensively tested in older adults. Known risks of QT prolongation and hypotension suggest that caution be exercised with the drug in this population. However, it has a low risk for extrapyramidal symptoms and akathisia. (See",
"      <a class=\"local\" href=\"#H76524721\">",
"       'Iloperidone'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?15/1/15383?source=see_link\">",
"       Lurasidone",
"      </a>",
"      has lower risk of weight gain, lipid dysregulation, and QT prolongation compared to other drugs in this class.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?34/21/35161?source=see_link\">",
"       Clozapine",
"      </a>",
"      is unique among second-generation antipsychotic drugs for its efficacy in treating psychotic symptoms of schizophrenia that persist in response to other antipsychotics and reduced rates of extrapyramidal symptoms and tardive dyskinesia. Potential adverse effects include agranulocytosis, seizure, and myocarditis. Patients taking clozapine require weekly to monthly monitoring of white blood cell counts (See",
"      <a class=\"local\" href=\"#H76524735\">",
"       'Clozapine'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?6/40/6793?source=see_link\">",
"       \"Guidelines for prescribing clozapine in schizophrenia\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H76524751\">",
"    <span class=\"h1\">",
"     DISCLOSURE",
"    </span>",
"    &nbsp;&mdash;&nbsp;Michael Jibson, MD, PhD, the author of this topic, has received funding from AstraZeneca for speaking on the use of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?19/56/20361?source=see_link\">",
"     quetiapine",
"    </a>",
"    in psychiatric care.",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     Iloperidone [package insert]. Vanda Pharmaceutical, Inc.; 2009. Available online at www.fanapt.com/fanapt-pi-may09.pdf.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/10/15530/abstract/2\">",
"      Potkin SG, Cohen M, Panagides J. Efficacy and tolerability of asenapine in acute schizophrenia: a placebo- and risperidone-controlled trial. J Clin Psychiatry 2007; 68:1492.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/10/15530/abstract/3\">",
"      Buchanan RW, Kreyenbuhl J, Kelly DL, et al. The 2009 schizophrenia PORT psychopharmacological treatment recommendations and summary statements. Schizophr Bull 2010; 36:71.",
"     </a>",
"    </li>",
"    <li>",
"     Risperdal [package insert]. Ortho-McNeil-Janssen Pharmaceuticals; 2010. Available online at file://www.risperdal.com/sites/default/files/shared/pi/risperdal.pdf.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/10/15530/abstract/5\">",
"      Currier GW, Simpson GM. Risperidone liquid concentrate and oral lorazepam versus intramuscular haloperidol and intramuscular lorazepam for treatment of psychotic agitation. J Clin Psychiatry 2001; 62:153.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/10/15530/abstract/6\">",
"      Marder SR, Meibach RC. Risperidone in the treatment of schizophrenia. Am J Psychiatry 1994; 151:825.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/10/15530/abstract/7\">",
"      Peuskens J. Risperidone in the treatment of patients with chronic schizophrenia: a multi-national, multi-centre, double-blind, parallel-group study versus haloperidol. Risperidone Study Group. Br J Psychiatry 1995; 166:712.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/10/15530/abstract/8\">",
"      Szarfman A, Tonning JM, Levine JG, Doraiswamy PM. Atypical antipsychotics and pituitary tumors: a pharmacovigilance study. Pharmacotherapy 2006; 26:748.",
"     </a>",
"    </li>",
"    <li>",
"     file://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm277022.htm (Accessed on July 11, 2012).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/10/15530/abstract/10\">",
"      Olesen OV, Linnet K. Determination of olanzapine in serum by high-performance liquid chromatography using ultraviolet detection considering the easy oxidability of the compound and the presence of other psychotropic drugs. J Chromatogr B Biomed Sci Appl 1998; 714:309.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/10/15530/abstract/11\">",
"      Kinon BJ, Volavka J, Stauffer V, et al. Standard and higher dose of olanzapine in patients with schizophrenia or schizoaffective disorder: a randomized, double-blind, fixed-dose study. J Clin Psychopharmacol 2008; 28:392.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/10/15530/abstract/12\">",
"      Lieberman JA, Stroup TS, McEvoy JP, et al. Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. N Engl J Med 2005; 353:1209.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/10/15530/abstract/13\">",
"      Fontaine CS, Hynan LS, Koch K, et al. A double-blind comparison of olanzapine versus risperidone in the acute treatment of dementia-related behavioral disturbances in extended care facilities. J Clin Psychiatry 2003; 64:726.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/10/15530/abstract/14\">",
"      Meehan KM, Wang H, David SR, et al. Comparison of rapidly acting intramuscular olanzapine, lorazepam, and placebo: a double-blind, randomized study in acutely agitated patients with dementia. Neuropsychopharmacology 2002; 26:494.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/10/15530/abstract/15\">",
"      Allen MH, Currier GW, Carpenter D, et al. The expert consensus guideline series. Treatment of behavioral emergencies 2005. J Psychiatr Pract 2005; 11 Suppl 1:5.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/10/15530/abstract/16\">",
"      Beasley CM Jr, Hamilton SH, Crawford AM, et al. Olanzapine versus haloperidol: acute phase results of the international double-blind olanzapine trial. Eur Neuropsychopharmacol 1997; 7:125.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/10/15530/abstract/17\">",
"      Tran PV, Dellva MA, Tollefson GD, et al. Extrapyramidal symptoms and tolerability of olanzapine versus haloperidol in the acute treatment of schizophrenia. J Clin Psychiatry 1997; 58:205.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/10/15530/abstract/18\">",
"      Bobes J, Rejas J, Garcia-Garcia M, et al. Weight gain in patients with schizophrenia treated with risperidone, olanzapine, quetiapine or haloperidol: results of the EIRE study. Schizophr Res 2003; 62:77.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/10/15530/abstract/19\">",
"      Leslie DL, Rosenheck RA. Incidence of newly diagnosed diabetes attributable to atypical antipsychotic medications. Am J Psychiatry 2004; 161:1709.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/10/15530/abstract/20\">",
"      Brooks JO 3rd, Chang HS, Krasnykh O. Metabolic risks in older adults receiving second-generation antipsychotic medication. Curr Psychiatry Rep 2009; 11:33.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/10/15530/abstract/21\">",
"      Correll CU, Manu P, Olshanskiy V, et al. Cardiometabolic risk of second-generation antipsychotic medications during first-time use in children and adolescents. JAMA 2009; 302:1765.",
"     </a>",
"    </li>",
"    <li>",
"     FDA MedWatch safety alert. Zyprexa (olanzapine): Use in adolescents. January 29, 2010.",
"    </li>",
"    <li>",
"     Zyprexa [package insert]. Eli Lilly and Company; 2010. Available online at file://pi.lilly.com/us/zyprexa-pi.pdf.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/10/15530/abstract/24\">",
"      McManus DQ, Arvanitis LA, Kowalcyk BB. Quetiapine, a novel antipsychotic: experience in elderly patients with psychotic disorders. Seroquel Trial 48 Study Group. J Clin Psychiatry 1999; 60:292.",
"     </a>",
"    </li>",
"    <li>",
"     Seroquel [package insert]. AstraZeneca Pharmaceuticals LP; 2011. Available online at file://www1.astrazeneca-us.com/pi/Seroquel.pdf.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/10/15530/abstract/26\">",
"      Borison RL, Arvanitis LA, Miller BG. ICI 204,636, an atypical antipsychotic: efficacy and safety in a multicenter, placebo-controlled trial in patients with schizophrenia. U.S. SEROQUEL Study Group. J Clin Psychopharmacol 1996; 16:158.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/10/15530/abstract/27\">",
"      Small JG, Hirsch SR, Arvanitis LA, et al. Quetiapine in patients with schizophrenia. A high- and low-dose double-blind comparison with placebo. Seroquel Study Group. Arch Gen Psychiatry 1997; 54:549.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/10/15530/abstract/28\">",
"      Mullen J, Jibson MD, Sweitzer D. A comparison of the relative safety, efficacy, and tolerability of quetiapine and risperidone in outpatients with schizophrenia and other psychotic disorders: the quetiapine experience with safety and tolerability (QUEST) study. Clin Ther 2001; 23:1839.",
"     </a>",
"    </li>",
"    <li>",
"     file://www.accessdata.fda.gov/drugsatfda_docs/label/2011/020639s049s054lbl.pdf (Accessed on July 11, 2012).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/10/15530/abstract/30\">",
"      Komossa K, Rummel-Kluge C, Schmid F, et al. Quetiapine versus other atypical antipsychotics for schizophrenia. Cochrane Database Syst Rev 2010; :CD006625.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/10/15530/abstract/31\">",
"      Citrome L. Using oral ziprasidone effectively: the food effect and dose-response. Adv Ther 2009; 26:739.",
"     </a>",
"    </li>",
"    <li>",
"     Ziprasidone [package insert]. Pfizer, Inc.; 2009. Available online at file://media.pfizer.com/files/products/uspi_geodon.pdf",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/10/15530/abstract/33\">",
"      Tandon, R, Harrigan E, Zorn, S. Ziprasidone: a novel antipsychotic with unique pharmacology and therapeutic potential. J Serotonin Res 1997; 4:159.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/10/15530/abstract/34\">",
"      Komossa K, Rummel-Kluge C, Hunger H, et al. Ziprasidone versus other atypical antipsychotics for schizophrenia. Cochrane Database Syst Rev 2009; :CD006627.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/10/15530/abstract/35\">",
"      Newcomer JW, Haupt DW. The metabolic effects of antipsychotic medications. Can J Psychiatry 2006; 51:480.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/10/15530/abstract/36\">",
"      Weiden PJ, Iqbal N, Mendelowitz AJ, et al. Best clinical practice with ziprasidone: update after one year of experience. J Psychiatr Pract 2002; 8:81.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/10/15530/abstract/37\">",
"      Kane JM, Carson WH, Saha AR, et al. Efficacy and safety of aripiprazole and haloperidol versus placebo in patients with schizophrenia and schizoaffective disorder. J Clin Psychiatry 2002; 63:763.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/10/15530/abstract/38\">",
"      Tran-Johnson TK, Sack DA, Marcus RN, et al. Efficacy and safety of intramuscular aripiprazole in patients with acute agitation: a randomized, double-blind, placebo-controlled trial. J Clin Psychiatry 2007; 68:111.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/10/15530/abstract/39\">",
"      Citrome L, Macher JP, Salazar DE, et al. Pharmacokinetics of aripiprazole and concomitant carbamazepine. J Clin Psychopharmacol 2007; 27:279.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/10/15530/abstract/40\">",
"      Alexopoulos GS, Streim J, Carpenter D, et al. Using antipsychotic agents in older patients. J Clin Psychiatry 2004; 65 Suppl 2:5.",
"     </a>",
"    </li>",
"    <li>",
"     Abilify [package insert]. Otsuka Pharmaceutical Company; 2011. Available online at file://www.abilify.com/pdf/pi.aspx.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/10/15530/abstract/42\">",
"      Komossa K, Rummel-Kluge C, Schmid F, et al. Aripiprazole versus other atypical antipsychotics for schizophrenia. Cochrane Database Syst Rev 2009; :CD006569.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/10/15530/abstract/43\">",
"      Boom S, Thyssen A, Crauwels H, et al. The influence of hepatic impairment on the pharmacokinetics of paliperidone. Int J Clin Pharmacol Ther 2009; 47:606.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/10/15530/abstract/44\">",
"      Nussbaum A, Stroup TS. Paliperidone for schizophrenia. Cochrane Database Syst Rev 2008; :CD006369.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/10/15530/abstract/45\">",
"      Potkin SG, Litman RE, Torres R, Wolfgang CD. Efficacy of iloperidone in the treatment of schizophrenia: initial phase 3 studies. J Clin Psychopharmacol 2008; 28:S4.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/10/15530/abstract/46\">",
"      Weiden PJ, Cutler AJ, Polymeropoulos MH, Wolfgang CD. Safety profile of iloperidone: a pooled analysis of 6-week acute-phase pivotal trials. J Clin Psychopharmacol 2008; 28:S12.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/10/15530/abstract/47\">",
"      Shahid M, Walker GB, Zorn SH, Wong EH. Asenapine: a novel psychopharmacologic agent with a unique human receptor signature. J Psychopharmacol 2009; 23:65.",
"     </a>",
"    </li>",
"    <li>",
"     Saphris [package insert]. Schering Corporation; 2009. Available online at file://www.spfiles.com/pisaphrisv1.pdf.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/10/15530/abstract/49\">",
"      Chapel S, Hutmacher MM, Haig G, et al. Exposure-response analysis in patients with schizophrenia to assess the effect of asenapine on QTc prolongation. J Clin Pharmacol 2009; 49:1297.",
"     </a>",
"    </li>",
"    <li>",
"     US Food &amp; Drug Administration Safety Communication: Serioius allergic reactions reported with the use of Saphris (asenapine maleate) file://www.fda.gov/Drugs/DrugSafety/ucm270243.htm (Accessed on March 30, 2012).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/10/15530/abstract/51\">",
"      Risbood V, Lee JR, Roche-Desilets J, Fuller MA. Lurasidone: an atypical antipsychotic for schizophrenia. Ann Pharmacother 2012; 46:1033.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/10/15530/abstract/52\">",
"      Ishibashi T, Horisawa T, Tokuda K, et al. Pharmacological profile of lurasidone, a novel antipsychotic agent with potent 5-hydroxytryptamine 7 (5-HT7) and 5-HT1A receptor activity. J Pharmacol Exp Ther 2010; 334:171.",
"     </a>",
"    </li>",
"    <li>",
"     Latuda (lurasidone hydrochloride) US prescribing information. file://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=afad3051-9df2-4c54-9684-e8262a133af8 (Accessed on December 12, 2012).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/10/15530/abstract/54\">",
"      Meyer JM, Loebel AD, Schweizer E. Lurasidone: a new drug in development for schizophrenia. Expert Opin Investig Drugs 2009; 18:1715.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/10/15530/abstract/55\">",
"      Loebel A, Cucchiaro J, Pikalov A, et al. Lurasidone in the Treatment of Acute Schizophrenia: Results of the Double-Blind, Placebo-Controlled, 6-Week, PEARL 3 Trial. Neuropsychopharmacology 2010; 35:S313.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/10/15530/abstract/56\">",
"      Citrome L. Lurasidone in schizophrenia: new information about dosage and place in therapy. Adv Ther 2012; 29:815.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/10/15530/abstract/57\">",
"      Nakamura M, Ogasa M, Guarino J, et al. Lurasidone in the treatment of acute schizophrenia: a double-blind, placebo-controlled trial. J Clin Psychiatry 2009; 70:829.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/10/15530/abstract/58\">",
"      Rado J, Janicak PG. Pharmacological and clinical profile of recently approved second-generation antipsychotics: implications for treatment of schizophrenia in older patients. Drugs Aging 2012; 29:783.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/10/15530/abstract/59\">",
"      Kane J, Honigfeld G, Singer J, Meltzer H. Clozapine for the treatment-resistant schizophrenic. A double-blind comparison with chlorpromazine. Arch Gen Psychiatry 1988; 45:789.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/10/15530/abstract/60\">",
"      Kreyenbuhl J, Buchanan RW, Dickerson FB, et al. The Schizophrenia Patient Outcomes Research Team (PORT): updated treatment recommendations 2009. Schizophr Bull 2010; 36:94.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/10/15530/abstract/61\">",
"      Barak Y, Wittenberg N, Naor S, et al. Clozapine in elderly psychiatric patients: tolerability, safety, and efficacy. Compr Psychiatry 1999; 40:320.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 14776 Version 8.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0502-61.234.146.186-FE4A772EBF-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f15_10_15530=[""].join("\n");
var outline_f15_10_15530=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H76524742\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H76524623\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H76524630\">",
"      TERMINOLOGY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H76524637\">",
"      PHARMACOLOGY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H90780126\">",
"      INDICATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H76524651\">",
"      SIDE EFFECTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H76524658\">",
"      COST",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H76524665\">",
"      FORMULATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H76524672\">",
"      INDIVIDUAL MEDICATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H76524679\">",
"      Risperidone",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H76524686\">",
"      Olanzapine",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H76524693\">",
"      Quetiapine",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H76524700\">",
"      Ziprasidone",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H76524707\">",
"      Aripiprazole",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H76524714\">",
"      Paliperidone",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H76524721\">",
"      Iloperidone",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H76524728\">",
"      Asenapine",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H30683618\">",
"      Lurasidone",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H76524735\">",
"      Clozapine",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H76524742\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H76524751\">",
"      DISCLOSURE",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"PSYCH/14776\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PSYCH/14776|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?32/57/33694\" title=\"table 1\">",
"      Adverse effects for antipsychotic meds",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?30/58/31663\" title=\"table 2\">",
"      Dosage and pharmacology of antipsychotics",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/6/23662\" title=\"table 3\">",
"      Oral antipsychotics cost comparison",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?32/7/32893\" title=\"table 4\">",
"      Antipsychotics for management of acute agitation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?9/36/9806\" title=\"table 5\">",
"      Dose and admin of LAI antipsychotic for schizophrenia",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?9/45/9950\" title=\"table 6\">",
"      Inhibitors and inducers of cytochrome P450 3A4",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?22/55/23418?source=related_link\">",
"      Acquired long QT syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?37/8/38026?source=related_link\">",
"      Bipolar disorder in adults: Pharmacotherapy for acute mania, mixed episodes, and hypomania",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?21/41/22167?source=related_link\">",
"      Causes of hyperprolactinemia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?4/31/4600?source=related_link\">",
"      First generation (Typical) antipsychotic medication poisoning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?7/24/7562?source=related_link\">",
"      First-generation antipsychotic medications: Pharmacology, administration, and comparative side effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?6/40/6793?source=related_link\">",
"      Guidelines for prescribing clozapine in schizophrenia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?20/4/20553?source=related_link\">",
"      Neuroleptic malignant syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?28/35/29241?source=related_link\">",
"      Pharmacotherapy for schizophrenia: Acute and maintenance phase treatment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?30/9/30871?source=related_link\">",
"      Pharmacotherapy for schizophrenia: Long-acting injectable antipsychotic drugs",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?43/45/44760?source=related_link\">",
"      Pharmacotherapy for schizophrenia: Side effect management",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?27/33/28185?source=related_link\">",
"      Prevention and treatment of delirium and confusional states",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?42/19/43320?source=related_link\">",
"      Second generation (atypical) antipsychotic medication poisoning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/40/27269?source=related_link\">",
"      Tardive dyskinesia: Clinical features and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?35/26/36264?source=related_link\">",
"      Tardive dyskinesia: Etiology and epidemiology",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?34/8/34952?source=related_link\">",
"      Tardive dyskinesia: Prevention and treatment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/48/27402?source=related_link\">",
"      Treatment of behavioral symptoms related to dementia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?28/62/29670?source=related_link\">",
"      Treatment of postpartum psychosis",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f15_10_15531="Treatment of auto PEEP";
var content_f15_10_15531=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PULM%2F62376&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=7\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PULM%2F62376&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=7\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Treatment of auto-PEEP",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Changes in ventilator setting",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Increase expiratory duration",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Decrease respiratory rate",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Decrease tidal volume",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Reduction in the ventilatory demand",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Decrease carbohydrate intake",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Reduce dead space",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Reduce anxiety, pain, fever, shivering",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Reduction of total flow resistance",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Use of large bore endotracheal tubes",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Frequent suctioning",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Bronchodilators",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Application of external PEEP nearly up to the level of initial PEEPi",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f15_10_15531=[""].join("\n");
var outline_f15_10_15531=null;
var title_f15_10_15532="Borg scale";
var content_f15_10_15532=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PULM%2F63981&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PULM%2F63981&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    The modified Borg Scale for assessing the intensity of dyspnea or fatigue",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <colgroup width=\"5%\">",
"     </colgroup>",
"     <colgroup width=\"95%\">",
"     </colgroup>",
"     <tbody>",
"      <tr>",
"       <td class=\"centered\">",
"        0",
"       </td>",
"       <td>",
"        Nothing at all",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"centered\">",
"        0.5",
"       </td>",
"       <td>",
"        Very, very slight (just noticeable)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"centered\">",
"        1",
"       </td>",
"       <td>",
"        Very slight",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"centered\">",
"        2",
"       </td>",
"       <td>",
"        Slight (light)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"centered\">",
"        3",
"       </td>",
"       <td>",
"        Moderate",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"centered\">",
"        4",
"       </td>",
"       <td>",
"        Somewhat severe",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"centered\">",
"        5",
"       </td>",
"       <td>",
"        Severe (heavy)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"centered\">",
"        6",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"centered\">",
"        7",
"       </td>",
"       <td>",
"        Very severe",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"centered\">",
"        8",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"centered\">",
"        9",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"centered\">",
"        10",
"       </td>",
"       <td>",
"        Very, very severe (maximal)",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    This Borg scale should be printed on heavy paper (11 inches high and perhaps laminated) in 20-point type size. At the beginning of the 6-minute exercise, show the scale to the patient and ask the patient this: \"Please grade your level of shortness of breath using this scale.\" Then ask this: \"Please grade your level of fatigue using this scale.\" At the end of the exercise, remind the patient of the breathing number that they chose before the exercise and ask the patient to grade their breathing level again. Then ask the patient to grade their level of fatigue, after reminding them of their grade before the exercise.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Sources:",
"     <br/>",
"     <ol>",
"      <li>",
"       Reproduced with permission from: Borg GA. Psychophysical bases of perceived exertion. Med Sci Sports Exerc 1982; 14:377. Copyright &copy; 1982 Lippincott Williams &amp; Wilkins.",
"      </li>",
"      <li>",
"       Reproduced with permission from: the American Thoracic Society. ATS statement: Guidelines for the six-minute walk test. Am J Respir Crit Care Med 2002; 166:111.",
"      </li>",
"     </ol>",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f15_10_15532=[""].join("\n");
var outline_f15_10_15532=null;
var title_f15_10_15533="Parenteral treatment of severe malaria in pregnancy";
var content_f15_10_15533=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ID%2F52961&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=4\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ID%2F52961&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=4\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Parenteral treatment of severe malaria in pregnancy*",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1_single\" colspan=\"2\">",
"        I. Artemisinin derivative",
"        <sup>",
"         &bull;",
"        </sup>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Artesunate",
"       </td>",
"       <td>",
"        2.4 mg/kg intravenously as first dose, followed by 2.4 mg/kg at 12 and 24 hours, followed by 2.4 mg/kg once daily",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\" colspan=\"2\">",
"        II. Quinine or quinidine",
"        <sup>",
"         &Delta;",
"        </sup>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Quinine dihydrochloride",
"        <sup>",
"         &loz;",
"        </sup>",
"       </td>",
"       <td>",
"        16.7 mg base/kg (= 20 mg salt/kg) in 5 percent dextrose loading dose over 4 hours, followed by 25 mg base/kg/day (20 to 30 mg salt/kg/day) divided into 2 to 3 equal administrations of 8.35 mg base/kg (= 10 mg salt/kg) over 2 hours at 8 or 12 hr intervals (maximum 1800 mg salt/day)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td rowspan=\"2\">",
"        Quinidine gluconate",
"        <sup>",
"         &sect;",
"        </sup>",
"       </td>",
"       <td>",
"        6.25 mg base/kg (= 10 mg salt/kg) loading dose intravenously (maximum 600 mg salt) in normal saline over 1-2 hrs, followed by 0.0125 mg base/kg/min (= 0.02 mg salt/kg/minute) continuous infusion for at least 24 hours",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Alternative: 15 mg base/kg (= 24 mg salt/kg) loading dose intravenously in normal saline over 4 hrs, followed by 7.5 mg base/kg (= 12 mg salt/kg) infused over 4 hrs every 8 hrs, starting 8 hrs after the beginning of the loading dose",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\" colspan=\"2\">",
"        <strong>",
"         PLUS",
"        </strong>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Clindamycin",
"       </td>",
"       <td>",
"        20 mg base/kg/day orally (maximum 1800 mg) divided into 3 equal doses. Treatment course is 7 days.",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     * In general, parenteral therapy is administered for severe disease. Once the patient is able to tolerate oral medications, treatment may be completed orally. Options include:",
"     <strong>",
"      1.",
"     </strong>",
"     Parenteral artesunate followed by mefloquine (for adults: 750 mg salt orally as initial dose followed by 500 mg salt orally 6 to 12 hrs later) or clindamycin.",
"     <strong>",
"      2.",
"     </strong>",
"     During the first trimester: parenteral quinine (or quinidine) with clindamycin (seven days therapy total); this is common practice for patients with malaria acquired in SE Asia, if artesunate is not available.",
"     <strong>",
"      3.",
"     </strong>",
"     During second or third trimester: parenteral quinine (at least three doses) until the patient is able to swallow, followed by oral therapy with an artemisinin combination drug (three days therapy total; see separate table summarizing oral artemisinin combination therapy).",
"     <br/>",
"     <span class=\"bullet\">",
"      &bull;",
"     </span>",
"     Artesunate can also be administered intramuscularly, orally, or via rectal suppository. In the United States, intravenous artesunate is not approved by the Food and Drug Administration but is available for emergency use under an investigational protocol by enrollment with the Centers for Disease Control (CDC). Artesunate is unstable in solution so is dispensed as a dry powder of artesunic acid together with an ampule of diluent (5 percent sodium bicarbonate solution or sodium phosphate solution as supplied by US CDC). The powder and liquid are mixed to provide a concentration of 10 mg/mL; the artesunate solution should be administered within one hour of preparation. Once the patient has received four doses of intravenous artesunate and is able to swallow, the treatment can be completed with a course of an active oral antimalarial drug based on known susceptibility data.",
"     <br/>",
"     &Delta; Important adverse effects include hypoglycemia, QT prolongation, tinnitus, reversible hearing loss, nausea, vomiting, dizziness, and visual disturbances. To avoid cardiotoxicity, a loading dose of quinine/quinidine should not be administered to patients who received mefloquine or other quinine derivatives within the previous 12 hours. Use of quinine in pregnancy requires monitoring for hypoglycemia; susceptibility to this adverse event is increased in pregnant women.",
"     <br/>",
"     <span class=\"lozenge\">",
"      &loz;",
"     </span>",
"     Quinine should be given by rate controlled intravenous infusion and never by intravenous injection (which can be lethal). Quinine can also be administered via intramuscular injection if intravenous infusions cannot be given: two injections of 10 mg/kg quinine (diluted to 60 mL) should be administered four hours apart. The anterior thigh is preferred over the gluteal region to minimize the risk of sciatic nerve damage.",
"     <br/>",
"     &sect; In the United States, intravenous quinidine is available for treatment of severe malaria. Quinidine can cause QT prolongation and should be administered by rate controlled intravenous infusion with continuous electrocardiographic and hemodynamic monitoring in an intensive care unit. Quinidine may be significantly absorbed to PVC tubing; tubing length should be minimized to approximately 12 inches.",
"    </div>",
"    <div class=\"reference\">",
"     CDC Malaria Hotline: (770) 488-7788 Monday-Friday 8a to 4:30p EST; (770) 488-7100 after hours, weekends and holidays.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f15_10_15533=[""].join("\n");
var outline_f15_10_15533=null;
var title_f15_10_15534="Common vulvar lesions 1";
var content_f15_10_15534=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=OBGYN%2F58497%7EOBGYN%2F74333&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=OBGYN%2F58497%7EOBGYN%2F74333&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Most vulvar lesions based on morphology",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tr>",
"      <td class=\"subtitle1\">",
"       Morphology",
"      </td>",
"      <td class=\"subtitle1\">",
"       Color",
"      </td>",
"      <td class=\"subtitle1\">",
"       Common diseases",
"      </td>",
"      <td class=\"subtitle1\">",
"       Infection",
"      </td>",
"      <td class=\"subtitle1\">",
"       Malignancy",
"      </td>",
"     </tr>",
"     <tr>",
"      <td colspan=\"1\" rowspan=\"8\">",
"       Papules, nodules",
"      </td>",
"      <td colspan=\"1\" rowspan=\"8\">",
"       Flesh- colored",
"      </td>",
"      <td>",
"       Vestibular papillae",
"      </td>",
"      <td>",
"       Genital warts",
"      </td>",
"      <td>",
"       Soft tissue malignancy",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Cyst",
"      </td>",
"      <td>",
"       Molluscum contagiosum",
"      </td>",
"      <td colspan=\"1\" rowspan=\"7\">",
"       &nbsp;",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Syringoma",
"      </td>",
"      <td colspan=\"1\" rowspan=\"6\">",
"       &nbsp;",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Hidradenoma papilliferum",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Skin tag",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Neurofibroma",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Lipoma",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Fibroma",
"      </td>",
"     </tr>",
"     <tr>",
"      <td colspan=\"1\" rowspan=\"4\">",
"       Patch, plaque",
"      </td>",
"      <td colspan=\"1\" rowspan=\"4\">",
"       White",
"      </td>",
"      <td>",
"       Post-inflammatory hypopigmentation",
"      </td>",
"      <td colspan=\"1\" rowspan=\"4\">",
"       &nbsp;",
"      </td>",
"      <td colspan=\"1\" rowspan=\"4\">",
"       &nbsp;",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Hyperkeratosis",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Vitiligo",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Lichen sclerosis et atrophicus",
"      </td>",
"     </tr>",
"     <tr>",
"      <td colspan=\"1\" rowspan=\"5\">",
"       Macule, patch",
"      </td>",
"      <td colspan=\"1\" rowspan=\"5\">",
"       Dark",
"      </td>",
"      <td>",
"       Physiologic",
"      </td>",
"      <td colspan=\"1\" rowspan=\"5\">",
"       &nbsp;",
"      </td>",
"      <td>",
"       Melanoma",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Post-inflammatory hyperpigmentation",
"      </td>",
"      <td>",
"       Vulvar intraepithelial neoplasia",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Genital lentigenes",
"      </td>",
"      <td>",
"       Carcinoma",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Junctional nevi",
"      </td>",
"      <td colspan=\"1\" rowspan=\"2\">",
"       &nbsp;",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Acanthosis nigricans",
"      </td>",
"     </tr>",
"     <tr>",
"      <td colspan=\"1\" rowspan=\"6\">",
"       Papule, nodule",
"      </td>",
"      <td colspan=\"1\" rowspan=\"6\">",
"       Dark",
"      </td>",
"      <td>",
"       Seborrheic keratosis",
"      </td>",
"      <td>",
"       Genital warts",
"      </td>",
"      <td>",
"       Dysplastic nevi",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Dermatofibroma",
"      </td>",
"      <td>",
"       Bowenoid papulosis",
"      </td>",
"      <td>",
"       Melanoma",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Ectopic breast tissue",
"      </td>",
"      <td colspan=\"1\" rowspan=\"4\">",
"       &nbsp;",
"      </td>",
"      <td>",
"       Kaposi's sarcoma",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Fox-Fordyce",
"      </td>",
"      <td colspan=\"1\" rowspan=\"3\">",
"       &nbsp;",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Compound melanocytic nevi",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Intradermal nevi",
"      </td>",
"     </tr>",
"     <tr>",
"      <td colspan=\"1\" rowspan=\"8\">",
"       Macule, patch, plaque",
"      </td>",
"      <td colspan=\"1\" rowspan=\"8\">",
"       Red",
"      </td>",
"      <td>",
"       Atopic dermatitis",
"      </td>",
"      <td>",
"       Candida",
"      </td>",
"      <td>",
"       Bowen's disease",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Neurodermatitis",
"      </td>",
"      <td>",
"       Dermatophyte",
"      </td>",
"      <td>",
"       Carcinoma in situ",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Contact dermatitis",
"      </td>",
"      <td>",
"       Erythrasma",
"      </td>",
"      <td>",
"       Carcinoma",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Psoriasis",
"      </td>",
"      <td>",
"       Bacterial vaginosis",
"      </td>",
"      <td>",
"       Extramammary",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Reiter's disease",
"      </td>",
"      <td>",
"       Trichomoniasis",
"      </td>",
"      <td>",
"       Paget's",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Lichen planus",
"      </td>",
"      <td colspan=\"1\" rowspan=\"3\">",
"       &nbsp;",
"      </td>",
"      <td colspan=\"1\" rowspan=\"3\">",
"       &nbsp;",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Zoon's plasma cell vulvitis",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       &nbsp;",
"      </td>",
"     </tr>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Most common vulvar lesions based on morphology (continued)",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Morphology",
"       </td>",
"       <td class=\"subtitle1\">",
"        Color",
"       </td>",
"       <td class=\"subtitle1\">",
"        Common diseases",
"       </td>",
"       <td class=\"subtitle1\">",
"        Infection",
"       </td>",
"       <td class=\"subtitle1\">",
"        Malignancy",
"       </td>",
"      </tr>",
"      <tr>",
"       <td colspan=\"1\" rowspan=\"8\">",
"        Papules, nodules",
"       </td>",
"       <td colspan=\"1\" rowspan=\"8\">",
"        Red",
"       </td>",
"       <td>",
"        Urticaria",
"       </td>",
"       <td colspan=\"1\" rowspan=\"8\">",
"        &nbsp;",
"       </td>",
"       <td colspan=\"1\" rowspan=\"8\">",
"        &nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Angiomas",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Angiokeratoma",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Urethral caruncle",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Endometriosis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Furunculosis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Inflamed cysts",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Hidradenititis suppurativa",
"       </td>",
"      </tr>",
"      <tr>",
"       <td colspan=\"1\" rowspan=\"4\">",
"        Pustule",
"       </td>",
"       <td colspan=\"1\" rowspan=\"4\">",
"        &nbsp;",
"       </td>",
"       <td>",
"        Folliculitis",
"       </td>",
"       <td>",
"        Candidiasis",
"       </td>",
"       <td colspan=\"1\" rowspan=\"4\">",
"        &nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Keratosis pilaris",
"       </td>",
"       <td>",
"        Herpes simplex",
"       </td>",
"      </tr>",
"      <tr>",
"       <td colspan=\"1\" rowspan=\"2\">",
"        &nbsp;",
"       </td>",
"       <td>",
"        Scabies",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Insect bites",
"       </td>",
"      </tr>",
"      <tr>",
"       <td colspan=\"1\" rowspan=\"10\">",
"        Vesicle, bullae, erosion",
"       </td>",
"       <td colspan=\"1\" rowspan=\"10\">",
"        &nbsp;",
"       </td>",
"       <td>",
"        Fixed drug reaction",
"       </td>",
"       <td>",
"        Bullous impetigo",
"       </td>",
"       <td colspan=\"1\" rowspan=\"10\">",
"        &nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Erythema multiforma",
"       </td>",
"       <td>",
"        Herpes simplex",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Bullous pemphigoid",
"       </td>",
"       <td>",
"        Herpes zoster",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Cicatrical pemphigoid",
"       </td>",
"       <td colspan=\"1\" rowspan=\"7\">",
"        &nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Pemphigus vulgaris",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Pemphigus vegetans",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Epidermolysis bullosa acquisita",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Lichen sclerosis et atrophicus",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Lichen planus",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Trauma",
"       </td>",
"      </tr>",
"      <tr>",
"       <td colspan=\"1\" rowspan=\"5\">",
"        Ulcer",
"       </td>",
"       <td colspan=\"1\" rowspan=\"5\">",
"        &nbsp;",
"       </td>",
"       <td>",
"        Idiopathic",
"       </td>",
"       <td>",
"        Syphilis",
"       </td>",
"       <td>",
"        Basal cell carcinoma",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Trauma",
"       </td>",
"       <td>",
"        Chancroid",
"       </td>",
"       <td>",
"        Squamous cell carcinoma",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Hidradenitis suppurativa",
"       </td>",
"       <td>",
"        Herpes simplex",
"       </td>",
"       <td colspan=\"1\" rowspan=\"3\">",
"        &nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Bechet's disease",
"       </td>",
"       <td>",
"        Granuloma inguinale",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Crohn's disease",
"       </td>",
"       <td>",
"        Lymphogranuloma venereum",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f15_10_15534=[""].join("\n");
var outline_f15_10_15534=null;
var title_f15_10_15535="Impaired coronary artery vasoreactivity predicts CV events";
var content_f15_10_15535=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=CARD%2F74218&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=CARD%2F74218&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Impaired coronary artery vasoreactivity predicts CV events",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 429px; height: 529px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Coronary artery&nbsp;vasoreactivity was evalauted in 147 patients with documented coronary heart disease (CHD) or risk factors for CHD; flow-dependent dilation, assessed with intracoronary papaverine or adenosine (upper panel), and flow-independent vasodilation, induced by nitroglycerin (lower panel), were divided into tertiles (percent arterial dilation). During a median follow-up of 6.7 years, impaired vascular reactivity was associated with a signficantly higher cardiovascular event rate (cardiovascular death, unstable angina, myocardial infarction, revascularization, stroke, peripheral artery revascularization); the incidence of events was highest in those with the least dilation.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Data from Schachinger V, Britten MB, Zeiher AM. Circulation 2000; 101:1899.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f15_10_15535=[""].join("\n");
var outline_f15_10_15535=null;
